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ABSTRACT 
 Herein is disclosed accounts of fundamentally different projects. The focus of this 
research enveloped the development of synthetic methods to access structurally complex small 
molecules, especially in the realm of C–C and C–N bond formations. The scope of reactions 
discussed revolve especially around ruthenium and palladium catalysis, accessing underexplored 
heterocyclic motifs. The utility of these techniques toward the synthesis of small molecules in 
drug discovery cannot be understated, as there are few ways to access these elusive moieties. The 
content is divided into the following four chapters: 
 
 The development of methods for the stereoselective synthesis of polysubstituted 1,3-
dienes is a challenge to synthetic chemistry. Herein is reported a selective approach for the 
synthesis of polysubstituted 1,3-dienes using the ruthenium hydride catalyzed intramolecular 
silylvinylation of alkynes under 80 psi of ethylene gas. This strategy affords a single diene 
isomer, is applicable to substrates with aryl and alkyl substitution at the propargyl and 
homopropargyl positions, and has been utilized in the synthesis of 5- and 6-membered 
oxasilacycles. 
 
 N-Substituted-3-amino-4-halopyridines are valuable synthetic intermediates, as they 
readily provide access to imidazopyridines and similar heterocyclic systems. The direct synthesis 
of N-substituted-3-amino-4-halopyridines is problematic, as reductive aminations and base 
promoted alkylations are difficult in these systems. A high yielding deprotection/alkylation 
protocol mediated by trifluoroacetic acid and trimethylsilyl trifluoromethanesulfonate is 
described, providing access to a wide scope of N-substituted-3-amino-4-halopyridines. This 
  
protocol furnishes many reaction products in high purity without chromatography. Similar 
reductive amination conditions were also established for deactivated anilines. 
 
 An amidation/cyclization approach for the synthesis of chlorinated imidazopyridines 
from 3-amino-polychloropyridines has been developed. Chlorinated imidazopyridines are often 
utilized in pharmaceutical settings as scaffolds for the discovery and optimization of biologically 
active small molecules, as they can be rapidly elaborated to explore chemical space. 
Regioselective alkylation of the imidazole ring of unsubstituted imidazopyridines is often 
problematic, however, with poorly selective alkylation conditions providing mixtures which are 
difficult to separate. This new method allows for regioselective access of chlorinated 
imidazo[4,5-b]pyridines from inexpensive and readily available 2-chloro-3-aminopyridine 
precursors. 
 
 Bosutinib is a drug developed by Pfizer in 2012 for the treatment of late stage chronic 
myeloid leukemia (CML). Bosutinib acts as a Src selective non-Receptor Tyrosine Kinase 
(nRTK) inhibitor, and it has also shown inhibition of breast and prostate cancer cells and 
suppression of solid tumors. Until recently, Src was originally thought to exist only within the 
cell cytoplasm. Herein is demonstrated the synthesis of a series of bosutinib probes for drug 
action studies to better understand the role of Src inhibition in the suppression of cancer cells. 
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1.0 RUTHENIUM HYDRIDE CATALYZED INTRAMOLECULAR 
SILYLVINYLATION OF TERMINAL ALKYNES 
1.1 Introduction 
 This chapter details research into a new method to synthesize highly substituted diene 
containing systems employing a rare silylvinylation reaction (Scheme 1.1). Highly substituted 
dienes, especially those containing tetrasubstituted olefins, represent a significant synthetic 
challenge. Research into a general and compelling solution towards these difficult targets led to 
the investigation of a silylvinylation reaction, which can be thought of as a unique combination 
of ruthenium hydride catalyzed alkyne vinylation merged with a hydrosilylation reaction. This 
approach toward conjugated dienes has demonstrated unrivaled selectivity, while the silicon 
moiety boasts a useful appendage for further derivatization.  
Scheme 1.1. The Intramolecular Silylvinylation Reaction 
 
1.2 Background 
 Conjugated dienes are ubiquitous in natural products and biologically active systems.
1,2
 
Synthesis of these relatively simple structural motifs has presented significant challenges in 
regio- and stereospecificity. As such, several efforts have been taken to create dienes efficiently 
and selectively; some of the most effective approaches utilize transition metal catalyzed cross 
couplings. Chemoselectivity in cross-couplings is attained by differentiating between sp
2
-
hybridized halides and metalloid cross-coupling partners (Figure 1.1). Specific examples, such as 
Suzuki (boron),
3
 Negishi (zinc),
4
 and Heck
5
 (activated alkene) reactions have met among the 
highest recognition, in receiving the Nobel prize in 2010. Other examples, which are strategically 
analogous utilize different metalloid coupling partners. These include the Kumada
6
 
2 
 
 
 
(magnesium), Stille (tin),
7
 and Hiyama-Denmark
8
 (silicon) cross-couplings which offer 
alternative methods to attain conjugated dienes. These groundbreaking studies have been pivotal 
to the development of synthetic strategies and to the emerging utility of organometallic catalysis 
in total synthesis. 
Figure 1.1. Traditional Palladium Catalyzed Cross-Couplings 
 
 Studies in palladium catalyzed metalloid cross-couplings have asserted unmatched 
selectivity and efficacy to sp
2
-sp
2
 hybridized C-C bond formation. There are some significant 
drawbacks, however, the most evident of which concerns efficiency with regard to waste 
generation.
9,10
 A typical cross-coupling demonstrates stoichiometric loss of both halogen and 
metalloid byproducts (Figure 1.2), generating significant waste streams, which in many cases 
(especially with the stannanes popularized by Stille) have significant toxicity. In addition, many 
of the reagents utilized to prepare vinyl halides or vinyl metalloids are toxic and/or expensive. 
Furthermore, synthesis of these atom-economically frivolous cross-coupling partners often stems 
from alkyne precursors.
11–17
 Significantly greener chemistry is desirable and attainable; 
eliminating steps to synthesize and couple vinyl metalloids with vinyl halides would offer the 
most immediate and logical ways to circumvent the issue of sustainability in metalloid cross-
couplings. Fortunately ruthenium catalysis has emerged, offering an atom-economical alternative 
that rivals palladium catalysis in efficiency and selectivity.
18
The broad field of ruthenium 
3 
 
 
 
catalysis has demonstrated cross-coupling of alkynes and alkenes directly, and has provided 
access to a variety of diene regio- and stereoisomers. 
Figure 1.2. Byproducts Observed from Cross-Couplings 
 
 The diversity in synthetic applications of alkynes and alkenes has been fine-tuned 
through study of a diverse group of ruthenium catalysts.
18,19
 Some of the most useful 
transformations in ruthenium catalysis include enyne metathesis (Figure 1.3, eq. 1),
20
 the 
ruthenium catalyzed Alder-ene reaction (Figure 1.3, eq. 2),
21,22
 cycloisomerization (Figure 1.03, 
eq. 3),
22–24
 and hydrovinylation reactions (Figure 1.3, eq. 4).
25–31
 These highly atom-economical 
reactions selectively effect quick access to several regio- and stereoisomers of dienes. The 
starting materials for these transformations are unactivated alkynes and alkenes, which is a 
significant advantage since no vinyl metalloid or vinyl halide needs to be synthesized as a 
prelude to diene formation. These reaction therefore proceed with significantly improved atom 
economy and far less waste, increasing their appeal as methods to access diene isomers. 
  
 
 
 
 
 
 
 
 
4 
 
 
 
Figure 1.3. Common Ruthenium-Catalyzed Transformations to make Dienes 
 
 The characteristic chemistry exhibited by these ruthenium catalysts has been thoroughly 
documented, and has been a crux in the development of new synthetic methods over the past 25 
years.
18–20
 Ruthenium carbene,
20
 cationic ruthenium complexes,
19,32–34
 and neutral ruthenium 
complexes
29,30
 have been the most privileged catalysts in alkyne functionalizations. However, 
there has been an increasing prevalence of ruthenium hydride catalysis in the last 15 
years.
23,27,28,35–39
 The utility of these less studied catalyst system is not surprising, as ruthenium 
hydrides are familiar intermediates in many ruthenium-catalyzed reactions (as a result of β-
hydride elimination).  
 
 
5 
 
 
 
1.2.1 Ruthenium Hydride Catalysis 
 The catalytic activity of ruthenium hydrides has been reported in several reaction types. 
One notable example by Mori and co-workers documented the ruthenium hydride-catalyzed 
cycloisomerization of enynes to afford exocyclic cyclopentenyl 1,3-dienes
23
 (Scheme 1.2). This 
method provided exclusively one diene stereoisomer, favoring the (E,E)-isomer in two different 
systems, each system differing by the chain length of the starting enyne. Mori also performed 
some intriguing studies on the mechanism of cycloisomerization, for example in the formation of 
diene 1.17 from alkyne 1.16. In the case of 2,6-enynes reversible hydroruthenation of the alkyne 
occurs, affording vinylruthenium species 1.20 (Scheme 1.2, eq. 1). Isomerization of 1.20 was 
proposed to occur via vinylidene intermediate 1.21, placing the ruthenium atom in proximity to 
the acrylate and allowing for migratory insertion, forming complex 1.23. After β-hydride 
elimination, cyclopentene 1.17 is formed as the only detected isomer.  
Scheme 1.2. Ruthenium Hydride Catalyzed Cycloisomerization 
 
6 
 
 
 
 In contrast, cycloisomerization of alkyne 1.24 leads to diene 1.27. The first step of this 
reaction is assumed to be hydroruthenation of the alkyne to afford vinylruthenium 1.25 (Scheme 
1.2, eq. 2). The initial proximity of ruthenium to the acrylate allows for intramolecular migratory 
insertion to yield intermediate 1.26. β-Hydride elimination then occurs, affording exocyclic diene 
1.27 as the only detected isomer. Both mechanisms proceeded through 5-exo-dig cyclizations 
and were amenable to electron rich and electron poor aryl-substituted enynes; the method 
exploited the use of a tightly arranged five-membered ring to govern selectivity. 
 Ruthenium hydrides have also been prevalent as catalysts in hydrovinylation reactions. In 
2009 Plietker and co-workers published the hydrovinylation of internal and terminal alkynes by 
acrylates using a ruthenium hydride catalyst
27
 (Scheme 1.3). Plietker showed that 
hydrovinylation using RuHCl(CO)(PPh3)3 displayed excellent regio- and stereoselectivity with 
unsymmetrical alkynes and a variety of acrylates and acrylamides. 27 Examples were reported in 
the manuscript with up to 98:2 Z:E selectivity and up to 96% yield. The method was highly 
regioselective with terminal alkynes and modestly regioselective with internal alkynes. When 
unsymmetrical alkynes were subjected to catalysis, poor selectivity was often observed except in 
the presence of a directing group (for example a benzylic ether or ester). Though the approach 
had limitations in selectivity, the method was more selective than analogous hydrovinylation 
reactions that used neutral ruthenium complexes, as reported in separate studies by Watanabe 
and Uemura.
29,30
 
Scheme 1.3. Ruthenium Hydride Catalyzed Hydrovinylation of Alkynes 
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 Marciniec and co-workers applied similar ruthenium hydride catalysis to the synthesis of 
borylsilyl-substituted 1,3-butadienes in 2008
28
 (Scheme 1.4). This transformation proceeded 
through the hydrovinylation of alkynes by vinylboronates, achieving up to 90:10 (E,E:E,Z) 
selectivity. The process was amenable to alkynyl silanes and alkyl acetylenes; selectivity was 
best governed by the sterically bulky presence at one end of the starting alkyne. Marciniec 
developed this method for the synthesis of potentially useful dienyl borate synthons; however, 
there was still the need to improve on these methods to afford higher stereoselectivity and a more 
diverse substrate scope. 
Scheme 1.4. Ruthenium Catalyzed Synthesis of 1,3-Butadienes 
 
1.2.2 Hydrosilylation of Alkynes 
 More recently, the ruthenium-catalyzed hydrosilylation of alkynes has been investigated, 
opening a new window of reactivity in ruthenium catalysis and providing easy access to highly 
stereoselective synthesis of E, Z, and geminally substituted vinylsilanes. Hydrosilylation and 
related reactions of note have also been reported with platinum,
40–43
 gold,
44
 and rhodium 
catalysts;
40,45–49
 still, reports in ruthenium catalysis have been most prominent in this emerging 
field.  
 In 2001 Trost and co-workers reported the hydrosilylation of terminal alkynes, catalyzed 
by cationic ruthenium complexes (Scheme 1.5).
33
 This method was amenable to several aliphatic 
and aryl substrates, and was well tolerated by multiple functional groups. The initial report 
described 9 examples in good to excellent yield and was highly selective for geminally 
8 
 
 
 
substituted olefins, achieving up to 20:1 branched to linear (b:l) ratio. When subjected to internal 
alkynes, the method was highly Z-selective, affording 7 substrates from 70-100% yield. This 
selectivity is attributed to an anti-silylruthenation favored over a syn-silylruthenation of the 
internal alkyne. Regioselectivity between unsymmetrical alkynes was also possible in the 
presence of a directing group (alcohols and esters were used in this study). 
Scheme 1.5. E-, Z-, and Geminally Selective Syntheses of Vinylsilanes 
 
 In 2002 the ruthenium catalyzed E-selective reduction of olefins was first reported by 
Trost (Scheme 1.5).
32
 This approach utilized the trans-silylruthenation of internal alkynes to 
afford  Z-vinylsilane intermediate 1.37 and was followed by copper-mediated protodesilylation 
to obtain E-alkenes selectively. Due to ensuing cleavage of the vinylsilane, regioselectivity was 
not an issue for this transformation. Under these mild conditions, 7 examples were described in 
good to excellent yield in the presence of esters, ketones, alcohols, acetals, and alkyl chlorides. 
 While using [RuCl2(p-cymene)]2, Chang reported the highly Z-selective synthesis of 
vinylsilanes (Scheme 1.6).
50
 This approach was compliant with alkenes, arenes, halides, ethers, 
and esters, affording up to 98:2 Z:E selectivity. When directed by an alcohol, the strategy 
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afforded solely the Z-isomer in many cases; however, a reversal in selectivity was observed for 
propargyl and homopropargylic alcohols, yielding geminally substituted vinylsilanes as the 
major products. 
Scheme 1.6. Chang's trans-hydrosilylation of Alkynes 
 
 In related work, Denmark and co-workers also reported on the ruthenium catalyzed 
intramolecular trans-hydrosilylation of internal alkynes in 2002 (Scheme 1.7).
51
 The observed 5-
membered oxasilacyclic oligomer 1.42 could be further functionalized by Hiyama-Denmark 
cross-couplings with various aryl iodides. This approach was highly selective for the Z-isomer of 
the trisubstituted homoallylic alcohol, affording 10 substrates in modest yield with high 
stereoselectivity. Only alkyl substituted alkynes were explored using this hydrosilylation method. 
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Scheme 1.7. Denmark's Intramolecular Hydrosilylation of Alkynes 
 
 In 2003, Denmark extended this methodology to include alkyl-substituted propargyl 
alcohols, exploiting a bis-silyl ether tether (like 1.45, Scheme 1.7).
42
 Subjecting the tethered 
propargyl alcohols to analogous reaction conditions as previously reported proceeded smoothly 
to yield disiloxacyclic oligomer 1.48; ensuing Hiyama-Denmark conditions yielded the highly E-
selective trisubstituted allylic alcohol. It was also found that the Z-isomer could be accessed 
selectively by the hydrosilylation of alkyne 1.45, using platinum divinyldimethylsiloxane 
(Pt(DVDS)), followed by Hiyama-Denmark protocol. This method was completely Z-selective 
and was amenable to 5 reported substrates in good yield. 
 The significant achievements presented by Trost, Chang, and Denmark laid the 
groundwork for further study in the utility of silicon-ruthenium chemistry and the 
functionalization of alkynes. Though these methods were highly selective, they were limited to 
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making di- and trisubstituted olefins, often requiring a directing group to attain adequate 
selectivity. More recently, Clark and co-workers extended this work to include the 
intramolecular silylvinylation of alkynes by various coupling partners.
35,37–39,52
 This approach 
exploited the unique reactivity of ruthenium hydride catalysts and the efficient use of a 
vinylsilicon tether in order to stereo- and regioselectively afford multisubstituted conjugated 
dienes. 
1.2.3 Ruthenium Hydride Catalyzed Silylvinylation of Internal Alkynes 
 Literature precedence in hydrosilylation reactions of alkynes and ruthenium hydride 
catalysis spurred investigation toward the ruthenium hydride catalyzed silylvinylation of alkynes. 
Clark et al. reported the ruthenium hydride catalyzed silylvinylation of internal alkynes with 
acrylate,
52
 vinyl boronate,
39
 and ethylene coupling partners (Scheme 1.8).
35,38
 This approach 
exploited high regio- and stereoselectivity through intramolecular silylruthenation of the alkyne 
and tandem cross-coupling of the activated alkene substrates. Careful screening showed that 
ruthenium complex Ru-I (RuHCl(CO)(PCy3)2) provided the most efficient catalytic activity 
when cross-coupling alkynes with acrylates and vinyl boronates. The unique approach was 
amenable to aryl- and alkyl-substituted alkynes, with various acrylate and vinyl boronate 
coupling partners, as demonstrated in 46 substrates between 45-92% isolated yield. 
Scheme 1.8. Clark's Silylvinylation of Alkynes with Acrylates and Vinyl Boronates 
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 The mechanism is thought first to proceed by phosphine dissociation to afford a 14-
electron ruthenium complex 1.53 (Scheme 1.9), as has been reported for ruthenium metathesis 
catalysts.
53,54
 The initial 16-electron complex Ru-I is not thought to be the active catalyst, due to 
reaction retardation when tricyclohexylphosphine is added. The lack of reactivity of 
RuHCl(CO)(PPh3)3 (an 18-electron ruthenium hydride complex) further attests that the 16-
electron ruthenium hydride is not the active catalyst. Moreover, dissociation of 2 phosphine 
ligands from an 18-electron complexes would be unlikely.  
 Following ligand dissociation, hydroruthenation of vinylsilane 1.50 ensues to attain 1.54. 
Interestingly hydroruthenation has shown to be selective for the vinylsilane over the alkyne, 
acrylate, and vinyl boronate under optimized conditions. Given the reversibility of 
hydroruthenation, selectivity is probably due to the entropic gain from ethylene release, and to 
the low bond dissociation energy of the silicon-carbon bond. After β-silylelimination and release 
of ethylene gas, ruthenium species 1.55 coordinates to the alkyne and cis-silylruthenation of the 
alkyne occurs. Although trans-silylruthenation has been reported by Trost
34
 and Denmark,
42,51
 it 
is believed that cis-silylruthenation occurs first due to a mixture of products (E and Z alkenes) 
being observed in aliphatic substrates (where R
2
 = alkyl). The vinylruthenium species 1.56 
isomerizes to the more thermodynamically stable trans-silylvinylated intermediate 1.57 before 
insertion of the vinyl coupling partner. After β-hydride elimination in intermediate 1.58, the 
active ruthenium hydride is restored and diene 1.52 is obtained. 
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Scheme 1.9: Mechanistic Hypothesis 
 
 During optimization of the silylvinylation reaction, other ruthenium hydrides were also 
screened. Surprisingly, Ru-II (RuHCl(CO)(PPh3)(SIMes)) exhibited a significantly different 
reaction pathway. Alkyne 1.50 was converted to the expected product 1.52 in only 42% by Ru-
II. Furthermore, vinylated diene 1.60 was observed as the major product, incorporating ethylene 
instead of the acrylate (Scheme 1.10). After further investigation of this serendipitous result, 
attempts were taken to synthesize 1.60 selectively.  
Scheme 1.10. New Reaction Discovered using Ru-II 
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 Though it was clear that the reaction could proceed without acrylate, coupling with 
adventitious ethylene only reached 70% conversion of 1.61 after heating at 85 °C for 8 hours in a 
sealed tube (Scheme 1.11). These conditions yielded a mixture of the desired vinylated product 
1.62 (solely as the Z-isomer) and previously unobserved cycloisomerized product 1.63. Positing 
that catalyst decomposition was responsible for the unsatisfactory yields, a series of additives 
were screened to increase the stability of the sensitive ruthenium intermediates in the reaction; 
this screen included olefins that could coordinate to ruthenium without exhibiting migratory 
insertion within the catalytic cycle. Logically, under ethylene atmosphere the reaction proceeded 
very well, reaching full conversion with an 85:5 ratio of 1.62:1.63. Unfortunately, an inseparable 
mixture (10:1 Z:E) of isomers was observed in 1.62. Several other olefins were screened, 
including acrylamides and other electron-deficient alkenes. The best results were obtained with 
catalytic amounts of methyl vinyl ketone as a transient protecting group, allowing full conversion 
with an 85:15 ratio of 1.62:1.63, solely observed as the Z-isomer. This method was evaluated 
through 20 substrates, ranging between 53-80% yield. Substitution at the alkyne terminus was 
tolerated with both electron rich and poor arenes. Propargyl and homopropargyl substitution 
were also amenable to the scope of the reaction. Still, terminal alkynes and alkyl-substituted 
alkynes were out of reach in this strategy toward conjugated dienes. 
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Scheme 1.11. Selected Entries for Optimization using Ru-II 
 
 Though streamlined conditions to synthesize ethylene-transposed dienes were attained, 
using ethylene as an additive was still an intriguing venture, despite that it previously gave a 
mixture of stereoisomers. Under optimized conditions, 15 substrates were isolated after reaction 
under 1 atmosphere of ethylene gas between 64-82% yield, and up to 28:1 Z:E ratio (Scheme 
1.12, eq. 1). The reaction was most selective for internal alkynes containing aryl substitution.  
Scheme 1.12. Silylvinylation of Internal Alkynes under Ethylene Atmosphere 
 
 At 1 atmosphere of ethylene, alkyl-substituted alkynes formed cycloisomerization 
product 1.67 exclusively (Scheme 1.12, eq. 2). This issue was circumvented by increasing the 
concentration of ethylene gas by performing them under 80 psi (Scheme 1.13, eq. 1). It was 
speculated that increased concentration of ethylene would decrease the rate of hydroruthenation 
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of the alkyne, eliminating the formation of cycloisomerization byproduct. Interestingly, a 
reversal of selectivity was observed with methyl-substituted alkynes in up to a 3:1 ratio of 
1.69:1.70. Under the same conditions with other alkyl and aryl substituents, the change in 
selectivity was not as drastic. For example, silylvinylation of alkyne 1.71 under ethylene at 80 
psi only afforded a 1.7:1 ratio of dienes 1.72:1.73.  
Scheme 1.13. Silylvinylation of Internal Alkynes under Ethylene Atmosphere (80 psi) 
 
 Control and reversal of Z:E selectivity was unique to ethylene as a cross coupling partner 
(as compared to coupling with acrylates and vinyl boronates). These findings prompted further 
study of silylvinylation of terminal alkynes by ethylene. Silylvinylation of terminal alkynes was 
always a challenge, never showing selectivity with vinyl boronates or acrylates. However, using 
superstoichiometric amounts of ethylene (at high pressure) looked like a promising area for 
further exploration. 
1.3 This Work: Silylvinylation of Terminal Alkynes 
 Several objectives were examined to investigate the title reaction pathway. 
Demonstrating silylvinylation of terminal alkynes was of highest importance, as terminal alkynes 
were incompatible to silylvinylation of alkynes by previously reported coupling partners (such as 
acrylates and vinyl boronates). In addition, the opportunity this transformation had to access the 
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opposite diene regioisomer as previous studies had showed was at hand. The utility of this 
transformation would be further evaluated by its amenability in a variety of substrates, including 
those with alkyl and aryl substitution to form 5- and 6-membered rings. Initial studies by Dr. 
Robert J. Wilson displayed positive results in a variety of solvents (Table 1.1).
37,55
 After 24 
hours, performing the silylvinylation of 1.74a in toluene, DCE, and 1,4-dioxane under ethylene 
atmosphere at 80 psi yielded modest results (Table 1.1, entries 1-3). The reaction in THF took 
less time and proceeded at a lower temperature, yielding 60% of 1.75a after 18 hours (Table 1.1, 
entry 4). Reaction in MeTHF failed to reach full conversion and only yielded 40%, even at 110 
°C (Table 1.1, entry 5). Increasing the temperature to 120 °C in THF showed no increase in yield 
(Table 1.1, entry 6). However, when increasing the temperature to 110 °C in CPME and dioxane 
(Table 1.1, entries 7 and 8), the crude yield increased to 65% and 63%, respectively. Performing 
the reaction at 110 °C also led to a quicker reaction time.  
Table 1.1. Selected Entries for Solvent Optimization 
 
Entry
a 
Solvent
 Temp. (°C) Time (h) Conversion
d
 (%)
 
Yield
d
 (%) 
1
b 
PhMe 80 24 100 40 
2
b 
DCE 80 24 100 45 
3
b 
Dioxane 80 24 100 54 
4
b 
THF 60 18 100 60 
5
c 
MeTHF 110 0.5 60 40 
6
c 
THF 120 1 100 60 
7
c 
CPME 110 0.5 100 65 
8
c 
Dioxane 110 0.5 100 63 
 
a: Reactions conducted by Robert Wilson; b: reactions conducted in solvent (0.2M); c: reactions conducted in 
solvent (0.1M); d: determined by 
1
H NMR using mesitylene internal standard. 
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 Table 1.2. Temperature and Catalyst Screen 
 
 a: reactions conducted at 0.1 M; b: reactions conducted by Robert Wilson; c: reactions conducted by Alex 
Dixon; d: determined by 
1
H NMR using mesitylene internal standard. 
 After displaying encouraging results in CPME and dioxane, a catalyst screen was 
investigated in each solvent. Ru-I, Ru-III, and Ru-IV showed poor reactivity in CPME (Table 
1.2, entries 1, 3, 4) and dioxane (Table 1.2, entries 6, 8, 9). Ru-V displayed promising reactivity 
in dioxane, affording 67% crude yield after 0.5 hours at 110 °C (Table 1.2, entry 10). Ruthenium 
hydride catalysts have been reported to isomerize 1,3-dienes
36,38,39,52
 and polymerize alkenes
40–42
 
at high temperatures. Therefore, efforts to decrease the reaction temperature were investigated to 
attain higher crude yields. In the presence of Ru-II, decreasing the temperature to 100 °C in 
CPME (Table 1.2, entry 11) or dioxane (Table 1.2, entry 12) significantly increased the crude 
yield of these transformations. In contrast, in the presence of Ru-V at 100 °C, the increase in 
Entry
a 
Catalyst Solvent Temp (°C) Time Conversion
d
 (%) Yield
d
 (%) 
1
b 
Ru-I CPME 110 0.5 80 21 
2
b 
Ru-II CPME 110 0.5 100 65 
3
b 
Ru-III CPME 110 0.5 90 52 
4
b 
Ru-IV CPME 110 0.5 100 44 
5
b 
Ru-V CPME 110 0.5 100 55 
6
c 
Ru-I Dioxane 110 0.5 58 19 
7
c
 Ru-II Dioxane 110 0.5 100 58 
8
c
 Ru-III Dioxane 110 0.5 70 42 
9
c
 Ru-IV Dioxane 110 0.5 100 50 
10
c
 Ru-V Dioxane 110 0.5 100 67 
11
c
 Ru-II CPME 100 0.5 100 73 
12
c
 Ru-II Dioxane 100 0.5 100 75 
13
c
 Ru-V Dioxane 100 0.5 100 69 
14
c
 Ru-II CPME 90 0.5 >96 76 
15
c
 Ru-II Dioxane 90 0.5 >93 73 
16
c
 Ru-II CPME 80 1 100 81 
17
c
 Ru-II CPME 70 2 100 79 
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yield was marginal (Table 1.2, entry 13). This finding led us to use Ru-II as our best catalyst for 
the remainder of optimization. Incremental decrease in reaction temperature slowed the reaction 
time (Table 1.2, entries 14-17) but increased yield after reaching full conversion. After careful 
monitoring of reaction temperature it was found that CPME was the most efficient solvent for 
catalysis after one hour at 80 °C, obtaining 81% crude yield by mesitylene internal standard 
(Table 1.2, entry 16). Further decrease of reaction temperature to 70 °C had little effect on the 
crude yield, even after 2 hours of reaction time (Table 1.2, entry 17). 
Table 1.3: Substrate Scope 
 
a
 highest isolated yield by Robert Wilson; 
b
 characterized by Robert Wilson; 
c
 highest isolated yield by Alex Dixon; 
d
 characterized by Alex Dixon 
 With optimized conditions in hand, the substrate scope of the silylvinylation was 
investigated (Table 1.3). These studies resulted in a 58% isolated yield of biaryl substrate 1.75a 
obtained by Robert Wilson. The instability of these dienes to flash column chromatography on 
silica gel was somewhat problematic and affected the isolated yields, which were appreciably 
lower than the crude yields observed by 
1
H NMR. Increased substitution at the propargyl (1.75b 
and 1.75c) and homopropargyl (1.75d and 1.75e) positions tended to enhance stability of the 
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dienes on silica.  We believe this is the case because the resulting steric hindrance prevents the 
formation of unwanted elimination byproducts.  
 Substrates 1.75b and 1.75c were isolated in 75% and 82%, respectively by Robert 
Wilson. Cyclohexyl substituted 1.75d was isolated in 55% yield and substrate 1.75e was isolated 
in 60% yield. Substrates with less substitution at the propargyl and homopropargyl positions 
were less stable and lower isolated yields were often observed. 4-Methyl substituted and 4-chloro 
substituted (1.75f and 1.75g) were isolated in 45% and 38% yield, respectively. n-Pentyl 
substituted 1.75h was isolated cleanly, but was much more volatile than the other substrates. The 
six-membered oxasilacycle 1.75i was obtained in 58% yield, albeit as an inseparable mixture of 
isomers as a 9.1:1 Z:E ratio. The 2-furyl substituted substrate 1.75j was isolated in 18% yield and 
was extremely unstable on silica. The stereoconfiguration of the Z-alkene was determined by 
NOESY for dienes 1.75a, 1.75b, 1.75c, 1.75d, and 1.75i; spectra are included in chapter 6.1. 
 Though further functionalization of silanes 1.75a-1.75j was not explored, previous work 
by Clark and co-workers showed that these vinylsilanes can be useful functional appendages. 
The silicon moiety of dienyl acrylate 1.76 could be cleaved with TBAF in THF to yield 
homoallylic diene 1.77 (Scheme 1.14, eq. 1).
52
 Acrylate 1.76 could also be converted to vinyl 
iodide 1.78 in the presence of iodine monochloride at -78 °C (Scheme 1.14, eq. 1). No 
stereochemical deterioration was detected in either of these cases. Negishi, Suzuki, Sonagashira, 
and a carbonylative coupling were carried out with the vinyl iodide, for even further 
derivatization.
52
 In another report an aryl group was installed at the alkene terminus by an 
oxidative Heck reaction of 1.79 (Scheme 1.14, eq. 2).
35
 The transformation was trans-selective, 
and the silicon moiety remained intact through the mild procedure. Finally, methyllithium-
mediated removal of the dimethylsilyl group of 1.81 was taken to break the O–Si bond (Scheme 
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1.14, eq. 3), while silicon remained bound to carbon. Diene 1.81 was also tolerant to alkene 
metathesis using Hoveyda-Grubbs Gen II (HG-II) catalyst.
56,57
 These selected examples from 
reported derivatization methods functionalized the dienes without stereochemical deterioration of 
the diene, or diene migration. Through diversity of functional group interconversions and the 
rapid synthesis of complex molecules, these investigations greatly expanded the scope for the 
synthesis of conjugated dienes and greatly strengthened the utility of ruthenium chemistry. 
Scheme 1.14. Selected Examples of Silane Derivatization  
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1.4 Conclusion 
 Efforts toward streamlining conditions to regio- and stereoselectively afford conjugated 
dienes were established in the first silylvinylation of terminal alkynes. As terminal alkynes were 
previously intolerant to silylvinylation by acrylates and vinyl boronates, the development of this 
ruthenium hydride catalyzed method was crucial to the outlook of our approach. The Z-selective 
intramolecular ruthenium hydride catalyzed synthesis of conjugated 1,3-dienes was 
demonstrated, proceeding via 5-exo-dig cyclizations. The new method exploited the use of a 
vinylsilicon tether, displaying high selectivity within the tightly prearranged system. This 
approach was amenable to several substrates, including alkyl and aryl substituted homopropargyl 
vinylsilanes, to make 5- and 6- membered oxasilacycles. This method represents an atom 
economical route to complex 1,1-disubstituted dienes, which are useful precursors for a variety 
of complex molecules. 
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1.5 Experimental Section 
General Procedures: Unless otherwise indicated, all reactions were conducted in oven (140 °C) 
or flame-dried glassware using distilled and degassed solvents under positive pressure of dry 
argon with standard Schlenk techniques. All air-sensitive reagents were stored in an MBraun 
labmaster glovebox containing dry argon gas. Dry tetrahydrofuran (THF), toluene, acetonitrile 
(CH3CN), diethyl ether (Et2O) and methylene chloride (DCM) were obtained by passing 
commercially available pre-dried, oxygen-free formulations through two activated alumina 
columns using an MBraun MB-SPS solvent purification system. Stainless steel syringes or 
cannulae that had been oven-dried (140 °C) and cooled under an argon atmosphere or in a 
desiccator were used to transfer air- and moisture-sensitive liquids. Yields refer to 
chromatographically and spectroscopically (
1
H NMR) homogeneous materials, unless otherwise 
stated.  Reactions were monitored by thin-layer chromatography (TLC) carried out on pre-coated 
glass plates of silica gel (0.25 mm) 60 F254 from EMD Chemicals Inc. using the indicated solvent 
system. Visualization was accomplished with ultraviolet light (UV 254 nm), or by shaking the 
plate in a sealed jar containing silica gel and Iodine.  Alternatively, plates were treated with one 
of the following solutions (this was accomplished by holding the edge of the TLC plate with 
forceps or tweezers and immersing the plate into a wide-mouth jar containing the desired 
staining solution) and carefully heating with a hot-air gun (450 °C) for approximately 1-2 min 
(NOTE: excess stain was removed by resting the TLC on a paper towel prior to heating): 10% 
phosphomolybdic acid in ethanol, 1% potassium permanganate/7% potassium carbonate/0.5% 
sodium hydroxide aqueous solution, and/or anisaldehyde in ethanol with 10% sulfuric acid.  
Flash column chromatography was performed using Silia Flash® P60 silica gel (40-63 μm) from 
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Silicycle.  All work-up and purification procedures were carried out with reagent grades solvents 
(purchased from VWR) in air. 
Instrumentation: Infrared (IR) spectra were recorded on a Thermo Nicolet IR-100 spectrometer, 
νmax in cm
-1
, and were obtained from samples prepared as thin films between NaCl plates. 
1
H 
NMR spectra were recorded on Bruker Avance DPX-300 (300 MHz) spectrometer and Bruker 
Avance III HD (400 MHz) spectrometer with CryoProbe Prodigy. Chemical shifts are reported in 
parts per million (ppm) and are calibrated using residual undeuterated solvent as an internal 
reference (CDCl3: δ 7.26 ppm; CD3OD: δ 3.31 ppm; (CD3)2SO: 2.50 ppm). Data are reported as 
follows: chemical shift, multiplicity, coupling constants (Hz), and integration. The following 
abbreviations or combinations thereof were used to explain the multiplicities: s = singlet, d = 
doublet, t = triplet, q = quartet, pent = pentet, sext = sextet, sept = septet, m = multiplet, br = 
broad. 
13
C NMR spectra were recorded on Bruker Avance DPX-300 (75 MHz) spectrometer and 
Bruker Avance III HD (100 MHz) spectrometer with CryoProbe Prodigy with complete proton 
decoupling. Chemical shifts are reported in ppm and are calibrated using residual undeuterated 
solvent as an internal reference (CDCl3: δ 77.16 ppm; CD3OD: δ 49.00 ppm). 
19
F NMR spectra 
were recorded on a Bruker Avance DPX-300 (282.4 MHz) spectrometer. Chemical shifts are 
reported in ppm and are calibrated using solvent as an external reference (CFCl3: δ 0.00 ppm). 
Melting points (m.p.) are uncorrected and were recorded using an Electrothermal Mel-Temp® 
melting point apparatus. Elemental Analyses were performed on a Costech ECS 4010 elemental 
analyzer with a thermal conductivity detector and 2 meter GC column maintained at 65°C. GC 
mass spectra were obtained on a ThermoFinnigan POLARIS Q Ion Trap with TRACE GC/MS. 
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Preparation of Silicon Tethered Terminal Alkynes: 
 
Preparation of precursors to 1.74a, 1.74d-1.74h, 1.75j: Alcohols 1.86a, 1.86d-h, and 1.86j were 
prepared following a previously employed literature procedure.
35
 Silylation of the resulting 
homopropargyl alcohols yielded vinylsilanes 1.74a-j. 
 
Preparation of precursor to 1.74i was carried out via Sonogashira reaction of 1.88 and 1.89,
58
 
followed by silylation of 1.86i. 
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(S)-4-benzyl-3-((2R,3S)-3-hydroxy)-2-methyl-3-phenylpropanoyl)oxazolidin-
2-one: To a flame dried 250 mL round bottom flask equipped with a stir bar was 
added oxazolidinone A (7.0 g, 30 mmol) and ethyl acetate (100 mL). To the stirred solution was 
added MgCl2 (570 mg, 6 mmol), triethylamine (5.7 mL, 45 mmol), and benzaldehyde (3.66 mL, 
36 mmol). The reaction was stirred overnight then the yellow solution was filtered through a 
plug of silica (5 cm x 5 cm) with diethyl ether (500 mL). The volatiles were removed in vacuo 
followed by the addition of methanol (50 mL) and 3 drops of trifluoroacetic acid. The solution 
was stirred for 1 h; a white precipitate formed, was filtered and washed with methanol (50 mL). 
The white solid was dried to obtain 8.28 g (81%). This material was used directly in the next step 
without further purification. As compared to literature data
59
 
1
H NMR (300 MHz, CDCl3): δ = 7.45-7.28 (m, 8H), 7.17-7.14 (m , 2H), 4.82 (d, J = 7.8 Hz, 
1H), 4.73-4.65 (m, 1H), 4.39-4.30 (m, 1H), 4.22-4.12 (m, 2H), 3.19 (dd, J = 13.5, 3.3 Hz, 1H), 
2.67 (dd, J = 13.5, 9.5 Hz, 1H), 1.11 (d, J = 6.6 Hz, 3H). 
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(S)-4-Benzyl-3-((2R,3S)-3-((tert-butyldimethylsilyl)oxy)-2-methyl-3-
phenylpropanoyl)oxazolidin-2-one: To a flame dried 250 mL round bottom 
flask equipped with a magnetic stir bar and cooled under Ar(g) , was added the 
aldol adduct (8.28 g, 24.4 mmol), CH2Cl2 (100 mL) , and 2,6-lutidine (3.4 mL, 29 mmol) with 
stirring. Once homogenous the solution was cooled to -45 °C in a dry ice-acetone bath. TBSOTf 
(6.75 mL, 29.3 mmol) was added dropwise via syringe and the solution was allowed to warm to 
r.t. The reaction was stirred for 30 minutes and was judged complete by TLC. Hexanes (150 mL) 
was added and the organic layer was washed with water (2 x 100 mL), and Brine (2 x 25 mL). 
The organic layer was dried with sodium sulfate, filtered, and concentrated in vacuo to afford the 
crude TBS protected product (quant. 11.07 g). This material was used directly in the next step 
without further purification. 
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To a flame dried 500 mL 3 neck round bottom flask equipped with an addition 
funnel and a magnetic stir bar was added THF (200 mL) and ethanethiol (6.0 mL, 
83 mmol) and cooled to -78 °C in a dry ice-acetone bath. To the cooled solution was added n-
BuLi (2.5 M in hexanes, 23 mL, 58 mmol) dropwise via addition funnel. After complete 
addition, the milky white solution was warmed to 0 °C and stirred for 1 h. The crude TBS 
protected aldol B (11.07 g, 24.4 mmol) was dissolved in THF (50 mL) and added slowly to the 
stirred solution. The reaction was judged complete by TLC at 2 h and 200 mL of ethyl 
acetate:hexanes (1:1) was added. The organics were washed with 1M NaOH (3 x 100 mL) and 
brine (3 x 100 mL), dried with MgSO4, filtered and concentrated in vacuo. The sticky solid was 
dissolved in CH2Cl2 (20 mL) and hexanes (150 mL) were added to precipitate the oxazolidinone. 
The solid was filtered and washed with hexanes (100 mL). The hexanes were concentrated to 
afford the thioester C (6.5 g, 79% over 2 steps) which was sufficiently pure to continue to the 
next step.  
TLC Rf (20% ethyl acetate/hexanes) = 0.89 
1
H NMR (400 MHz, CDCl3) δ = 7.33-7.24 (m, 5H), 4.76 (d, J = 9.2 Hz, 1H), 2.94-2.86 (m, 3H), 
1.28 (t, J = 7.4 Hz, 3H), 0.82 (d, J = 7.0 Hz, 3H), 0.80 (s, 9H), -0.03 (s, 3H), -0.31 (s, 3H). 
 13
C NMR (100 MHz, CDCl3) δ = 202.9, 142.6, 128.3, 127.9, 127.2, 77.7, 57.4, 25.8, 23.4, 18.2, 
14.9, 14.8, -4.6, -5.4. 
Anal. calcd. for C18H30O2S: C, 63.85; H, 8.93; found C 63.61; H, 9.02 
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To a 50 mL round bottom flask equipped with a magnetic stir bar was added 5% Pd/C 
(692 mg, 0.325 mmol) then thioester C (1.10 g, 3.25 mmol) in acetone (7 mL). To the 
stirred solution was added triethylsilane (1.56 mL, 9.75 mmol) dropwise and the mixture was 
stirred for 7 h. The reaction was filtered through a pad of celite with acetone (60 mL) and the 
volatiles were removed in vacuo to afford a light yellow oil (0.875 g, 96%). 
*
Pd(OAc)2 can be 
used and the reaction is complete in 0.5 h. This compound was prepared previously and matched 
the literature data.
60
 
TLC Rf (10% ether/hexanes) = 0.54 
1
H NMR (400 MHz, CDCl3) δ = 9.81 (d, J = 2.7 Hz, 1H), 7.36-7.25 (m, 5H), 4.76 (d, J = 7.6 Hz, 
1H), 2.68 (pd, J = 7.0 Hz, 2.7 Hz, 1H), 0.88 (d, J = 6.7 Hz, 3H), 0.84 (s, 9H), 0.01 (s, 3H), -0.25 
(s, 3H) 
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To a flame dried 100 mL round bottom flask equipped with a magnetic stir bar and 
cooled under Ar(g) , was added THF (5 mL) and di-isopropylamine (0.55 mL, 3.86 
mmol). The solution was cooled to -78 °C then n-BuLi (2.44M in hexanes, 1.58 mL, 3.86 mmol) 
was added dropwise. The mixture was stirred for 30 minutes followed by the addition of 
TMSCH2N2 (2.0M in hexanes, 1.93 mL, 3.86 mmol) dropwise. After 30 minutes at -78 °C, 
aldehyde D (0.833 g, 3.0 mmol) in THF (5 mL) was added dropwise and stirred for 1h then 
warmed to rt and quenched with water (30 mL). The aqueous layer was extracted with diethyl 
ether (3 x 20 mL), dried with MgSO4, filtered and concentrated in vacuo. The crude oil was 
applied to a silica gel column (2.5 x 15 cm) and eluted with 5% ethyl ether in hexanes to afford 
703 mg (86%) of clear oil.  
TLC Rf (10% ethyl acetate/hexanes) = 0.94 
1
H NMR (300 MHz, CDCl3) δ = 7.35-7.25 (m, 5H), 4.60 (d, J = 6.0 Hz, 1H), 2.71 (pd, J = 7.0 
Hz, 2.4 Hz, 1H), 2.06 (d, J = 2.7 Hz, 1H), 1.01 (d, J = 6.7 Hz, 3H), 0.87 (s, 9H), 0.05 (s, 3H),  
-0.15 (s, 3H) 
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 (1S,2S)-2-Methyl-1-phenylbut-3-yn-1-ol: To a 20 mL scintillation vial equipped 
with a magnetic stir bar was added the TBS protected alkyne (400 mg, 1.46 mmol), 
MeCN (3.0 mL, 0.5M), and KF·2H2O (192 mg, 2.04 mmol). To the stirred suspension was added 
trimethylchlorosilane (0.28 mL, 2.19 mmol) dropwise and the yellow solution as stirred for 3 h. 
The reaction was quenched by the dropwise addition of saturated aqueous NaHCO3 (4 mL), 
extracted with CH2Cl2 (2 x 30 mL) and the combined organic layers were washed with H2O (40 
mL) and brine (20 mL). The organics were dried with MgSO4, filtered and concentrated in 
vacuo. The crude oil was applied to a silica gel column (2.5 x 15 cm) and eluted with 25% ethyl 
acetate in hexanes to afford 161 mg (69%) of  E as a clear oil. 
TLC Rf (10% ether/hexanes) = 0.15 
1
H NMR (400 MHz, CDCl3) δ = 7.38-7.29 (m, 5H), 4.51 (d, J = 7.1 Hz, 1H), 2.80 (pd, J = 7.1, 
2.4 Hz 1H), 2.21 (d, J = 2.5 Hz, 1H), 1.10 (d, J = 7.0 Hz, 3H) 
 13
C NMR (100 MHz, CDCl3) δ = 141.4, 128.5, 128.2, 126.8, 85.6, 77.6, 71.5, 35.2, 17.5 
Optical Rotation: c = 0.960 αD = -74.8628 
FT-IR (NaCl, thin film) ν = 3568, 3296, 2979, 2879, 1453, 1173, 701 cm-1 
Anal. calcd. for C11H12O: C, 82.24; H, 8.63; found C 82.13; H, 8.49 
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 ((1-1([1,1’-Biphenyl]-4-yl)but-3-yn-1-yl)oxy)dimethyl(vinyl)silane (1.74a): 
To a flame-dried 100 mL round bottom flask was added imidazole (1.00 g, 
14.76 mmol) and DMAP (0.181 g, 1.48 mmol), dichloromethane (40 mL), and 
alcohol 1.86a (1.30 g, 7.38 mmol). The mixture was allowed to stir until complete dissolution 
and then cooled to 0 °C in an ice-water bath. Vinyldimethylchlorosilane (0.93 mL, 6.71 mmol) 
was then added dropwise. After addition, the reaction was allowed to warm to room temperature. 
After 7 h, the reaction was complete as judged by TLC analysis and quenched with the addition 
of sat. 40 mL aq NH4Cl. The organic layer was dried with Na2SO4 and concentrated in vacuo to 
yield a yellow oil. The crude product was purified on a silica gel column using 250 mL of 10:1 
hexanes:ether to give the product (1.63 g, 79%) as a yellow oil. 
TLC Rf (10% EtOAc / Hexanes) = 0.39 
1
H NMR (400 MHz, CDCl
3
) δ= 7.62-7.59 (m, 2H), 7.58-7.55 (m, 2H), 7.45-7.41 (m, 4H), 7.36-
7.32 (m, 1H), 6.11 (dd, J = 20.0 Hz, 14.8 Hz, 1H), 6.00 (dd, J = 14.8 Hz, 4.4 Hz, 1H), 5.77 (dd, J 
= 20.0 Hz, 4.4 Hz, 1H), 4.89 (t, J = 6.4 Hz, 1H), 2.66 (ddd, J = 16.4, 6.8, 2.8 Hz, 1H), 2.57 (ddd, 
J=16.6, 6.1, 2.7 Hz, 1H),  1.99 (t, J = 2.8 Hz, 1H), 0.20 (s, 3H), 0.15 (s, 3H). 
13
C NMR (100 MHz, CDCl
3
) δ= 142.7, 141.0, 140.5, 137.6, 133.6, 128.9, 127.3, 127.2, 127.0, 
126.5, 81.6, 73.5, 70.3, 30.7, -1.32, -1.48. 
FT-IR (NaCl, thin film) ν = 3305, 2121 cm-1. 
Anal. Calc. for C20H22OSi: C, 78.38; H, 7.24; Found: C, 78.36; H, 7.14 
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Dimethyl(((1S,2R)-2-methyl-1-phenylbut-3-yn-1-yl)oxy)(vinyl)silane (1.74b): To 
a flame-dried 100 mL round bottom flask was added imidazole (0.850 g, 12.48 
mmol) and DMAP (0.153 g, 1.25 mmol), dichloromethane (40 mL), and alcohol 
1.86b
39
 (1.00 g, 6.24 mmol). The mixture was allowed to stir until complete dissolution and then 
cooled to 0 °C in an ice-water bath. Vinyldimethylchlorosilane (1.3 mL, 9.36 mmol) was then 
added neat, via syringe, dropwise. After addition the reaction mixture was allowed to warm to 
room temperature. After 15 minutes, the reaction was complete as judged by TLC analysis and 
quenched with the addition of 40 mL sat. aq NH4Cl. The aqueous phase was extracted with 
dichloromethane (3 x 20 mL), and the combined organics were washed with brine (40 mL), dried 
with MgSO4, concentrated in vacuo to give a slightly colored oil. The crude product was purified 
on a silica gel column (2.5 x 12 cm) using 100 mL hexanes, 300 mL 99:1 hexanes:ether, 100 mL 
30:1 hexanes:ether to give the product (1.28 g, 84%) as a colorless oil. 
TLC Rf (10% Ether / Hexanes) = 0.75 
1
H NMR (400 MHz, CDCl
3
) δ= 7.29 (m, 5H), 6.04 (dd, J = 19.6, 14.8 Hz, 1H), 5.95 (dd, J = 
14.8, 4.4 Hz, 1H), 5.71 (dd, J = 20.0, 4.8 Hz, 1H), 4.59 (d, J = 6.8 Hz, 1H), 2.70 (pd, J = 7.2, 2.8 
Hz, 1H), 1.99 (d, J = 2.4 Hz, 1H), 1.19 (d, J = 7.2 Hz, 3H), 0.12 (s, 3H), 0.07 (s, 3H). 
13
C NMR (100 MHz, CDCl
3
) δ= 142.9, 137.7, 133.3, 128.0, 127.6, 127.1, 86.8, 78.0, 70.4, 35.4, 
16.9, -1.31, -1.48. 
FT-IR (NaCl, thin film) ν = 3310, 2114 cm-1. 
[α]D
23λ 589 nm (c 0.51, CHCl3) = -47.3° 
Anal. Calc. for C15H20OSi: C, 73.71; H, 8.25; Found: C, 73.74; H, 8.19 
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Dimethyl(((1S,2S)-2-methyl-1-phenylbut-3-yn-1-yl)oxy)(vinyl)silane (1.74c): To 
a flame-dried 50 mL round bottom flask was added imidazole (150 mg, 2.2 mmol) 
and DMAP (30 mg, 0.22 mmol), dichloromethane (15 mL), and alcohol 1.86c (161 
mg, 1.01 mmol). The mixture was allowed to stir until complete dissolution and then cooled to 0 
°C in an ice-water bath. Vinyl dimethyl chlorosilane (0.21 mL, 1.51 mmol) was then added neat, 
via syringe, dropwise. After addition, the reaction mixture was allowed to warm to room 
temperature. After 3 h, the reaction was complete as judged by TLC analysis and quenched with 
the addition of 40 mL sat. aq NH4Cl. The organic layer was dried with MgSO4 and concentrated 
in vacuo to yield a yellow oil. The crude product was purified on a silica gel column eluting with 
1% ethyl ether in hexanes to afford the product (219 mg, 89%) as a colorless oil. 
TLC Rf (10% ether/hexanes) = 0.79 
1
H NMR (400 MHz, CDCl3) δ = 7.33-7.25 (m, 5H), 6.05 (dd, J = 19.6, 14.8 Hz, 1H), 5.95 (dd, J 
= 14.8, 4.4 Hz, 1H), 5.72 (dd, J = 19.6, 4.4 Hz, 1H), 4.60 (d, J = 6.4 Hz, 1H), 2.75 (pd, J = 7.0, 
2.4 Hz, 1H), 2.07 (d, J = 2.4 Hz, 1H), 1.02 (d, J=7.0 Hz, 3H), 0.13 (s, 3H), 0.07(s, 3H) 
 13
C NMR (100 MHz, CDCl3) δ = 142.1, 137.6, 133.3, 127.9, 127.6, 127.0, 86.6, 77.8, 70.0, 
35.2, 16.8, -1.3, -1.5 
FT-IR (NaCl, thin film) ν = 2979, 2879, 1453, 1173, 701 cm-1 
Anal. calcd. for C15H20OSi: C, 73.71; H, 8.25; found C 73.59; H, 8.07 
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Dimethyl((1-1(prop-2-yn-1-yl)cyclohexyl)oxy)(vinyl)silane (1.74d): To a flame-
dried 100 mL round bottom flask was added imidazole (1.00 g, 14.76 mmol) and 
DMAP (0.181 g, 1.48 mmol), dichloromethane (40 mL), and alcohol 1.86d (1.02 g, 
7.38 mmol). The mixture was allowed to stir until complete dissolution and then cooled to 0 °C 
in an ice-water bath. Vinyldimethylchlorosilane (0.93 mL, 6.71 mmol) was then added neat, via 
syringe, dropwise. After addition, the reaction was allowed to warm to room temperature. After 
25 h, the reaction was complete as judged by TLC analysis and quenched with the addition of 40 
mL sat. aq NH4Cl. The organic layer was dried with Na2SO4 and concentrated in vacuo to yield a 
colorless oil. The crude product was purified on a silica gel column using 250 mL of 20:1 
hexanes:ether to give the product (1.26 g, 85%) as a colorless oil. 
TLC Rf (5% EtOAc / Hexanes) = 0.61 
1
H NMR (400 MHz, CDCl
3
) δ= 6.22 (dd, J = 20.4, 14.8 Hz, 1H), 5.93 (dd, J = 14.8, 3.9 Hz, 
1H), 5.76 (dd, J = 20.3, 3.9 Hz, 1H), 2.39 (d, J = 2.8 Hz, 2H), 2.01 (t, J = 2.8 Hz, 1H), 1.66-1.55 
(m, 6H), 1.55-1.47 (m, 1H), 1.46-1.35 (m, 2H), 1.32-1.18 (m, 1H), 0.22 (s, 6H) 
13
C NMR (100 MHz, CDCl
3
) δ= 140.2, 131.7, 81.8, 75.0, 70.8, 37.6, 33.0, 25.7, 22.4, 0.9 
FT-IR (NaCl, thin film) ν = 3313, 2121cm-1. 
Anal. Calc. for C13H22OSi: C, 70.21; H, 9.97; Found: C, 70.35; H, 10.20 
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Dimethyl((2-phenylpent-4-yn-2-yl)oxy)(vinyl)silane (1.74e): To a flame-dried 100 
mL round bottom flask was added imidazole (0.93 g, 13.68 mmol) and DMAP (0.17 
g, 1.37 mmol), dichloromethane (40 mL), and alcohol 1.86e (1.10 g, 6.84 mmol). The mixture 
was allowed to stir until complete dissolution and then cooled to 0 °C in an ice-water bath. Vinyl 
dimethyl chlorosilane (1.42 mL, 10.26 mmol) was then added neat, via syringe, dropwise.  After 
addition, the reaction was allowed to warm to room temperature. After 4 h, the reaction was 
complete as judged by TLC analysis and quenched with the addition of 40 mL 10% aq NH4Cl. 
The organic layer was dried with MgSO4 and concentrated in vacuo to yield a colorless oil. The 
crude product was purified on a silica gel column using 250 mL of 20:1 hexanes:ether to give the 
product (1.04 g, 62%) as a colorless oil. 
TLC Rf (10% EtOAc / Hexanes) = 0.86 
1
H NMR (400 MHz, CDCl
3
) δ= 7.35 (m, 5 H), 6.10 (dd, J = 20.4, 14.8 Hz, 1 H), 5.91 (dd, J = 
14.8, 4.0 Hz, 1H), 5.73 (dd, J = 20.0, 4.0 Hz, 1H), 2.68 (dd, J =16.5, 2.7 Hz, 1H), 2.62 (dd, 
J=16.5, 2.6 Hz, 1H), 1.94 (t, J = 2.8 Hz, 1 H), 1.75 (s, 3 H), 0.16 (s, 3 H), 0.14 (s, 3 H) 
13
C NMR (100 MHz, CDCl
3
) δ= 147.2, 139.6, 132.1, 128.0, 127.1, 125.5, 81.5, 76.7, 70.7, 36.6, 
28.1, 0.6, 0.5 
FT-IR (NaCl, thin film) ν = 3311, 2121 cm-1. 
Anal. Calc. for C15H20OSi: C, 73.71; H, 8.25; Found: C, 73.73; H, 8.25 
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Dimethyl ((1-(4-methylphenyl)but-3-yn-1-yl)oxy)(vinyl)silane (1.74f): To a 
flame-dried 250 mL round bottom flask and magnetic stir bar was added 
dichloromethane (100 mL), imidazole (2.59 g, 38 mmol), alcohol 1.86f (3.05 
g, 19 mmol) and 4-dimethylaminopyridine (464 mg, 3.8 mmol) at room temperature under 
argon. The yellow mixture was cooled in an ice water bath. Vinyldimethylchlorosilane (4.0 mL, 
28.5 mmol) was added via syringe to form a white precipitate. After complete addition of the 
silane, the reaction was allowed to warm to room temperature. Reaction was monitored by thin 
layer chromatography (10% diethyl ether: hexanes). The reaction was judge complete by after 2 
hours and 100 mL of saturated NH4Cl(aq) was added the round bottom flask. The resulting two 
layers were separated; the aqueous layer was extracted three times with 15 mL of 
dichloromethane. The combined organic layers were washed with brine, dried with magnesium 
sulfate, filtered through a course porosity funnel, and concentrated in vacuo to yield a yellow oil. 
The oil was dissolved in 100 mL hexanes and stirred with activated carbon for six hours. The 
resulting mixture was filtered through a silica plug eluting 100 mL 1% diethyl ether:hexanes. 
The resulting clear solution was concentrated in vacuo to yield 3.94 grams (85%) of a clear oil. 
TLC Rf (10% diethyl ether : hexanes) = 0.70  
1
H NMR (400 MHz, CDCl3): δ = 7.29 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 7.8 Hz, 2H), 6.14 (dd, J = 
20.0, 14.8 Hz, 1H), 6.02 (dd, J = 14.8, 4.2 Hz, 1H), 5.80 (dd, J = 20.0, 4.3 Hz, 1H), 4.85 (t, J = 
6.4 Hz, 1H), 2.65 (ddd, J = 16.6, 7.0, 2.6 Hz, 1H), 2.56 (ddd, J = 16.6, 6.0, 2.7 Hz), 2.38 (s, 3H), 
1.99 (t, J = 2.6 Hz, 1H), 0.22 (s, 3H), 0.17 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 140.7, 137.6, 137.2, 133.3,128.9, 126.0, 81.7, 73.6, 70.1, 30.7, 
21.3, -1.4, -1.5. 
Anal. calc for C15H20OSi: C 73.71, H 8.25; found: C 73.64, H 8.00. 
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Dimethyl ((1-(4-chlorophenyl)but-3-yn-1-yl)oxy)(vinyl)silane (1.74g): To a 
flame-dried 100 mL round bottom flask was added imidazole (1.36 g, 20 
mmol) and DMAP (0.244 g, 2 mmol), dichloromethane (60 mL), and alcohol 
1.86g (1.80 g, 10 mmol). The mixture was allowed to stir until complete dissolution and then 
cooled to 0 °C in an ice-water bath. Vinyldimethylchlorosilane (1.66 mL, 12 mmol) was then 
added neat, via syringe, dropwise. After addition, the reaction was allowed to warm to room 
temperature. After 6 hours the reaction was complete as judged by TLC analysis and quenched 
with the addition of 50 mL sat. aq NH4Cl. The organic layer was dried with MgSO4 and 
concentrated in vacuo to yield a colorless oil. The crude product was purified on a silica gel 
column using 250 mL of 30:1 hexanes:ether to give the product (2.11 g, 80%) as a colorless oil. 
TLC Rf (20% ethyl acetate/hexanes) = 0.78 
1
H NMR (300 MHz, CDCl3): δ = 7.32-7.27 (m, 4H), 6.08 (dd, J = 18.8, 14.8 Hz, 1H), 5.99 (dd, 
J = 14.8, 5.3 Hz, 1H), 5.75 (dd, J = 18.9, 5.3 Hz, 1H), 4.81 (t, J = 6.5 Hz, 1H), 2.61 (ddd, J = 
16.6, 6.6, 2.6 Hz, 1H), 2.50 (ddd, J = 16.6, 6.3, 2.6 Hz, 1H), 1.97 (t, J = 2.6 Hz), 0.18 (s, 3H), 
0.13 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ = 142.1, 137.3, 133.7, 133.3, 128.4, 127.5, 81.1, 73.0, 70.5, 30.6, 
-1.4, -1.6 
FT-IR (NaCl, thin film): ν = 3307.3, 3052.1, 3013.2, 1654.9 cm-1 
Anal. calc for C14H17ClOSi: C 63.50, H 6.47; found: C 63.47, H 6.63. 
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Dimethyl(non-1-yn-4-yloxy)(vinyl)silane (1.74h): To a flame-dried 100 mL 
round bottom flask was added imidazole (0.81 g, 11.84 mmol) and DMAP (0.14 g, 
1.18), dichloromethane (40 mL), and alcohol 1.86h (0.83 g, 5.92 mmol). The mixture was 
allowed to stir until complete dissolution and then cooled to 0 °C in an ice-water bath. 
Vinyldimethylchlorosilane (1.22 mL, 8.88 mmol) was then added neat, via syringe, dropwise. 
After addition, the reaction mixture was allowed to warm to room temperature.  After 3.5 h, the 
reaction was complete as judged by TLC analysis and quenched with the addition of 40 mL sat. 
aq NH4Cl. The organic layer was dried with Na2SO4 and concentrated in vacuo to yield a yellow 
oil. The crude product was purified on a silica gel column (2 x 15 cm) using 250 mL of 100:1 
hexanes:ether, 250 mL of 50:1 hexanes:ether, to give the product (1.33 g, 65%) as a colorless oil. 
TLC Rf (10% Ether / Hexanes): 0.70 
1
H NMR (400 MHz, CDCl3) δ= 6.17 (dd, J = 20.4, 14.8 Hz, 1H), 6.01 (dd, J = 14.8, 4.0 Hz, 
1H), 5.79 (dd, J = 20.4, 4.0 Hz, 1H), 3.79 (dtd, J = 7.5, 6.2, 4.4 Hz, 1H), 2.35 (ddd, J = 16.6, 5.8, 
2.6 Hz, 1H), 2.30 (ddd, J = 16.6, 6.3, 2.6 Hz), 1.98 (t, J = 2.8 Hz, 1H), 1.44 (m, 8H), 0.89 (t, J = 
7.2 Hz, 3H), 0.211 (s, 3H), 0.209 (s, 3H) 
13
C NMR (100 MHz, CDCl3) δ= 138.1, 133.3, 82.0, 71.4, 70.1, 36.8, 32.0, 27.7, 25.3, 22.8, 
14.3, -1.22, -1.27 
FT-IR (NaCl, thin film) ν = 3315, 2122 cm-1. 
Anal. Calc. for C8H13OSi: C, 69.58; H, 10.78; Found: C, 69.88; H, 10.54 
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1-Ethynyl-2-(dimethylvinylsiloxymethyl)benzene (1.74i): To a flame-dried 100 mL 
round bottom flask was added imidazole (0.17 g, 2.42 mmol) and DMAP (0.03 g, 0.24 
mmol), dichloromethane (8 mL), and alcohol 1.86i (160 mg, 1.21 mmol). The mixture 
was allowed to stir until complete dissolution and then cooled to 0 °C in an ice-water bath. 
Vinyldimethylchlorosilane (0.20 mL, 1.45 mmol) was then added neat, via syringe, dropwise.  
After addition, the reaction was allowed to warm to room temperature. After 0.5 h, the reaction 
was complete as judged by TLC analysis and quenched with the addition of 10 mL saturated 
NH4Cl(aq). The aqueous layer was extracted with dichloromethane (3 x 5 mL). The combined 
organics were washed with 10 mL brine, dried with MgSO4 and concentrated in vacuo to yield a 
colorless oil. The crude product was purified on a silica gel column using 200 mL of 99:1 
hexanes:ether to give the product (159 mg, 61%) as a colorless oil. 
TLC Rf (10% Et2O / Hexanes) = 0.48; 
1
H NMR (400 MHz, CDCl3) δ = 7.54 (dd, 1H, J = 7.76, 0.56 Hz), 7.46 (dd, 1H, J = 7.64, 1.08 
Hz), 7.37 (td, 1H, J = 7.6, 1.2 Hz), 7.23-7.19 (m, 1H), 6.18 (dd, 1H, J = 20.1, 14.9 Hz), 6.04 (dd, 
1H, J=14.9, 4.1 Hz), 5.83 (dd, 1H, J=20.1, 4.1 Hz), 4.88 (s, 2H), 3.29 (s, 1H), 0.25 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ = 143.4, 137.2, 133.7, 132.6, 129.1, 126.8, 126.4, 119.3, 82.1, 
81.2, 63.0, -2.0; 
FT-IR (NaCl, thin film) ν = 3300, 3052, 1265 cm-1. 
Anal. Calc. for C15H20OSi: C, 72.17; H, 7.45; found: C, 72.06; H, 7.29 
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Dimethyl((1-(2'-furyl)but-3-yn-1-yl)oxy)(vinyl)silane (1.74j): To a flame-dried 
50 mL round bottom flask was added imidazole (545 mg, 8 mmol) and DMAP (98 
mg, 4.0 mmol), dichloromethane (25 mL), and alcohol 1.86j (545 mg, 4.0 mmol). 
The mixture was allowed to stir until complete dissolution and then cooled to 0 °C in an ice-
water bath. Vinyl dimethyl chlorosilane (0.66 mL, 4.8 mmol) was added neat, via syringe, 
dropwise. After addition, the reaction mixture was allowed to warm to room temperature. After 1 
h, the reaction was complete as judged by TLC analysis and quenched with the addition of 25 
mL sat. aq NH4Cl. The organic layer was dried with MgSO4 and concentrated in vacuo to yield a 
yellow oil. The crude product was purified on a silica gel column eluting with 1% ethyl ether in 
hexanes to afford the product (600 mg, 68%) as a colorless oil. 
TLC Rf (10% diethyl ether:hexanes) = 0.56  
1
H NMR (400 MHz, CDCl3): δ = 7.37 (dd, J = 1.8, 0.8 Hz, 1H), 6.32 (dd, J = 3.1, 1.8 Hz, 1H), 
6.26 (d, J = 3.1 Hz, 1H), 6.10 (dd, J = 19.8, 14.8 Hz, 1H), 6.00 (dd, J = 14.8, 4.4 Hz, 1H), 5.76 
(dd, J = 19.8, 4.4 Hz, 1H), 4.86 (t, J = 6.8 Hz, 1H), 2.76 (ddd, J = 16.6, 6.8, 2.6 Hz, 1H), 2.68 
(ddd, J = 16.6, 6.8, 2.6 Hz, 1H), 1.96 (t, J = 2.6 Hz, 1H), 0.19 (s, 3H), 0.16 (s, 3H) 
13
C NMR (100 MHz, CDCl3): δ = 155.2, 142.0, 137.3, 133.6, 110.2, 106.9, 80.8, 70.2, 67.3, 
27.0, -1.5, -1.7. 
IR (NaCl, thin film) ν = 3306, 3051, 2960, 1594, 1254, 1075 cm-1. 
Anal. Calc. for C12H16O2Si: C, 65.41; H, 7.32; found: C, 65.40; H, 7.16 
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General procedure for high pressure reactions: 
 
An oven dried Fischer Porter bottle equipped with a magnetic stir bar was brought into an argon 
filled glove box. To the Fischer Porter bottle was added RuHCl(CO)(SIMes)PPh3 and the alkyne  
in cyclopentyl methyl ether. The bottle was plugged with a septum and removed from the glove 
box. The septum was replaced with a Swagelok regulator and the system was purged with 
ethylene (80 psi) and vented three times, then refilled to 80 psi and heated to 80 °C for the 
allotted time. Upon completion by TLC, the reaction was filtered through a short plug of silica 
gel (eluted with dichloromethane, ethyl acetate, or diethyl ether), concentrated in vacuo and a 
crude yield was obtained by 
1
H NMR with mesitylene (0.33 equivalents) as an internal standard. 
The crude product was purified by flash chromatography on silica gel. 
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(Z)-5-([1,1'-Biphenyl]-4-yl)-3-allylidene-2,2-dimethyl-1,2-oxasilolane 
(1.75a): prepared according to the general procedure; RuH (11 mg, 0.015 
mmol), alkyne 1.74a (92 mg, 0.30 mmol) in 3 mL cyclopentyl methyl ether, 
1h. Flash column chromatography (5% diethylether:hexanes) 58% (53 mg) as a clear oil. 
TLC Rf (10% diethylether/hexanes) = 0.57 
1
H NMR (400 MHz, CDCl3): δ = 7.60-7.56 (m, 4H), 7.45-7.42 (m, 4H), 7.36-7.32 (m, 1H), 6.74 
(d, J = 10.8 Hz, 1H), 6.31 (dt, J = 16.6, 10.4 Hz, 1H), 5.23 (d, J = 16.6 Hz, 1H), 5.17 (d, J = 10.0 
Hz, 1H), 5.06 (dd, J = 9.5, 5.3 Hz, 1H), 2.96 (dd, J = 15.5, 5.1 Hz, 1H), 2.70-2.63 (m, 1H), 0.43 
(s, 3H), 0.42 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ = 145.2, 143.0, 140.8, 140.0, 137.7, 137.0, 128.5, 126.9, 126.9, 
126.9, 125.7, 117.5, 77.4, 45.6, -0.0, -0.1; 
FT-IR (NaCl, thin film) ν = 3028, 2956, 2926, 1592, 1486, 1252, 903 cm -1 
Anal. calc. for C20H22OSi, C, 78.38; H, 7.24; found C, 78.30; H, 6.98 
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(4S,5S,Z)-3-allylidene-2,2,4-trimethyl-5-phenyl-1,2-oxasilolane (1.75b): 
prepared according to the general procedure; RuH (4 mg, 0.006 mmol), alkyne 
1.74b (73 mg, 0.30 mmol) in 1.5 mL toluene, 24h. Flash column chromatography (2% 
diethylether:hexanes) 82% (60 mg) as a clear oil.  
TLC Rf (10% diethylether/hexanes) = 0.74 
1
H NMR (400 MHz, CDCl3): δ= 7.32-7.20 (m, 5H), 6.68 (d, J = 10.8 Hz, 1H), 6.32 (dt, J = 16.6, 
10.1 Hz, 1H), 5.24 (d, J = 16.6 Hz, 1H), 5.17 (d, J = 10.1 Hz, 1H), 5.14 (d, J =  5.0 Hz, 1H), 2.88 
(m, 1H), 0.64 (d, J =  7.1 Hz, 3H), 0.47 (s, 3H), 0.39 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ= 152.0, 141.6, 137.7, 137.4, 128.1, 126.9, 126.0, 117.8, 86.7, 
47.3, 16.7, 0.8, 0.2; 
FT-IR (NaCl, thin film) ν = 3026, 2951, 1590, 1450, 1251, 988 cm -1 
[α]D
23λ 589 nm (c 0.600, CHCl3) = -56.01° 
Anal. calc. for C15H20OSi, C, 73.71; H, 8.25; found C, 73.71; H, 8.37; 
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(4R,5S,Z)-3-Allylidene-2,2,4-trimethyl-5-phenyl-1,2-oxasilolane (1.75c): 
prepared according to the general procedure; RuH (4 mg, 0.006 mmol), alkyne 
1.74c (73 mg, 0.3 mmol) in 1.5 mL toluene, 21h. Flash column chromatography (1-2% gradient 
elution, diethylether:hexanes, 1.5 x 12 cm) 75% (55 mg) as a clear oil.  
TLC Rf (10% diethylether/hexanes) = 0.48 
1
H NMR (400 MHz, CDCl3): δ = 7.37-7.26 (m, 5H), 6.57 (dd, J = 10.6, 2.6 Hz, 1H), 6.37 (dt, J 
= 16.7, 10.6 Hz, 1H), 5.26 (d, J = 16.7 Hz, 1H), 5.18 (d, J = 10.2 Hz, 1H), 4.37 (d, J =  8.9 Hz, 
1H), 2.55 (m, 1H), 1.03 (d, J = 6.6 Hz, 3H), 0.43 (s, 3H), 0.40 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ = 149.9, 142.7, 136.9, 136.1, 128.0, 127.4, 126.3, 117.6, 84.9, 
48.4, 13.8, 0.0, -0.1 
FT-IR (NaCl, thin film) ν = 3028, 2956, 2926, 1592, 1486, 1252, 903 cm -1 
[α]D
23λ 589 nm (c 0.640, CHCl3) = -139.70° 
Anal. calc. for C15H20OSi, C, 73.71; H, 8.25; found C, 73.96; H, 7.99; 
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(Z)-3-Allylidene-2,2-dimethyl-1-oxa-2-silaspiro[4.5]decane (1.75d): prepared 
according to the general procedure; RuH (11 mg, 0.015 mmol), alkyne 1.74d (66 
mg, 0.3 mmol) in 3 mL cyclopentyl methyl ether, 1h. Flash column chromatography (2% 
diethylether:hexanes, 1.5 x 12 cm) 55% (36 mg) as a clear oil.  
TLC Rf (10% diethylether/hexanes) = 0.57 
1
H NMR (400 MHz, CDCl3): δ = 6.65 (d, J = 10.6 Hz, 1H), 6.26 (dt, J = 16.7, 10.6 Hz, 1H), 
5.16 (d, J = 16.7 Hz, 1H), 5.09 (d, J = 10.1 Hz, 1H), 2.47 (s, 2H), 1.67-1.35 (m, 10H), 0. 30 (s, 
6H); 
13
C NMR (100 MHz, CDCl3): δ = 146.8, 138.0, 137.5, 116.8, 80.1, 48.0, 39.3, 25.7, 23.2, 1.2; 
FT-IR (NaCl, thin film) ν = 2932, 2857, 1251, 974, 825 cm -1 
Anal. calc. for C13H22OSi, C, 70.71; H, 9.97; found C, 70.30; H, 9.70; 
 
 
 
 
 
 
 
 
 
47 
 
 
 
(Z)-3-Allylidene-2,2,5-trimethyl-5-phenyl-1,2-oxasilolane (1.75e): prepared 
according to the general procedure; RuH (11 mg, 0.015 mmol), alkyne 1.74e (73 
mg, 0.3 mmol) in 3 mL cyclopentyl methyl ether, 1.5h. Flash column chromatography (1-2% 
gradient elution, diethylether:hexanes, 1.5 x 12 cm) 60% (44 mg) as a clear oil.  
TLC Rf (10% diethylether/hexanes) = 0.54 
1
H NMR (400 MHz, CDCl3): δ= 7.45-7.42 (m, 2H), 7.34-7.30 (m, 2H), 7.23-7.19 (m, 1H), 6.68 
(d, 1H, J = 10.8 Hz), 6.26 (dt, 1H, J = 16.7, 10.2 Hz), 5.18 (dd, 1H, J=16.7, 0.8 Hz), 5.11 (dd, 
1H, J=10.0, 0.7 Hz), 2.93 (d, 1H, J = 16.2 Hz), 2.84 (dd, 1H, J = 15.7, 1.2 Hz), 1.52 (s, 3H), 0.43 
(s, 3H), 0.29 (s, 3H); 
13
C NMR (100 MHz, CDCl3): δ = 149.1, 145.8, 138.2, 137.4, 128.2, 126.5, 124.8, 117.5, 81.7, 
50.8, 31.8, 1.4, 0.6; 
FT-IR (NaCl, thin film) ν = 3052, 2978, 1421, 1264 cm-1 
Anal. calc. for C15H20OSi, C, 73.71; H, 8.25; found C, 73.58; H, 8.25. 
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(Z)-5-(4'-Methylphenyl)-3-allylidene-2,2-dimethyl-1,2-oxasilolane 
(1.75f): prepared to the general procedure; RuH (11 mg, 0.015 mmol), 
alkyne 1.74f (73 mg, 0.30 mmol) in 3 mL cyclopentyl methyl ether, 1 hr. Flash column 
chromatography (5% diethyl ether:hexanes) yielded 45% (33 mg) as a clear oil. 
TLC Rf  (10% diethyl ether:hexanes) = 0.56 
1
H NMR (400 MHz, CDCl3): δ = 7.25 (d, J = 7.8 Hz, 2H), 7.15 (d, J = 7.8 Hz, 2H), 6.71 (d, J = 
10.8 Hz, 1H), 6.29 (dt, J = 16.7, 10.4 Hz, 1H), 5.21 (d, J = 16.7 Hz, 1H), 5.15 (d, J = 10.0 Hz, 
1H), 4.98 (dd, J = 9.3, 5.3 Hz, 1H), 2.89 (ddd, J = 15.9, 5.2, 1.1 Hz, 1H), 2.61 (ddd, J = 15.9, 
9.3, 2.0 Hz, 1H), 2.34 (s, 3H), 0.40 (s, 3H), 0.39 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 145.9, 141.3, 137.9, 137.4, 137.0, 129.1, 125.5, 117.7, 77.9, 
46.1, 21.3, 0.3, 0.2. 
FTIR (NaCl, thin film) ν = 3053, 2983, 1592, 1514, 1422, 1265 cm-1. 
Anal. Calc. for C15H20OSi: C, 73.71; H, 8.25; found: C, 73.76; H, 8.22. 
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(Z)-5-(4'-Chlorophenyl)-3-allylidene-2,2-dimethyl-1,2-oxasilolane 
(1.75g): prepared to the general procedure; RuH (11 mg, 0.015 mmol), 
alkyne 1.74g  (78 mg, 0.30 mmol) in 3 mL cyclopentyl methyl ether, 1 hr. Flash column 
chromatography (3% diethyl ether:hexanes) yielded 38% (30 mg) as a clear oil. 
TLC Rf (10% diethyl ether:hexanes) = 0.58  
1
H NMR (400 MHz, CDCl3): δ = 7.32-7.28 (m, 4H), 6.71 (d, J = 10.8 Hz, 1H), 6.27 (dt, J = 
16.7, 10.4 Hz, 1H), 5.22 (d, J = 16.7 Hz, 1H), 5.16 (d, J = 10.0 Hz, 1H), 4.97 (dd, J = 9.4, 5.3 
Hz, 1H), 2.90 (ddd, J = 15.9, 5.2, 1.1 Hz, 1H), 2.54 (ddd, J = 15.9, 9.4, 2.0 Hz, 1H), 0.40 (s, 3H), 
0.40 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 145.1, 142.9, 138.2, 137.2, 133.0, 128.6, 126.9, 118.1, 77.3, 
46.0, 0.2, 0.1. 
IR (NaCl, thin film) ν = 3053, 2962, 1593, 1491, 1265 cm-1. 
Anal. Calc. for C14H17ClOSi: C, 63.50; H, 6.47; found: C, 63.43; H, 6.43. 
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(Z)-5-Pentyl-3-allylidene-2,2-dimethyl-1,2-oxasilolane (1.75h): prepared 
to the general procedure; RuH (11 mg, 0.015 mmol), alkyne 1.74h (67 mg, 
0.30 mmol) in 3 mL cyclopentyl methyl ether, 0.5 hr. Flash column chromatography (3% diethyl 
ether:hexanes) yielded 49% as a clear oil.  
TLC Rf (10% diethyl ether:hexanes) = 0.70  
1
H NMR (400 MHz, CDCl3): δ = 6.67 (dtd, 1H, J = 10.8, 1.7, 0.6 Hz ), 6.25 (dt, 1H, J=16.7, 
10.3 Hz), 5.17 (dd, 1H, J=16.7, 0.7 Hz), 5.11 (dd, 1H, J = 10.0, 0.6 Hz), 4.02-3.95 (m, 1H), 2.66 
(dd, 1H, J=15.9, 5.3 Hz), 2.29 (dd, 1H, J=15.8, 7.5 Hz), 1.49-1.20 (m, 8H), 0.88 (t, 3H, J=6.8 
Hz), 0.31 (s, 3H), 0.30 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ = 146.3, 137.8, 137.5, 117.2, 43.1, 38.2, 32.1, 25.6, 22.8, 14.2, 
0.6, 0.2. 
IR (NaCl, thin film) ν = 3049, 2910, 2855 
Anal. Calc. for C13H24OSi: C, 69.58; H, 10.78; found: C, 69.56; H, 10.93. 
 
 
 
 
 
 
 
 
51 
 
 
 
(Z)-4-Allylidene-3,3-dimethyl-2-oxa-3-sila-1,2,3,4-tetrahydronaphthalene 
(1.75i): prepared to the general procedure; RuH (22 mg, 0.03 mmol), alkyne 1.74i 
(130 mg, 0.6 mmol) in 6 mL cyclopentyl methyl ether, 0.5h. Flash column 
chromatography (1-2% gradient elution, diethylether:hexanes, 1.5 x 12 cm) 58% (75 mg) as a 
clear oil.  
TLC Rf (10% diethyl ether/hexanes) = 0.48 
1
H NMR (400 MHz, CDCl3): δ = 7.55 (dd, 1H, J = 7.8, 0.8 Hz), 7.29 (dt, 1H, J = 7.5, 1.5 Hz), 
7.19 (dt, 1H, J = 7.4, 1.2 Hz), 7.16 (d, 1H, J = 11.4 Hz), 7.11 (dd, 1H, J = 7.5, 0.8 Hz), 6.63 
(ddd, 1H, J = 16.4, 11.4, 9.9 Hz), 5.45 (ddd, 1H, J=16.4, 1.5, 0.9 Hz), 5.36 (ddd, 1H, J=9.9, 1.5, 
0.8 Hz), 4.81 (s, 2H), 0.42 (s, 6H); 
13
C NMR (100 MHz, CDCl3): δ = 140.7, 139.6, 138.1, 137.7, 136.2, 128.2, 127.0, 126.6, 125.2, 
121.0, 66.0, 0.0; 
FT-IR (NaCl, thin film) ν = 3050, 2956, 2842, 1263 cm-1 
Anal. calc. for C13H16OSi: C, 72.17; H, 7.45; found: C, 72.11; H, 7.52. 
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(Z)-5-(2'-Furyl)-3-allylidene-2,2-dimethyl-1,2-oxasilolane (1.75j): prepared 
to the general procedure; RuH (11 mg, 0.015 mmol), alkyne 1.74j (66 mg, 0.30 
mmol) in 3 mL cyclopentyl methyl ether, 1 hr. Flash column chromatography 
(3% diethyl ether:hexanes) yielded 18% (12 mg) as a clear oil. 
TLC Rf (10% diethyl ether:hexanes) = 0.45  
1
H NMR (400 MHz, CDCl3): δ = 7.38 (dd, 1H, J=1.8, 0.8 Hz), 6.75 (d, 1H, J=10.9 Hz), 6.31 
(dd, 1H, J = 3.1, 1.7 Hz), 6.29-6.23 (m, 2H), 5.22 (dd, 1H, J = 16.7, 0.7 Hz), 5.15 (dd, 1H, 
J=10.0, 0.8 Hz), 5.06 (t, 1H, J = 6.8 Hz), 2.96-2.85 (m, 2H), 0.37 (s, 3H), 0.33 (s, 3H) 
13
C NMR (100 MHz, CDCl3): δ = 156.2, 144.5, 142.4, 138.3, 137.3, 117.9, 110.2, 106.4, 71.3, 
41.2, 0.4, 0.2. 
IR (NaCl, thin film) ν = 3054, 2986, 2305, 1422, 1265 cm-1.  
Anal. Calc. for C12H16O2Si: C, 65.41; H, 7.32; found: C, 65.40; H, 7.33. 
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2.0 SEQUENTIAL DEPROTECTION/REDUCTIVE AMINATION OF N-BOC-3-
AMINO-4-HALOPYRIDINES 
 
2.1 Introduction 
 In this chapter a new method for the synthesis of N-alkylated 3-amino-4-halopyridines is 
developed. These substrates were of interest as starting materials for the synthesis of specific 
imidazopyridine isomer, imidazo[4,5-c]pyridines. These substrates are difficult to access through 
direct alkylation because mixtures result under typical alkylation conditions. Utilizing modified 
conditions that combined the deprotection of a Boc protecting group and a reductive amination, 
good yields of N-alkylated 3-amino-4-halopyridines were achieved. This allowed ready access to 
the imidazo[4,5-c]pyridines, which are of interest in the pharmaceutical industry. 
2.2 Background 
 An imidazopyridine is a bicyclic nitrogenous heterocyclic compound, named for its 
adjacent imidazole and pyridine rings (Figure 2.1).
61,62
 There are several imidazopyridine 
regioisomers, including imidazo[4,5-b]pyridines (IPb) and imidazo[4,5-c]pyridines (IPc), varying 
at the points of articulation between the bonds of the two heteroarenes. The parent unsubstituted 
imidazopyridines are in tautomeric equilibrium when in solution.
61
 The thermodynamically 
favorable tautomers are 2.04 and 2.05 for IPb and IPc, respectively. This is due to aromatic 
stabilization of the lone pair on the imidazole nitrogen (N-3 for IPb and N-1 for IPc), donating its 
lone pair to the aromatic system of pyridine through resonance.  
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Figure 2.1. Tautomerism for Selected Imidazopyridine Regioisomers 
 
 Many imidazopyridines are naturally occurring and display significant and diverse 
biological activity.
63–70
 For example, IPc-containing ageladine A 2.09 was isolated from the 
marine sponge Agelas nakamurai in 2003 and displayed antiangiogenic matrix metalloproteinase 
inhibition (Figure 2.2).
63
 Since its isolation, a one-pot synthesis and further biological screening 
of ageladine and ageladine analogues was reported in 2011.
64
 
Figure 2.2. Natural Products Containing an Imidazo[4,5-c]pyridine 
 
 Grossularines 2.10 constitute another group of biologically active natural products, 
isolated from the tunicate Dendrodoa grossularia in 1984 (Figure 2.2).
66,67
 Grossularines have 
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shown tumor cell suppression through cyclin-dependent kinase inhibition. The original structure 
of grossularines were not reported to contain an imidazopyridine core; following further 
investigation, the revised structure was elucidated in 1989.
67,71
 Since then two total syntheses of 
the grossularines were reported in 1995,
72,73
 and a biomimetic synthesis has also been 
proposed.
74
 
 Though there are countless biologically useful IPb and IPc reported, facile syntheses of 
imidazopyridines have remained limited.
75–83
 An entire window of medicinal chemistry in the 
pharmaceutical industry is therefore closed to these underprivileged adenosine-like 
bioisoteres.
61,84–86
  
2.2.1 Synthesis of Imidazo[4,5-c]pyridines 
 A lengthy synthesis of IPc was reported in 2016,
87
 starting from 2-chloropyridine 2.11 
(Scheme 2.1). Oxidation of the pyridine nitrogen with m-CPBA provided pyridine N-oxide 2.12, 
which acted as a directing group for selective nitration at the 4-position of pyridine. Ensuing 
iron-mediated reduction of the N-oxide and nitro group of 2.13 yielded 4-amino-2-chloropyridine 
2.14. A second nitration and reduction were carried out to afford 2.16, followed by a 
condensation reaction, forming the imidazole ring in 2.17. Finally, a poorly selective alkylation 
of the imidazopyridine was undertaken to yield compound 2.18a and 2.18b, which were 
separated through silica gel column chromatography. No yields were reported in this synthesis 
until the final step, and only three examples were reported by this approach. 
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Scheme 2.1. Synthesis of IPc as Purine Analogues 
 
 Another study was reported in 2016 that afforded the N-3 substituted IPc (Scheme 2.2).
79
 
This palladium-catalyzed approach utilized 4-amino-3-bromopyridines as starting materials, and 
it installed benzylamino functionality through a Buchwald-Hartwig cross coupling using 
palladium pre-catalyst 2.21. 3,4-Diaminopyridine 2.22 was converted into IPc 2.23 by a formic 
acid-mediated condensation. This improved two step protocol was amenable to 5 different IPc in 
good yield and was also tolerant to IPb and other nitrogenous heterocycles.  
Scheme 2.2. Palladium Catalyzed Synthesis of IPc 
 
 The approach in our laboratories was reported in 2014 and started from N-Boc-3-amino-
4-chloropyridine 2.25 (Scheme 2.3).
75
 The strategy employed a copper catalyzed arylation or 
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sodium hydride-mediated alkylation (and subsequent deprotection), followed by a palladium-
catalyzed amidation to yield N-3 substituted IPc.  
Scheme 2.3. Clark's Synthesis of IPc 
 
 The palladium-catalyzed technique afforded 14 substrates, from 52-91% yield, but 
suffered from low yields in the preparation of its precursors. The copper-catalyzed 
arylation/deprotection worked well, but the alkylation/deprotection method to make 2.30 limited 
the approach toward alkyl-substituted IPc. 
2.2.2 Alkylation of 3-Amino-4-halopyridines 
 The previous alkylation protocol was revisited to streamline the synthesis of the IPc 
heterocycle. As reductive amination remains an inexpensive and selective method to alkylate 
nitrogen, it seemed a logical starting point. Unfortunately conditions utilized in similar systems
76
 
(such as 3-amino-2-chloropyridine) failed for 3-amino-4-chloropyridines (Scheme 2.4). We 
attribute this to the difference in pKa of the two pyridines (pKa of 4-chloropyridinium is 3.83
88
 as 
the pKa of 2-chloropyridinium 0.75
89
). Presumably, the increased basicity of 3-amino-4-
chloropyridine can act as an unintended buffer in the reaction system, slowing the formation of 
the imine or decelerating the reduction of the imine by limiting its protonation. Furthermore, 3-
amino-4-chloropyridine 2.35 was deemed as an unsuitable starting material due to its instability 
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under ambient conditions. The need for constant repurification of 2.35 made necessary the search 
for a bench stable starting material. 
Scheme 2.4. Previous Alkylation Strategies of 3-Aminopyridines 
 
 N-Boc-3-amino-4-chloropyridine 2.25 was envisioned as our starting material for the 
preparation of 2.30, as it was used in the previous approach.
75
 In the study a route to protected 
pyridine 2.25 was established, though the yield was not reported. Thus a more scalable and 
efficient approach was needed to carry out this project (Scheme 2.5). First a mono-Boc 
protection of 3-aminopyridine 2.36 was taken to afford 2.37. A highly selective directed 
metalation of 2.37 with n-butyllithium was accomplished,
90
 followed by quench with a halogen 
electrophile to afford 2.25, 2.38, or 2.39. 
Scheme 2.5. Synthesis of N-Boc-3-amino-4-halopyridine 
 
 Quéguiner and co-workers published a similar directed metalation approach, albeit with a 
pivalate directing group.
91
 We instead chose to use a Boc protecting group, as it could more 
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easily be cleaved by acid
92
 prior to the reductive amination step. In addition, the directed 
metalation proceeded well in DME, without the need for toxic additives to break up lithiate 
aggregation
93
 (for example, HMPA or TMEDA). Finally, we found that precursors 2.25, 2.38, 
and 2.39 were able to be stored under ambient conditions without noticeable degradation for up 
to six months. 
2.3 This Work: Deprotection/Reductive Amination of 3-Amino-4-halopyridines 
 With an adequate starting material in hand, we began optimization for a sequential Boc-
removal/reductive amination method for the divergent synthesis of N-substituted 3-amino-4-
halopyridines (as IPc precursors). The basic premise was that as Boc deprotection and reductive 
amination can both occur under acidic conditions, it would be possible to perform both 
operations in a single flask procedure. This would minimize the amount of time needed to 
perform these operations and greatly facilitate access to the desired system. In the event, a 
number of variables could be modified to perform both reactions in the same flask (acid, 
reducing agent, solvent, etc.). 
Scheme 2.6. Reaction Pathway for Sequential Deprotection/Reductive Amination 
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 It is well understood that poorly nucleophilic amine substrates require harsher acidic 
conditions to assist imine formation and facilitate reduction therein (Scheme 2.6, eq. 1).
94,95
 
Furthermore, reducing agents become less selective between the imine and carbonyl reactant 
with increased acid strength; consumption of the carbonyl electrophile can hinder product 
formation (Scheme 2.6, eq. 2).
96
 With these limitations in mind, we initially screened Brønsted 
acids to facilitate in situ Boc-removal. Sodium triacetoxyborohydride was the reducing agent 
chosen for optimization due to its reported site selectivity.
95–98
 Trifluoroacetic acid (TFA) is 
known to deprotect tert-butyl carbamates and mediate reductive amination for weakly basic 
amines, so it was evaluated first (Table 2.1).
75–77,92
 
Table 2.1. Optimization 
 
Entry 
Additive 
(Equiv) 
2.30a
a
 
 
2.35
a
 2.46
a
  2.47
a
 
1 - 45  - - 45 
2 TFA (1) 53  - - 33 
3 TFA (2) 63  - - 28 
4 TFA (10) 30  55 - - 
5
b
 BF3•OEt2 (5) 19  12 9 - 
6
b
 TiCl4 (5) 12  32 12 - 
7
b
 AlCl3 (5) 10  31 21 - 
8
b
 TMSOTf (5) 53  15 10 - 
9 TMSOTf (2) 90  - - 4 
10
c 
TfOH (1) 50  33 - - 
11
c 
TMSOTf (1.1) 55  - 20 - 
a
Yield as determined using 
1
H NMR with a mesitylene internal standard. 
b
Lewis acids were used to deprotect the 
Boc group without TFA. 
c
Reaction performed with 1.1 equivalents of benzaldehyde. 
61 
 
 
 
 After TFA-mediated Boc-deprotection, excess acid was removed in vacuo. As 
ammonium salts have been reported to mediate reductive amination,
95
 pyridinium 
trifluoroacetate salt 2.45  was subjected to reductive amination with benzaldehyde, affording 
45% yield of 2.30a (Table 2.1, entry 1). The reduction was sluggish as only 45% yield of imine 
2.47 was detected by 
1
H NMR (Table 2.1, entry 1). An increased yield of 2.30a was observed 
when 1 and 2 additional equivalents of TFA was added to mediate reductive amination (Table 
2.1, entries 2 and 3), but in the presence of 10 equivalents of TFA reaction efficiency decreased 
(Table 2.1, entry 4). This may have been due to the reduction of the aldehyde when large excess 
of TFA was used. Lewis acids were also screened to facilitate reductive amination (Table 2.1, 
entries 5-9). Interestingly under Lewis acid catalyzed conditions, ethylated byproduct 2.46 was 
also observed. This byproduct is presumably formed from decomposing NaBH(OAc)3 (into 
acetaldehyde), which subsequently acts as an electrophile in reductive amination. This 
phenomenon has previously been reported in similar reductive amination methods.
96,98,99
 
TMSOTf proved to be the most effective Lewis acid screened to facilitate reductive amination, 
providing 96% conversion of imine 2.47 and 90% crude yield of 2.30a (Table 2.1, entry 9). 
Experiments carried out with TfOH were not as effective (Table 2.1, entry 10), likely because 
water generated by imine formation is not effectively scavenged. Under optimized conditions, it 
was necessary to include an excess of both TMSOTf and aldehyde to promote imine formation 
and to prevent competitive ethylation (Table 2.1, entry 11). 
 Using these optimized conditions, benzylated substrate 2.30a was isolated in 79% yield 
on a 1 mmol scale, and 83% yield on a 15 mmol scale (Table 2.2). In the latter experiment, 2.30a 
was isolated without chromatography. This protocol demonstrated excellent substrate tolerance. 
High yields were obtained with halo-substituted aryl aldehydes (Table 2.2, substrates 2.30b-e) 
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and with electron-deficient aryl aldehydes (Table 2.2, substrates 2.30f-h). Cinnamyl-substituted 
2.30i was isolated in 76% yield, and the trans-olefin remained intact through the reduction. 
Biphenyl functionality was introduced with an 86% yield of 2.30j. Electron-rich substrates 
(many of which are sensitive to acidic conditions) were also evaluated with good results (Table 
2.2, substrates 2.30k-t). Furfuryl-subtituted 2.30k showed good tolerance to the harshly acidic 
reaction and purification conditions. p-Tolyl, piperonyl, and 2,3-dimethoxybenzyl (DMB) 
substrates (Table 2.2, 2.30l-n) also gave product in excellent yields. Acid labile substrates 2,4- 
(2.30o) and 2,5-DMB (2.30p) were obtained without the addition of TMSOTf in a reduced 
reaction time of 1 h. The sterically encumbering neopentylamine 2.30q was also obtained in 85% 
yield from pivaldehyde, with no observed methyl rearrangement. Reductive amination of 
enolizable aldehydes was also efficient, as 2.30r and 2.30s were obtained without the addition of 
TMSOTf. Ketones like cyclohexanone also performed well under the reaction conditions, 
affording 2.30t in 75% yield. In addition, 3-amino-4-bromopyridine and 3-amino-4-iodopyridine 
gave good yields with a variety of carbonyl substrates under analogous conditions (Table 2.2, 
2.48a-d and 2.49a-d). Most benzylic amine products were accessed with greater than 95% purity 
(as determined by 
1
H NMR) without utilization of silica gel column chromatography. 
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Table 2.2. Substrate Scope 
 
a
Reaction performed on a 15 mmol scale. 
b
No TMSOTf was added 
2.4 Reductive Amination of Deactivated Anilines 
 Given the excellent yields obtained with 3-amino-4-halopyridines, the optimized 
conditions were also evaluated with some aniline substrates that have been reported to be slow to 
undergo reductive amination due to electronic deactivation of the aniline nucleophile (2,4-
dinitroaniline) and/or steric reasons (2,4,6-tribromoaniline and 2,6-diisopropyaniline) (Table 
2.3).
96,99
 Tribromoaniline provided benzylated 2.51 in 96% yield under these conditions. 
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Reductive amination of 2,4-dinitroaniline provided a 63% yield of 2.52, while 2,6-
diisopropylaniline proceeded, yielding 70% of 2.53. The excellent yield with these difficult 
substrates is again attributed to the use of TMSOTf, which facilitates imine formation by 
removing water, and produces the strong acid TfOH, activating the imine for reduction. TMSOTf 
has only rarely been utilized in reductive amination reactions,
99,100
 but these results indicate that 
this Lewis acid should be investigated in difficult cases where the amine partner is deactivated 
and/or significantly hindered. 
Table 2.3. Reductive Amination of Poorly Nucleophilic Anilines 
 
2.5 Conclusion  
 In summary, an efficient, general procedure for the reductive amination of 3-amino-4-
halo-pyridines is disclosed. A useful single vessel protocol has been devised using N-Boc-3-
amino-4-halopyridines as the starting materials. This approach was amenable to alkyl and aryl 
substituted carbonyl coupling partners, of electron-rich and electron-poor nature. Halogen 
variation was well tolerated under these conditions on both the aminopyridine and carbonyl 
coupling partners. Acid-mediated precipitation of the followed by formation of the free base 
provided the monoalkylated amines in high purity, avoiding the use of silica gel chromatography 
in many systems. This protocol was used in the efficient synthesis of N-alkylated 3-amino-4-
halopyridines and may be of use in similar systems which resist reductive amination under 
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standard conditions. Optimization of this strategy streamlined a divergent and efficient synthesis 
of IPc, starting from the inexpensive 3-aminopyridine. This approach was also used for the 
reductive amination of sterically and/or electronically deactivated anilines, strengthening the 
scope and outlook for strategies in nitrogen alkylation. 
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2.6 Experimental Section 
For General Experimental, refer to Chapter 1, p. 23-24. 
General procedure A 
To a round bottom flask equipped with a magnetic stir bar and rubber septum, was added, N-
Boc-3-amino-4-halopyridine (1 equiv) followed by neat TFA (10 equiv.) via syringe. 
CAUTION: Vigorous gas evolution and an exothermic reaction occurs. The Boc-removal was 
monitored by thin layer chromatography (3-amino-4-halopyridines have an Rf = 0.20 in 1:1 ethyl 
acetate: hexanes). The reaction mixture was concentrated in vacuo and the crude oil was 
dissolved in ethyl acetate and concentrated in vacuo three times to yield the solid pyridinium 
trifluoroacetate salt. DCM (0.5 M) was added to form a slurry to which the carbonyl (2 equiv) 
and TMSOTf (2 equiv) were added, sequentially. The mixture was stirred for 1 hour at ambient 
temperature before sodium triacetoxyborohydride (3 equiv) was added as a single portion. The 
mixture was allowed to stir at rt for 24 hours. The reaction mixture was quenched by the addition 
of 20 mL of NaOH(aq) (20% w/v) and 20 mL of DCM. The resulting two layers were separated 
and the aqueous layer was extracted with DCM (3 x 15 mL). The combined organic layers were 
washed with 30 mL of brine, dried over magnesium sulfate, filtered through a coarse porosity 
fritted funnel and concentrated in vacuo. The crude material was dissolved in 25 mL of diethyl 
ether and 2 mL of 1M HCl in ether (2 equivalents) was added dropwise to the vigorously stirring 
ether solution at room temperature. The resulting slurry was allowed to stir for 1 hour in a 0 °C 
(ice/water) and solvent was removed by needle filtration. The resulting solid was washed with an 
additional 25 mL of diethyl ether and needle filtered again. The resulting salt was treated with 20 
mL of (20% w/v) NaOH(aq) and 20 mL of DCM.  The aqueous layer was extracted with 15mL 
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DCM and the combined organic layers were dried over anhydrous magnesium sulfate, filtered 
through a coarse porosity fritted funnel and concentrated in vacuo to yield pure product.    
General Procedure B 
To a round bottom flask equipped with a magnetic stir bar and rubber septum, was added, N-
Boc-3-amino-4-halopyridine (1 equiv) then added TFA (10 equiv) via syringe, neat. CAUTION: 
Vigorous gas evolution and an exothermic reaction occurs. The Boc-removal was monitored by 
thin layer chromatography (3-amino-4-halopyridines have an Rf = 0.20 in 1:1 ethyl acetate: 
hexanes). The reaction mixture was concentrated in vacuo. The crude oil was dissolved in ethyl 
acetate and concentrated in vacuo three times to yield the solid pyridinium trifluoroacetate salt. 
DCM (0.5 M) then the carbonyl (2 equiv) were added to form a slurry mixture. Reaction stirred 
for 1 hour before adding sodium triacetoxyborohydride (2 equiv). Reduction was allowed to 
occur for 1 hour. The reaction was quenched and collected with (20% w/v) NaOH(aq) and DCM. 
The resulting two layers were separated and the aqueous layer was extracted with DCM (3 x 15 
mL). The combined organic layers were washed with brine, dried over anhydrous magnesium 
sulfate, filtered through a coarse porosity fritted funnel and concentrated in vacuo.  
General Procedure C 
To a round bottom flask equipped with a magnetic stir bar and rubber septum, was added, N-
Boc-3-amino-4-halopyridine (1 equiv) then added TFA (10 equiv) via syringe, neat. CAUTION: 
Vigorous gas evolution and an exothermic reaction occurs. The Boc-removal was monitored by 
thin layer chromatography (3-amino-4-halopyridines have an Rf = 0.20 in 1:1 ethyl acetate: 
hexanes). The reaction mixture was concentrated in vacuo. The crude oil is dissolved in ethyl 
acetate and concentrated in vacuo three times to yield the solid pyridinium trifluoroacetate salt. 
DCM (0.5 M) then the carbonyl (1.1 equiv) were added to form a slurry mixture. Reaction was 
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stirred for 1 hour before adding sodium triacetoxyborohydride (3 equiv). Reduction was allowed 
to occur for 24 hours. The reaction was quenched and collected with 20% (w/v) NaOH aqueous 
solution and DCM. The resulting two layers were separated and the aqueous layer was extracted 
three times with DCM (3 x 15 mL). The combined organic layers were washed with brine, dried 
over magnesium sulfate, filtered through a coarse porosity fritted funnel and concentrated in 
vacuo. The crude mixture was dissolved in 25 mL of diethyl ether. 2 mL of 1M ethereal 
hydrogen chloride (2 equivalents) was added dropwise to the vigorously stirring ether solution at 
room temperature. The resulting slurry was allowed to stir for 1 hour in a 0 °C ice-water bath. 
Slurry was removed from ice bath and stirring, and was subject to needle filtration. The resulting 
solid was treated with an additional 25 mL of diethyl ether and needle filtered again. The 
resulting wash was discarded and the pyridinium salt was collected with 20 mL (20% w/v) 
NaOH(aq) and 20 mL DCM. The aqueous layer was extracted once more with 15 mL DCM. The 
combined organics were dried over anhydrous magnesium sulfate, filtered through a coarse 
porosity fritted funnel and concentrated in vacuo. 
 
General Procedure for directed metalation 
A flame-dried 3 neck round bottom flask equipped with a magnetic stir bar, addition funnel, 
immersion thermometer, and septum was charged with N-Boc-3-aminopyridine and 1,2-
dimethoxyethane (~0.3 M). The reaction mixture was cooled to -78 °C (dry ice/acetone) and n-
BuLi (2.4 equiv, hexanes solution) was added dropwise to yield an opaque mixture that was 
allowed to warm to -20 °C and stir for 2 hours. The reaction mixture was again cooled to -78 °C 
and a solution of electrophilic halogen source (1.5 equiv) in 1,2 dimethoxyethane (~1.6 M) was 
added dropwise. The resulting solution was allowed to warm to room temperature with removal 
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of cooling bath and stir overnight. The reaction was quenched by the addition of saturated 
ammonium chloride and the layers were separated. The aqueous layer was extracted 3 times with 
methyl tert-butyl ether. The combined organic layers were washed with brine, dried over 
anhydrous magnesium sulfate, filtered through a coarse porosity fritted filter, and then 
concentrated in vacuo. The crude material was adsorbed onto silica gel and loaded directly onto 
silica gel column, eluting with 30% ethyl acetate: hexanes.  
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N-Boc-3-Aminopyridine (2.37). A 250 mL, 3-neck round bottom flask 
equipped with 100 mL addition funnel and magnetic stir bar was charged with 
3-aminopyridine (20 g, 213 mmol), isopropanol (60 mL), and water (23 mL), and the mixture 
was cooled to 0 °C in an ice-water bath. The addition funnel was charged with a solution of di-
tert-butyl dicarbonate (53 g, 244 mmol) in isopropanol (30 mL). Gas evolution occurred during 
the dropwise addition. Upon completion of the dropwise addition, the reaction was removed 
from ice bath, allowed to warm to room temperature and stirred overnight. Reaction was 
concentrated in vacuo and the resulting thick oil was dissolved in methyl tert-butyl ether. The 
resulting two layers were separated with a separatory funnel. The aqueous layer was extracted 
with methyl tert-butyl ether three times. The collected organic was washed with brine, dried over 
anhydrous magnesium sulfate, filtered through a coarse porosity fritted filter, then concentrated 
in vacuo to yield 35.5 grams of white solid (86%): Compared to literature data
101
 mp 115-117 
°C; 
1
H NMR (400 MHz, CDCl3) δ 8.43 (d, J = 2.4 Hz, 1H), 8.28 (dd, J =  4.7, 1.4 Hz, 1H), 7.97 
(d, J = 7.0 Hz, 1H), 7.24 (dd, J = 8.4, 4.7 Hz, 1H), 6.57 (bs, 1H), 1.53 (s, 9H). 
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N-Boc-3-Amino-4-chloropyridine (2.25). Following the general procedure 
for directed metalation using hexachloroethane as the electrophile on a 100 
mmol (19.4 g) scale, a yield of 14.55g of an pale yellow solid was obtained 
(64%): mp:105-106 °C; Rf 0.52 (1:1 ethyl acetate:hexanes);  
1
H NMR (400 MHz, CDCl3) δ 9.36 
(s, 1H), 8.20 (d, J =5.2 Hz, 1H), 7.29 (d, J=5.2 Hz, 1H), 6.83 (bs, 1H), 1.55 (s, 9H); 
13
C NMR 
(100 MHz, CDCl3) δ 152.0, 144.2, 142.2, 132.7, 131.1, 123.8, 82.1, 28.4. IR (KBr pellet) ν = 
3224, 3135, 2973, 1725, 1573, 1085 cm
-1
; Anal. Calcd for C10H13ClN2O2: C, 52.52; H, 5.73; N, 
12.25; Found: C, 52.45; H, 5.47; N, 12.32. 
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N-Boc-3-Amino-4-bromopyridine (2.38). Following the general procedure 
for directed metalation using 1,2-dibromoethane as the electrophile on a 60 
mmol (11.66 g) scale, a yield of 8.63g of a white solid was obtained (53%): mp 
108-109 °C; Rf 0.41 (1:1 ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 9.31 (s, 1H), 
8.10 (d, J =5.2 Hz, 1H), 7.45 (d, J =5.2 Hz, 1H), 6.83 (bs, 1H), 1.54 (s, 9H); 
13
C NMR (100 
MHz, CDCl3) δ 152.0, 144.3, 142.3, 133.9, 127.1, 122.2, 82.1, 28.4; IR (KBr pellet) 3228, 3125, 
1974, 1727, 1568, 1456, 1164 cm
-1
; Anal. Calcd for C10H13BrN2O2: C, 43.97; H, 4.80; N, 10.26. 
Found: C, 43.78; H, 4.81; N, 10.00.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
 
 
N-Boc-3-Amino-4-iodopyridine (2.39). Following the general procedure for 
directed metalation using iodine as the electrophile on a 60 mmol (11.66 g) 
scale, a yield of 10.23g of a pale yellow solid was obtained (53%): mp: 87-88 °C; Rf  0.41 (1:1 
ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 9.14 (s, 1H), 7.91 (d, J =5.1 Hz, 1H), 7.69 
(d, J =5.1 Hz, 1H), 6.66 (bs, 1H), 1.55 (s, 9H); 
13
C NMR (100 MHz, CDCl3) δ 152.2, 144.6, 
142.1, 136.6, 133.7, 99.7, 82.0, 28.4; IR (KBr pellet) 3381, 3068, 2980, 1726, 1561, 1509, 1250 
cm
-1
; Anal. Calcd for C10H13N2IO2: C, 37.52; H, 4.09; N, 8.75. Found: C, 37.78; H, 4.05; N, 
8.74;  
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3-Amino-4-chloropyridinium trifluoroacetate (2.45). A 25 mL round 
bottom flask and magnetic stir bar was charged with N-Boc-3-amino-4-
chloropyridine (228mg, 1.0 mmol) and TFA (741 μL, 10 mmol). Upon 
completion of the Boc-removal, the yellow solution was concentrated in vacuo to yield 231 mg 
of a pale yellow solid (95%): mp 134-135 °C; Rf  0.12 (50% ethyl acetate : hexanes); 
1
H NMR 
(400 MHz, CDCl3) δ 8.56 (s, 1H), 7.91 (d, J = 5.8 Hz, 1H), 7.58 (d, J = 5.84 Hz, 1H);
 13
C NMR 
(100 MHz, (CD3)2SO) δ 159.2 (q, JC-F = 34.1 Hz), 144.2, 131.0, 130.4, 129.7, 126.6, 116.6 (q, 
JC-F = 293.4 Hz); 
19
F NMR (376.5 MHz, CDCl3) δ -76.2; IR (KBr, pellet) 3375, 3196, 3044, 
2644, 2112, 1675, 1560, 1489, 1206; Anal. Calcd for C7H6ClF3N2O2: C, 34.66; H, 2.49; N, 
11.55. Found: C, 34.63; H, 2.65; N, 11.51.  
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N-(Ethyl)-3-amino-4-chloropyridine (2.46). To a 100 mL flame-dried round-
bottom flask equipped with a magnetic stir was charged with N-Boc-3-amino-4-
chloropyridine (1.14 g, 5 mmol) and DMF (0.5M). The resulting mixture was 
cooled to 0 °C (ice-water) and sodium hydride (60% by wt, 300 mg, 7.5 mmol) was added 
(CAUTION: gas evolution). After 1 hour, bromoethane (0.56 mL, 7.5 mmol) was added 
dropwise via syringe at 0 °C. After addition was complete the cooling bath was removed and the 
reaction mixture was allowed to warm to room temperature. After 30 minutes at room 
temperature the reaction mixture was quenched with 10 mL water. The resulting layers were 
separated and the aqueous layer was extracted with ethyl acetate (3 x 15 mL). The organic layers 
were collected, washed with 30 mL brine, dried over anhydrous magnesium sulfate, filtered 
through a coarse porosity fritted funnel and concentrated in vacuo to yield a yellow oil. The 
crude mixture was diluted in 10 mL DCM and 3.5 mL of TFA was added dropwise via syringe. 
The reaction was monitored by TLC and upon completion the reaction was quenched with water 
and (20% w/v) NaOH(aq) was added until the aqueous layer was pH 8. The aqueous layer was 
extracted with DCM (3 x 15 mL). The combined organics were washed with brine, dried over 
magnesium sulfate, filtered through a coarse porosity fritted funnel, and concentrated in vacuo. 
The crude material was subjected to flash column chromatography (2.5cm x 15cm) eluting with 
1L 10% ethyl acetate: hexanes to yield 224 mg of white solid (29%). mp 26-27 °C; Rf = 0.4 (1:1 
ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.87 (d, J = 4.8 Hz, 1H), 
7.17 (d, J = 5.2 Hz, 1H), 4.09 (s, 1H), 3.29-3.26 (m, 2H), 1.34 (t, J = 7.2 Hz, 3H) 
13
C NMR  
(100 MHz, CDCl3) δ 140.6, 138.4, 133.4, 127.3, 123.7, 38.0, 14.7; IR (KBr, pellet) 3410, 2969, 
1579, 1507, 1414, 1325 cm
-1
; Anal. Calcd for C7H9ClN2: C, 53.68; H, 5.79; N, 17.89. Found: C, 
53.72; 5.74; N, 17.88. 
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N-(Benzyl)-3-amino-4-chloropyridine (2.30a). Following general 
procedure A: 193 mg of pale yellow solid containing 5% of pyridine 2.35 
was collected. 2.30a could be further purified via flash column 
chromatography, eluting with 3% ethyl acetate: 3% triethylamine: 3% benzene: 91% hexanes to 
yield 173 mg of pale yellow crystalline solid (79%). mp 100-103 °C; Rf 0.42 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.90 (d, J = 5.1 Hz, 1H), 7.38 - 7.29 (m, 
5H), 7.20 (d, J = 5.1 Hz, 1H), 4.62 (bs, 1H), 4.46 (d, J = 5.7 Hz, 2H); 
13
C NMR (100 MHz, 
CDCl3) δ 140.3, 138.9, 137.9, 133.8, 128.9, 127.7, 127.6, 127.4, 123.8, 47.7; IR (KBr, pellet) 
3428, 1636, 1579, 1259; Anal. Calcd for C12H11ClN2: C, 65.91; H, 5.07; N, 12.81. Found. C, 
65.79; H, 5.08; N, 12.80. 
 
In addition, a 15 mmol scale reaction for 2.30a was performed following general procedure A: 
Following the work-up and purification via general procedure A: product was recrystallized in 
10% methanol: hexanes solution to yield 2.73 g of pale yellow solid (83%).  
 
Following the Boc-removal protocol to yield 3-aminopyridinium trifluoroacetate, the salt was 
recrystallized using ethyl acetate and subject to conditions following general procedure A: 
pyridinium salt (121 mg, 0.5 mmol), DCM (0.5 M), benzaldehyde (102 μL, 1 mmol), then 
TMSOTf (181 μL, 1 mmol) were combined in a 25 mL round-bottom flask, equipped with stir 
bar and rubber septum, and allowed to stir for 1 hr at rt. Sodium triacetoxyborohydride (318 mg, 
1.5 mmol) was added in one portion and allowed to stir for 24 hr. Following the work-up and 
purification via general procedure A, 90 mg of white solid was obtained (83%). 
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N-(4-Bromobenzyl)-3-amino-4-chloropyridine (2.30b). Following 
general procedure A: 273 mg of pale orange crystalline solid was 
obtained (92%): mp 104-105 °C; Rf 0.65 (50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.96 (s, 1H), 7.91 (d, J = 4.8 Hz, 1H), 7.50-7.47 (m, 2H), 7.23-
7.19 (m, 2H), 7.20 (d, J = 5.1 Hz, 1H), 4.63 (bs, 1H), 4.43 (d, J = 5.8 Hz, 2H); 
13
C NMR (100 
MHz, CDCl3) δ 140.2, 139.4, 137.0, 133.9, 132.2, 129.1, 127.9, 124.0, 121.7, 47.2; IR (KBr, 
pellet) 3244, 1577, 1512, 1407, 1329, 1234, 1073 cm
-1
; Anal. Calcd for C12H10BrClN2: C, 48.43; 
H, 3.39; N, 9.41. Found. C, 48.43; H, 3.49; N, 9.58. 
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N-(2-Chlorobenzyl)-3-amino-4-chloropyridine (2.30c). Following 
general procedure A: 2.30c was further purified via flash column 
chromatography eluted with 3% ethyl acetate: 3% triethylamine: 3% 
benzene: 91% hexanes afforded 196 mg of pale yellow crystalline solid (77%): mp 81-83 °C; Rf 
0.47 (50% ethyl acetate: hexanes);
 1
H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.93 (d, J = 5.1 
Hz, 1H), 7.46-7.38 (m, 2H), 7.30-7.27 (m, 2H), 7.23 (d, J = 5.1 Hz, 1H), 4.79 (bs, 1H), 4.61 (d, J 
= 6.1 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 140.1, 139.3, 135.2, 134.0, 133.6, 130.0, 129.1, 
129.0, 127.9, 127.3, 124.0, 45.5; IR (KBr, pellet) 3245, 3068, 2955, 1583, 1558, 1509, 1417, 
1330, 1259, 1069 cm
-1
; Anal. Calcd for C12H10Cl2N2: C, 56.94; H, 3.98; N, 11.07. Found. C, 
56.91; H, 3.98; N, 11.09. 
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N-(4-Fluorobenzyl)-3-amino-4-chloropyridine (2.30d). Following 
general procedure A: 2.30d was recrystallized in 30:1 hexanes: ethyl 
acetate afforded 180 mg of slight yellow crystalline solid (76%): mp 
80-83 °C; Rf 0.37 (50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.99 (s, 1H), 7.90 
(d, J = 5.1 Hz, 1H), 7.35-7.31 (m, 2H), 7.20 (d, J = 5.1 Hz, 1H), 7.07-7.03 (m, 2H), 4.60 (bs, 
1H), 4.43 (d, J = 5.6 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 162.5 (d, JC-F= 244.8 Hz), 140.2, 
139.2, 133.9, 133.7 (d, JC-F= 3.2 Hz), 129.1 (d, JC-F= 8.0 Hz), 127.8, 123.9, 115.9 (d, JC-F= 21.6 
Hz), 47.2; 
19
F NMR (376.5 MHz, CDCl3) δ -115.3; IR (KBr, pellet) 3321, 3054, 2913, 1579, 
1506, 1325, 1228, 1070 cm
-1
; Anal. Calcd for C12H10ClFN2: C, 60.90; H, 4.26; N, 11.84. Found. 
C, 60.92; H, 4.31; N, 11.87. 
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N-(4-Chlorobenzyl)-3-amino-4-chloropyridine (2.30e). Following 
general procedure A: 2.30e was further purified via flash column 
chromatography eluted with 3% acetone: 3% triethylamine: 3% 
benzene: 91% hexanes afforded 208 mg of slight orange crystalline solid (82%): mp 93-95 °C; Rf 
0.50 (50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.96 (s, 1H), 7.90 (d, J = 5.1 
Hz, 1H), 7.35-7.30 (m, 4H), 7.20 (d, J = 5.1 Hz, 1H), 4.63 (bs, 1H), 4.44 (d, J = 5.7 Hz, 2H); 
13
C 
NMR (100 MHz, CDCl3) δ 140.2, 139.3, 136.5, 133.9, 133.6, 129.2, 128.7, 127.9, 124.0, 47.2; 
IR (KBr, pellet) 3436, 3235, 2847, 1578, 1513, 1489, 1416, 1330, 1089 cm
-1
; Anal. Calcd for 
C12H10Cl2N2: C, 56.94; H, 3.98; N, 11.07. Found: C, 57.08; H, 4.03; N, 10.75. 
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N-(4-Cyanobenzyl)-3-amino-4-chloropyridine (2.30f). Following 
general procedure A: 2.30f was further purified via flash column 
chromatography eluted with 3% ethyl acetate: 3% triethylamine: 3% 
benzene: 91% hexanes, then recrystallized in hexanes to afford 178 mg of pale yellow crystalline 
solid (73%): mp 107-108 °C; Rf 0.20 (50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) 
δ 7.93-7.87 (m, 2H), 7.65 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 5.0 Hz, 1H), 
4.79 (bs, 1H), 4.56 (d, J = 6.0 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 143.7, 139.7, 133.8, 
132.8, 128.1, 127.7, 124.1 (2 overlapping), 118.7, 111.8, 47.3; IR (KBr, pellet) 3236, 3055, 
2226, 1577, 1508, 1327, 1239, 1069, 823, 692, 556 cm
-1
; Anal. Calcd for C13H10ClN3: C, 64.07; 
H, 4.14; N, 17.24. Found. C, 64.07; H, 4.16; N, 17.43. 
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N-(4-Nitrobenzyl)-3-amino-4-chloropyridine (2.30g). Following 
general procedure A: 2.30g was further purified via silica plug eluted 
with 50% ethyl acetate: hexanes afforded 240 mg of green solid 
(91%): mp 118-119 °C; Rf 0.28 (50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 
8.24-8.21 (m, 2H), 7.93 (d, J = 5.1 Hz, 1H), 7.88 (s, 1H), 7.54-7.52 (m, 2H), 7.23 (d, J = 5.1 Hz, 
1H), 4.81 (bs, 1H), 4.61 (d, J = 6.0 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 147.7, 145.7, 139.9, 
139.8, 133.7, 128.2, 127.8, 124.3, 124.1, 47.2; IR (KBr, pellet) 3221, 3071, 2925, 1579, 1516, 
1345, 1069 cm
-1
; Anal. Calcd for C12H10ClN3O2: C, 54.66; H, 3.82; N, 15.94. Found. C, 54.63; 
H, 3.84; N, 16.14. 
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N-(4-(Trifluoromethyl)benzyl)-3-amino-4-chloropyridine (2.30h). 
Following general procedure A: 2.30h was further purified via flash 
column chromatography eluted with a gradient elution of 10% to 
30% ethyl acetate: hexanes, affording 209 mg of white crystalline solid (73%): mp 94-96 °C; Rf 
0.31 (50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.93 (s, 1H), 7.91 (d, J = 5.1 
Hz, 1H), 7.61 (d, J = 8.1 Hz, 2H), 7.48 (d, J = 8.1 Hz, 2H), 7.21 (d, J = 5.1 Hz, 1H), 4.73 (bs, 
1H), 4.55 (d, J = 5.8 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) 142.2 (q, JC-F = 1.4 Hz), 140.0, 
139.5, 133.9, 130.2 (q, JC-F = 32.3 Hz), 128.0, 127.5, 126.0 (q, JC-F= 3.8 Hz), 124.2 (q, JC-F = 
270.4 Hz), 124.0, 47.3; 
19
F NMR (376.5 MHz, CDCl3) δ -63.1; IR (KBr, pellet) 3272, 3054, 
2942, 1619, 1582, 1507, 1414 cm
-1
; Anal. Calcd for C13H10ClF3N2: C, 54.47; H, 3.52; N, 9.77. 
Found. C, 54.23; H, 3.49; N, 9.90. 
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N-Cinnamyl-3-amino-4-chloropyridine (2.30i). Following general 
procedure A: 2.30i was further purified via flash column chromatography 
eluted with 3% ethyl acetate: 3% triethylamine: 3% benzene: 91% 
hexanes afforded 185 mg of white solid (76%): mp 65-67 °C; Rf  0.28 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3): δ 8.10 (s, 1H), 7.91 (d, J =5.1 Hz, 1H), 7.39-7.36 (m, 
2H), 7.34-7.30 (m, 2H), 7.27-7.23 (m, 1H), 7.20 (d, J =5.1 Hz, 1H), 6.66 (d, J =15.9 Hz, 1H), 
6.31 (dt, J =15.9, 5.8 Hz, 1H), 4.44 (bs, 1H), 4.08 (td, J =5.8, 1.5 Hz, 1H); 
13
C NMR (100 MHz, 
CDCl3): δ 140.4, 139.0, 136.6, 134.0, 132.7, 128.8, 128.0, 127.8, 126.6, 125.5, 123.9, 45.7; IR 
(KBr, pellet) 3274, 3055, 3020, 2936, 1576, 1552, 1071 cm
-1
; Anal. Calcd for C14H13ClN2: C, 
68.71; H, 5.35; N, 11.45. Found: C, 68.75; H, 5.41; N, 11.46. 
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N-(4-Phenylbenzyl)-3-amino-4-chloropyridine (2.30j). Following 
general procedure A: 2.30j was further purified via flash column 
chromatography eluted with 3% ethyl acetate: 3% triethylamine: 3% 
benzene: 91% hexanes afforded 220 mg of off-white crystalline solid (87%): mp 98-100 °C; Rf 
0.53 (50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 7.91 (d, J = 5.1 
Hz, 1H), 7.60-7.57 (m, 4H), 7.47-7.43 (m, 4H), 7.38-7.33 (m, 1H), 7.21 (d, J = 5.1 Hz, 1H), 4.66 
(bs, 1H), 4.43 (d, J = 5.6 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 140.8, 140.7, 140.3, 139.9 
136.9, 133.8, 128.8, 128.0, 127.8, 127.6, 127.4, 127.1, 123.8, 47.4; IR (KBr, pellet) 3270, 1581, 
1514, 1487, 1418, 1259 cm
-1
; Anal. Calcd for C18H15ClN2: C, 73.34; H, 5.13; N, 9.50. Found: C, 
73.45; H, 5.15; N, 9.83. 
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N-(Furfuryl)-3-amino-4-chloropyridine (2.30k). Following general 
procedure A: 2.30k was further purified via flash column chromatography 
eluted with 1% ethyl acetate: 1% triethylamine: 1% benzene: 97% hexanes 
then crystallized in of hexanes to afford 114 mg of off white solid (55%): mp 59-61 °C; Rf 0.47 
(50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.92 (d, J = 5.1 Hz, 
1H), 7.39 (dd, J = 1.8 Hz, 0.8 Hz, 1H), 7.19 (d, J = 5.1 Hz, 1H), 6.34 (dd, J = 3.2 Hz, 1.8 Hz, 
1H), 6.29 (dd, J = 3.2 Hz, 0.8 Hz, 1H), 4.60 (bs, 1H), 4.45 (d, J = 5.9 Hz, 2H); 
13
C NMR (100 
MHz, CDCl3) δ 151.3, 142.6, 140.1, 139.4, 134.0, 128.1, 124.0, 110.6, 107.9, 40.9; IR (KBr, 
pellet) 3431, 3199, 3075, 3014, 2953, 1581, 1556, 1517, 1438 cm
-1
; Anal. Calcd for 
C10H9ClN2O: C, 57.57; H, 4.35; N, 13.43. Found: C, 57.51; H, 4.35; N, 13.68. 
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N-(4-Methylbenzyl)-3-amino-4-chloropyridine (2.30l). Following 
general procedure A:  204 mg of 2.30l was obtained as a pale orange 
crystalline solid (88%): mp 80-82 °C; Rf 0.50 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.88 (d, J = 5.1 Hz, 1H), 7.26 (d, J = 8.0 
Hz, 2H), 7.20-7.16 (m, 3H), 4.57 (bs, 1H), 4.41 (d, J = 5.6 Hz, 2H), 2.35 (s, 3H); 
13
C NMR (100 
MHz, CDCl3) δ 140.5, 138.9, 137.6, 134.9, 133.9, 129.7, 127.7, 127.5, 123.9, 47.6, 21.2; IR 
(KBr, pellet) 3238, 3079, 3018, 2930, 2850, 1577, 1512, 1415, 1332, 1262 cm
-1
; Anal. Calcd for 
C13H13ClN2: C, 67.10; H, 5.63; N, 12.04. Found: C, 67.21; H, 5.61; N, 12.19.  
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N-(Piperonyl)-3-amino-4-chloropyridine (2.30m). Following 
general procedure A: 2.30m was purified via flash column 
chromatography eluted with 3% ethyl acetate: 3% triethylamine: 3% 
benzene: 91% hexanes to afford 224 mg of white crystalline solid (86%): mp 88-92 °C; Rf 0.52 
(50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.89 (d, J = 5.1 Hz, 
1H), 7.19 (d, J = 5.1 Hz, 1H), 6.87-6.77 (m, 3H), 5.96 (d, J = 1.7 Hz, 2H), 4.57 (bs, 1H), 4.36 (d, 
J = 5.6 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 148.3, 147.3, 140.3, 139.1, 134.0, 131.8, 127.8, 
123.9, 120.8, 108.7, 108.0, 101.3, 47.7; IR (KBr, pellet) 3412, 2901, 1578, 1501, 1416, 1245 cm
-
1
; Anal. Calcd for C13H11ClN2O2: C, 59.44; H, 4.22; N, 10.66. Found. C, 59.36; H, 4.25; N, 
10.65. 
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N-(2,3-Dimethoxybenzyl)-3-amino-4-chloropyridine (2.30n). 
Following general procedure A: 2.30n was further purified via flash 
column chromatography eluted with 10% ethyl acetate: hexanes, 
then 20% ethyl acetate: hexanes to afford 232 mg of pale yellow crystalline solid (83%): mp 76-
79 °C; Rf 0.44 (50% ethyl acetate: hexanes);
 1
H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.88 (d, 
J = 5.1 Hz, 1H), 7.17 (d, J = 5.1 Hz, 1H), 7.03 (t, J = 7.9 Hz, 1H), 6.91 (dd, J = 7.7 Hz, 1.5 Hz, 
1H), 6.88 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 4.67 (bs, 1H), 4.47 (d, J = 6.0 Hz, 2H), 3.90 (s, 3H), 3.88 
(s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 153.0, 147.4, 140.5, 138.8, 134.0, 131.6, 127.8, 124.4, 
123.9, 120.8, 112.3, 61.0, 55.9, 43.0; IR (KBr, pellet) 3387, 2997, 2964, 2933, 2831, 1582, 1510, 
1480, 1449, 1418 cm
-1
; Anal. Calcd for C14H15ClN2O2: C, 60.33; H, 5.42; N, 10.05. Found. C, 
60.10; H, 5.59; N, 9.90. 
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N-(2,4-Dimethoxybenzyl)-3-amino-4-chloropyridine (2.30o). 
Following general procedure B: 2.30o was further purified via flash 
column chromatography eluted with 10% ethyl acetate: hexanes to 
afford 97 mg of slight yellow crystalline solid (70%): mp 70-71 °C; Rf 0.37 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.85 (d, J = 5.1 Hz, 1H), 7.18 (d, J = 8.9 
Hz, 1H), 7.15 (d, J = 5.1 Hz, 1H), 6.48 (d, J = 2.3 Hz, 1H), 6.44 (dd, J = 8.2 Hz, 2.4 Hz, 1H), 
4.67 (app. t, J = 5.4 Hz, 1H), 4.38 (d, J = 6.1 Hz, 2H), 3.85 (s, 3H), 3.78 (s, 3H); 
13
C NMR (100 
MHz, CDCl3) δ 160.7, 158.7, 140.8, 138.6, 134.3, 129.9, 127.8, 123.8, 118.5, 104.2, 98.9, 55.5, 
55.5, 42.9; IR (KBr, pellet) 3246, 1620, 1582, 1510, 1209 cm
-1
; Anal. Calcd for C14H15ClN2O2: 
C, 60.33; H, 5.42; N, 10.05. Found: C, 59.99; H, 5.52; N, 9.97. 
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N-(2,5-Dimethoxybenzyl)-3-amino-4-chloropyridine (2.30p). 
Following general procedure B: 2.30p was further purified via flash 
column chromatography eluted with 10% ethyl acetate: hexanes to 
afford 106 mg of slight yellow crystalline solid (76%): mp 70-71 °C; Rf 0.37 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 7.86 (d, J = 5.1 Hz, 1H), 7.16 (d, J = 5.1 
Hz, 1H), 6.86 (d, J = 2.8 Hz, 1H), 6.83 (d, J = 8.8 Hz, 1H), 6.77 (dd, J = 8.8 Hz, 3.0 Hz, 1H), 
4.76-4.73 (m, 1H), 4.43 (d, J = 6.2 Hz, 2H), 3.84 (s, 3H), 3.74 (s, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 153.7, 151.6, 140.5, 138.7, 134.1, 127.7, 127.1, 123.7, 115.3, 112.6, 111.3, 55.8, 55.7, 
43.0; IR (KBr, pellet) 3278, 3063, 2997, 2956, 2836, 1577, 1501, 1417, 1270, 1235 cm
-1
; Anal. 
Calcd for C14H15ClN2O2: C, 60.33; H, 5.42; N, 10.05. Found. C, 60.28; H, 5.42; N, 9.95. 
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N-(2,2-Dimethylpropyl)-3-amino-4-chloropyridine (2.30q). Following 
general procedure A: 2.30q was further purified via flash column 
chromatography eluted with 1% ethyl acetate: 1% triethylamine: 1% 
benzene: 97% hexanes to afford 136 mg of pale yellow crystalline solid (68%): mp 35-37 °C; Rf 
0.51 (50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 7.84 (d, J = 5.1 
Hz, 1H), 7.15 (d, J = 5.1 Hz, 1H), 4.21 (bs, 1H), 3.01 (d, J = 6.0 Hz, 2H), 1.03 (s, 9H); 
13
C NMR 
(100 MHz, CDCl3) δ 141.3, 138.2, 133.6, 127.4, 123.8, 55.2, 32.2, 27.6; IR (KBr, pellet) 3427, 
3224, 2961, 2864, 2502, 1580, 1517, 1417 cm
-1
; Anal. Calcd for C10H15ClN2: C, 60.45; H, 7.61; 
N, 14.10. Found: C, 60.43; H, 7.50; N, 14.17. 
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N-(n-Butyl)-3-amino-4-chloropyridine (2.30r). Following general 
procedure C: 2.30r was further purified via flash column chromatography 
eluted with 1% ethyl acetate: 1% triethylamine: 1% benzene: 97% hexanes 
to afford 125 mg of off-white crystalline solid (68%): mp 38-39 °C; Rf 0.43 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.86 (d, J = 4.6 Hz, 1H), 7.16 (d, J = 5.0 
Hz, 1H), 4.15 (bs, 1H), 3.25-3.21 (m, 2H), 1.71-1.64 (m, 2H), 1.50-1.41 (m, 2H), 0.98 (t, J = 7.4 
Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 140.7, 138.2, 133.4, 127.2, 123.7, 43.1, 31.4, 20.2, 13.8; 
IR (KBr, pellet) 3309, 2953, 2935, 2868, 1580, 1555, 1484, 1410 cm
-1
; Anal. Calcd for 
C9H13ClN2: C, 58.54; H, 7.10; N, 15.17. Found C, 58.54; H, 7.11; N, 15.22. 
94 
 
 
 
N-(Cyclohexylmethyl)-3-amino-4-chloropyridine (2.30s). Following 
general procedure C: 2.30s was further purified via flash column 
chromatography eluted with 10% ethyl acetate: hexanes to afford 180 mg 
of slight yellow crystalline solid (80%): mp 67-70 °C; Rf 0.59 (50% ethyl acetate: hexanes); 
1
H 
NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.83 (d, J = 5.1 Hz, 1H), 7.14 (d, J = 5.1, 1H), 4.25 (bs, 
1H), 3.06 (t, J = 6.2 Hz, 2H), 1.86-1.57 (m, 6H), 1.32-1.12 (m, 3H), 1.06-0.94 (m, 2H); 
13
C 
NMR (100 MHz, CDCl3) δ 140.8, 138.1, 133.5, 127.3, 123.8, 50.0, 37.5, 31.2, 26.6, 26.0; IR 
(KBr, pellet) 3383, 3054, 2923, 2845, 1577, 1508, 1459 cm
-1
; Anal. Calcd for C12H17ClN2: C, 
64.14; H, 7.63; N, 12.47. Found. C, 64.12; H, 7.54; N, 12.18. 
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N-(Cyclohexyl)-3-amino-4-chloropyridine (2.30t). Following general 
procedure A: 2.30t was further purified via flash column chromatography 
eluted with 3% acetone: 3% triethylamine: 3% benzene: 91% hexanes 
afforded 79 mg of white crystalline solid (75%): mp 64-65 °C; Rf 0.68 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.82 (d, J = 5.1 Hz, 1H), 7.15 (d, J = 5.1 
Hz, 1H), 4.09 (d, J = 7.1 Hz, 1H), 3.41-3.38 (m, 1H), 2.09-2.05 (m, 2H), 1.81-1.76 (m, 2H), 
1.69-1.64 (m, 1H), 1.44-1.37 (m, 2H), 1.31-1.20 (m, 3H); 
13
C NMR (100 MHz, CDCl3) δ 139.9, 
138.0, 134.1, 127.4, 124.1, 51.4, 33.3, 25.9, 24.9; IR (KBr, pellet) 3410, 3051, 2932, 2852, 1578, 
1506, 1449, 1414 cm
-1
; Anal. Calcd for C11H15ClN2: C, 62.70; H, 7.18; N, 13.30. Found. C, 
62.84; H, 7.18; N, 13.29. 
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N-(Benzyl)-3-amino-4-bromopyridine (2.48a). Following general 
procedure A: 2.48a was further purified via flash column chromatography, 
eluted with 10% ethyl acetate: 90% hexanes to yield 197 mg of pale purple 
crystalline solid (75%): mp 102-103 °C; Rf 0.44 (50% ethyl acetate: hexanes); 
1
H NMR (400 
MHz, CDCl3) δ 7.97 (s, 1H), 7.79 (d, J =5.1 Hz, 1H), 7.38-3.36 (m, 5H), 7.34-7.28 (m, 1H), 4.65 
(app t, 1H), 4.46 (d, J =5.6 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 141.5, 139.2, 138.0, 133.8, 
129.0, 127.9, 127.5, 127.2, 118.6, 48.0; IR (KBr, pellet) 3331, 3051, 2360, 1577, 1508, 1453, 
1413, 1256 cm
-1
; Anal. Calcd for C12H11BrN2: C, 54.77; H, 4.21; N, 10.65; Found: C, 54.79; H, 
4.21; N, 10.66. 
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N-(4-Methylbenzyl)-3-amino-4-bromopyridine (2.48b). Following 
general procedure A: 2.48b was recrystallized in hexanes to afford 229 
mg of pale orange crystalline solid (83%): mp 85-86 °C; Rf 0.44 (50% 
ethyl acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.97 (s, 1H), 7.79 (d, J = 5.0 Hz, 1H), 
7.35 (d, J = 5.1 Hz, 1H), 7.26 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 4.60 (bs, 1H), 4.41 
(d, J = 5.6 Hz, 2H), 2.35 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 141.5, 139.0, 137.6, 134.9, 
133.8, 129.7, 127.5, 127.2, 118.6, 47.7, 21.3; IR (KBr, pellet) 3424, 3250, 3055, 3020, 2935, 
2850, 1575, 1550, 1508, 1452, 1412 cm
-1
; Anal. Calcd for C13H13BrN2: C, 56.34; H, 4.73; N, 
10.11. Found: C, 56.40; H, 4.74; N, 10.04. 
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N-(4-Chlorobenzyl)-3-amino-4-bromopyridine (2.48c). Following 
general procedure A: 2.48c was further purified via silica plug eluted 
with 50% ethyl acetate: hexanes, then recrystallized with hexanes 
afforded 213 mg of an off-white crystalline solid (72%): mp 87-88 °C; Rf 0.40 (50% ethyl 
acetate: hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.80 (d, J = 5.1 Hz, 1H), 7.37 (d, 
J=5.1 Hz, 1H), 7.34 (d, J=8.7 Hz, 2H), 7.30 (d, J=8.7 Hz, 2H), 4.66 (bs, 1H), 4.44 (d, J = 5.7 Hz, 
2H); 
13
C NMR (100 MHz, CDCl3) δ 141.2, 139.4, 136.5, 133.8, 133.6, 129.2, 128.7, 127.3, 
118.8, 47.3; IR (KBr, pellet) 3241, 3055, 2934, 2896, 2848, 1574, 1551, 1508, 1488, 1413 cm
-1
; 
Anal. Calcd for C12H10BrClN2: C, 48.43; H, 3.39; N, 9.41. Found: C, 48.41; H, 3.43; N, 9.36. 
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N-(2,3-Dimethoxybenzyl)-3-amino-4-bromopyridine (2.48d). 
Following general procedure A: 2.48d was further purified via silica 
plug eluted with 50% ethyl acetate: hexanes, then recrystallized in 
hexanes to afford 257 mg of pale orange solid (80%): mp 83-85 °C; Rf 0.32 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.77 (d, J = 5.1 Hz, 1H), 7.33 (d, J = 5.1 
Hz, 1H), 7.03 (t, J = 7.9 Hz, 1H), 6.92-6.87 (m, 2H), 4.69 (bs, 1H), 4.48 (d, J = 5.9 Hz, 2H), 
3.90 (s, 3H), 3.88 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 158.0, 147.4, 141.6, 138.9, 133.9, 
131.6, 127.2, 124.3, 120.8, 118.6, 112.3, 61.0, 56.0, 43.1; IR (KBr, pellet) 3260, 3086, 2955, 
2932, 1573, 1544, 1480, 1413, 1274 cm
-1
; Anal. Calcd for C14H15BrN2O2: C, 52.03; H, 4.68; N, 
8.67. Found: C, 52.14; H, 4.81; N, 8.84. 
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N-(Benzyl)-3-amino-4-iodopyridine (2.49a). Following general 
procedure A: 2.49a was further purified via flash column chromatography, 
eluted with 10% ethyl acetate: 90% hexanes to yield 238 mg of off-white 
crystalline solid (77%): mp 90-92 °C; Rf 0.44 (50% ethyl acetate: hexanes); 
1
H NMR (400 MHz, 
CDCl3) δ 7.84 (s, 1H), 7.60 (d, J=4.8 Hz, 1H ), 7.58 (d, J=5.2 Hz, 1H), 7.38-3.36 (m, 4H), 7.34-
7.28 (m, 1H), 4.53 (bs, 1H), 4.46 (d, J =5.6 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 143.8, 
139.4, 137.9, 133.8, 132.8, 129.0, 127.8, 127.4, 95.1, 48.2; IR (KBr, pellet) 3328, 3061, 3015.6, 
2908, 1564, 1540, 1502, 1452, 1409 cm
-1
; Anal. Calcd for C12H11IN2: C, 46.47; H, 3.58; N, 9.03. 
Found: C, 46.46; H, 3.61; N, 9.02. 
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N-(4-Methylbenzyl)-3-amino-4-iodopyridine (2.49b). Following 
general procedure A: 2.49b was further purified via silica plug eluted 
with 50% ethyl acetate: hexanes, then recrystallized in hexanes to afford 
253 mg of a pale orange crystalline solid (78%): mp 65-66 °C; Rf 0.47 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.60 (d, J=4.8 Hz, 1H), 7.57 (d, J=4.8 Hz, 
1H), 7.25 (d, J = 7.9 Hz, 2H), 7.17 (d, J = 7.9 Hz, 2H), 4.46 (bs, 1H), 4.41 (d, J = 5.4 Hz, 2H), 
2.35 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 143.9, 139.3, 137.5, 134.9, 133.8, 132.9, 129.7, 
127.5, 95.1, 48.1, 21.3; IR (KBr, pellet) 3396, 3034, 2908, 2855, 1564, 1503, 1417 cm
-1
; Anal. 
Calcd for C13H13IN2: C, 48.17; H, 4.04; N, 8.64. Found: C, 48.16; H, 3.93; N, 8.53. 
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N-(4-Chlorobenzyl)-3-amino-4-iodopyridine (2.49c). Following 
general procedure A: 303 mg of 2.49c was obtained as a white 
crystalline solid (88%): mp 107-114 °C; Rf 0.40 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.78 (s, 1H), 7.61 (d, J=4.8 Hz, 1H), 7.59 (d, J=5.2 Hz, 
1H), 7.34 (d, J=8.6 Hz, 2H), 7.29 (d, J=8.6 Hz, 2H), 4.52 (bs, 1H), 4.44 (d, J = 5.6 Hz, 2H); 
13
C 
NMR (100 MHz, CDCl3) δ 143.6, 139.7, 136.5, 133.8, 133.6, 132.8, 129.2, 128.7, 95.3, 47.7; IR 
(KBr, pellet) 3389, 3043, 2929, 2868, 1559, 1497, 1446 cm
-1
; Anal. Calcd for C12H10ClIN2: C, 
41.83; H, 2.93; N, 8.13. Found: C, 41.76; H, 2.98; N, 8.05. 
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N-(2,3-Dimethoxybenzyl)-3-amino-4-iodopyridine (2.49d). 
Following general procedure A: 317 mg of 2.49d was obtained as a 
brown/red solid (85%): mp 118-120 °C; Rf 0.35 (50% ethyl acetate: 
hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.90 (s, 1H), 7.58 (d, J= 5.0 Hz, 1H), 7.56 (d, J=5.0 Hz, 
1H), 7.03 (t, J = 8.0 Hz, 1H), 6.89 (td, J=8.9, 1.5 Hz, 2H), 4.57 (bs, 1H), 4.47 (d, J = 5.8 Hz, 
2H), 3.91 (s, 3H), 3.88 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 153.0, 147.4, 144.0, 139.2, 133.8, 
131.5, 124.3, 120.7, 112.3, 95.1, 61.0, 56.0, 43.5; IR (KBr, pellet) 3413, 3001, 2970, 2935, 2834, 
1561, 1479, 1410, 1270 cm
-1
; Anal. Calcd for C14H15IN2O2: C, 45.42; H, 4.08; N, 7.57. Found: 
C, 45.50; H, 4.09; N, 7.55. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104 
 
 
 
N-Benzyl-2,4,6-tribromoaniline (2.51): An oven-dried 10 mL round 
bottom flask with magnetic stir bar was charged with 2,4,6-
tribromoaniline (330 mg, 1 mmol), benzaldehyde (0.20 mL, 2 mmol), 
and CH2Cl2 (2 mL, 0.5 M). Trimethylsilyl trifluoromethanesulfonate (0.36 mL, 2 mmol) was 
added in one portion and the mixture was stirred for 1 hour. To the mixture was added sodium 
triacetoxyborohydride (636 mg, 3 mmol) and the reaction was stirred 18 hours, before diluting 
with 10 mL CH2Cl2 and quenching with 20 mL of 20% (m/v) NaOH(aq). The aqueous layer was 
extracted 3 times with 10 mL portions of CH2Cl2. The combined organics were dried with 
MgSO4, filtered and concentrated in vacuo. The resulting oil was further purified via flash 
column chromatography (silica deactivated with a 1% triethylamine : 99% hexanes solution), 
eluting 402 mg of 2.51 with hexanes as a clear oil (96%): Rf 0.59 (10% ethyl acetate:hexanes); 
1
H NMR (400 MHz, CDCl3) δ 7.61 (s, 2H), 7.40-7.27 (m, 5H), 4.41 (s, 2H), 4.15 (bs, 1H); 
13
C 
NMR (100 MHz, CDCl3) δ 144.2, 139.1, 135.1, 128.8, 128.3, 127.8, 117.7, 114.4, 52.2; IR 
(NaCl, thin film) ν = 3051, 2983, 1264 cm-1; Anal. Calcd for C13H10Br3N: C, 37.18; H, 2.40; N, 
3.34. Found: C, 37.04; H, 2.44; N, 3.30. 
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N-Benzyl-2,4-dinitroaniline (2.52): An oven-dried 10 mL round 
bottom flask with magnetic stir bar was charged with 2,4-
dinitroaniline (183 mg, 1 mmol), benzaldehyde (0.20 mL, 2 mmol), 
and CH2Cl2 (2 mL, 0.5 M). Trimethylsilyl trifluoromethanesulfonate (0.36 mL, 2 mmol) was 
added in one portion and the mixture was stirred for 1 hour. To the mixture was added sodium 
triacetoxyborohydride (636 mg, 3 mmol) and the reaction was stirred 18 hours, before diluting 
with 10 mL CH2Cl2 and quenching with 20 mL of 20% (m/v) NaOH(aq). The aqueous layer was 
extracted 3 times with 10 mL portions of CH2Cl2. The combined organics were dried with 
MgSO4, filtered and concentrated in vacuo. The resulting crude solid was triturated with 10 mL 
of Et2O and 171 mg of 2.52 was collected by filtration as a yellow solid (63%): Compared to 
literature data
102
 
1
H NMR (400 MHz, CDCl3) δ 9.17 (d, J = 2.6 Hz, 1H), 8.91 (bs, 1H), 8.24 (dd, 
J = 9.5, 2.6 Hz, 1H), 7.43-7.33 (m, 5H), 6.91 (d, J = 9.5 Hz, 1H), 4.65 (d, J = 5.6 Hz, 2H); 
13
C 
NMR (100 MHz, CDCl3) δ 148.3, 136.7, 135.7, 131.0, 130.5, 129.5, 128.5, 127.2, 124.4, 114.5, 
47.7. 
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N-Benzyl-2,6-diisopropylaniline (2.53): An oven-dried 10 mL round 
bottom flask with magnetic stir bar was charged with 2,4-dinitroaniline 
(183 mg, 1 mmol), benzaldehyde (0.20 mL, 2 mmol), and CH2Cl2 (2 mL, 
0.5 M). Trimethylsilyl trifluoromethanesulfonate (0.36 mL, 2 mmol) was added in one portion 
and the mixture was stirred for 1 hour. To the mixture was added sodium triacetoxyborohydride 
(636 mg, 3 mmol) and the reaction was stirred 18 hours, before diluting with 10 mL CH2Cl2 and 
quenching with 20 mL of 20% (m/v) NaOH(aq). The aqueous layer was extracted 3 times with 10 
mL portions of CH2Cl2. The combined organics were dried with MgSO4, filtered and 
concentrated in vacuo. The crude oil was further purified via flash column chromatography 
(silica deactivated with a 1% triethylamine : 99% hexanes solution), eluting a mixture of benzyl 
alcohol: 2.53, which was purified further through the acidification/freebase method in General 
procedure A. This yielded 187 mg of 2.53 as a clear oil (70%): Compared to literature data
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1
H 
NMR (400 MHz, CDCl3) δ 7.42-7.28 (m, 5H), 7.12 (m, 3H), 4.05 (s, 2H), 3.31 (sept, J = 6.2 Hz, 
2H), 3.15 (bs, 1H), 1.23 (d, J = 6.2 Hz, 12H) ; 
13
C NMR (100 MHz, CDCl3) δ 143.0, 142.9, 
140.3, 128.7, 128.1, 127.6, 124.2, 123.8, 56.2, 27.9, 24.4. 
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3.0 REGIOSELECTIVE PALLADIUM-CATALYZED AMIDATION OF 
POLYCHLORINATED 3-AMINOPYRIDINES 
3.1 Introduction 
 An amidation/cyclization approach for the synthesis of chlorinated imidazopyridines 
from 3-amino-polychloropyridines has been developed. Chlorinated imidazopyridines are often 
utilized in pharmaceutical settings as scaffolds for the discovery and optimization of biologically 
active small molecules, as they can be rapidly elaborated to explore chemical space. 
Regioselective alkylation of the imidazole ring of unsubstituted imidazopyridines is problematic, 
however, with common alkylation conditions providing mixtures which are difficult to separate. 
This new methodology allows for regioselective access of chlorinated imidazopyridines from 
inexpensive and readily available 3-amino-2-chloropyridine precursors. 
3.2 Background 
 Selective functionalization of polyhalogenated aromatics has received significant 
attention in the last 15 years, primarily in the context of palladium-catalyzed cross coupling 
reactions.
104,105
 This isn't surprising as selective transition metal catalysis can provide quick 
access to biologically useful building blocks (many of which are heterocyclic), with pendant 
halogens for further functionalization.
106,107
 Selectivity within polyhalogenated aromatics and 
heteroaromatics has been explored in systems through experimental and theoretical means;
108–110
 
Some of the earlier methods exploited the differences in sp
2
-hybridized C–X bond strength111–113 
(Figure 3.1, eq. 1), as the weaker bonds react with palladium first (in order of decreasing 
reactivity, C–I > C–Br > C–Cl >> C–F). In the case of aromatics containing multiple of the same 
halogen, selectivity can be attained by other means: through electronic variation of the C–X 
108 
 
 
 
bond,
112,114
 (Figure 3.1, eq. 2), steric protuberance
115
 (Figure 3.1, eq. 3), or utilization of a 
directing group
116,117
 (Figure 3.1, eq. 4). 
Figure 3.1. Regioselective Cross-Coupling Strategies 
 
  Versatility of these C–C and C–N bond formations have been expressed through 
selective couplings to functionalize benzimidazoles,
80,111
 pyridines,
108,109,117–119
 
pyrimidines,
114,115
 pyrazines,
116
 and other heterocyclic systems.
112,120–127
 This collection of 
methods is especially attractive because it allows for the rapid and divergent elaboration of these 
privileged heterocyclic motifs. In general, C–N bond formation remains one of the most 
important organic reactions in small molecule synthesis, as nitrogen functionality is ubiquitous in 
biologically active molecules.
128
 
3.2.1 Imidazopyridines 
 Investigation of C–N bond formation in structurally similar, yet less-studied heterocyclic 
moieties had become of significant interest, primarily in imidazo[4,5-b]pyridines (IPb). IPb and 
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its regioisomers are under-explored motifs present in several biologically active small 
molecules.
65,70,129–132
 Several previous approaches toward IPb utilized a condensation reaction 
starting from 2,3-diaminopyridines.
65,78,133,134
  
Scheme 3.1. Khanna's Approach toward IPb 
 
 Khanna and co-workers showed that a direct alkylation of IPb lead to a mixture of 
regioisomers in a 3.6:1.6:1 ratio of N3:N4:N1 benzylation
134
 (Scheme 3.1, eq. 1). This low 
selectivity could be circumvented by a lengthy synthesis, starting from 3-amino-2-nitropyridine 
3.16 (Scheme 3.1, eq. 2). In the presence of formic acid and acetic anhydride, the 3-amine was 
effectively converted to formamide 3.17, differentiating the 3-amine from the 2-amine after 
subsequent hydrogenation of 3.17 in the presence of Raney nickel. Condensation of 3.18 with 
various aldehydes followed by reduction yielded derivatives of IPb 3.19 regioselectively. 
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Scheme 3.2. Approaches toward Chlorinated IPb 
 
 Similar approaches toward chlorinated IPb, have been conducted from 2,3-diamino-5-
chloropyridine 3.20
135,136
 (Scheme 3.2). A moderately selective methylation afforded a 90:10 
mixture of IPb regioisomers 3.21 and 3.22
135
 (Scheme 3.2, eq. 1), but the protocol was only 
tolerant to methyl iodide as an electrophile. In contrast, when imidazopyridine 3.20 was 
subjected to a copper-catalyzed arylation, virtually a statistical mixture of 3.23 and 3.24 was 
observed
136
 (Scheme 3.2, eq. 2). It is clear from these findings that an alternative method was 
needed to streamline the synthesis of IPb to facilitate further exploration of these biologically 
useful heterocyclic entities. 
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Scheme 3.3. Palladium Catalyzed Amidation toward IPb and Related Heterocycles 
 
 Our group has reported on the palladium-catalyzed amidation of various structurally 
related heterocycles, affording substituted imidazo[4,5-b]pyridines (IPb),
76,77
 imidazo[4,5-
c]pyridines (IPc),
75
 and imidazo[4,5-b]pyrazines
76
 (Scheme 3.3). The collection of amidation 
reactions proceeded in the presence of various XPhos ligands or bidentate phosphines. While 
these conditions performed well in simple systems, they were incompatible with polychlorinated 
heterocycles. In efforts to expand the scope to more rapidly access complex heterocyclic 
scaffolds, we investigated a selective approach to synthesize chlorinated IPb. 
3.3 This Work: Synthesis of Chlorinated Imidazo[4,5-b]pyridines 
 Our goals for this study were to rapidly synthesize chlorinated IPb with alkyl and aryl N1-
substitution. Chemoselective oxidative insertion into the desired aryl chloride was imperative to 
maximize overall reaction yield and for preventing oligomerization. We believed the inherent 
electronic similarity between the chlorides at the 2- and 6-positions of starting pyridine 3.27 
could be overcome, should the endogenous amine act as a directing group. Moreover, this 
approach would avoid implementation of permanent or transient steric barriers and complex 
chelating auxiliaries. Finally, ligand choice would be pivotal in governing selectivity in oxidative 
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insertion of palladium (between the chlorides of the 2- and 6-positions); a ligand too reactive 
would decrease selectivity, which would limit the utility of the proposed method. As in previous 
studies a non-nucleophilic base was also employed to help facilitate coordination of formamide 
to palladium and to aid in condensation, thereby closing the imidazole ring.
75–77
 
Table 3.1. Optimization 
 
 
 
 
 
 
 
 
 
 
a
Reaction conditions: 1.0 equiv of 3.27a, (2 mol %) Pd2(dba)3·CHCl3, (10 mol %) Ligand,1.5 equiv of formamide, 2.0 
equiv of Cs2CO3, 0.2 M solvent, 110 °C. 
b
Crude yield with mesitylene internal standard. 
 Bisphosphino palladium complexes had shown considerable success in our previous 
amidation methods.
77
 We began screening in 1,4-dioxane as it was a suitable solvent in our 
previous studies. Compound 3.27a and formamide in the presence of Pd2(dba)3·CHCl3, 
DPEPhos, and Cs2CO3 displayed full conversion in 1,4-dioxane and an admirable crude yield of 
3.28a, at 70% (Table 1, entry 1). A small amount of hydrodehalogenated pyridine 3.30a was also 
formed under these conditions. This product proved to be more prevalent in other solvent 
Entry
a
 Ligand Solvent 
Yield 
3.28a (%)
b
 
Yield 
3.30a (%)
b 
1 DPEPhos 1,4-dioxane 70 3 
2 DPEPhos 10:1 dioxane: t-AmOH 64 10 
3 DPEPhos 1:1 dioxane: t-AmOH 60 13 
4 DPEPhos Toluene 45 30 
5 Xantphos 1,4-dioxane 52 0 
6 dppf 1,4-dioxane 34 0 
7 DPM 1,4-dioxane 45 5 
8 dppp 1,4-dioxane 0 0 
9 rac-BINAP 1,4-dioxane 0 0 
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systems. For example, when we examined our previously reported solvent system of 10:1 
dioxane:t-amyl alcohol. These conditions provided a lower yield of 64% was obtained for 3.28a, 
while 10% of 3.30a was observed by crude 
1
H NMR (Table 1, entry 2). Increasing the 
concentration to 1:1 dioxane:t-amyl alcohol further reduced the crude yield of 3.28a while 
increasing the yield of 3.30a (Table 1, entry 3). Reaction in toluene provided a modest yield of 
45% but had a higher proclivity to hydrodehalogenation at 30% of 3.30a (Table 1, entry 4). 
Other bidentate phosphine ligands were evaluated under similar amidation conditions. Xantphos 
was completely selective for amidation over hydrodehalogenation, but only provided 52% crude 
yield of 3.28a (Table 1, entry 5). 1,1'-Bis(diphenylphosphinoferrocene) (dppf) provided 34% 
yield of 3.28a (Table 1, entry 2). Bis(diphenylphosphino)methane (DPM) was also screened, 
affording 45% crude yield (Table 1, entry 7). Neither 1,3-bis(diphenylphosphino)pentane (dppp) 
nor racemic 1,1'-bisnaphthyl-2,2'-bis(diphenyl)phosphine (BINAP) yielded any imidazopyridine 
or hydrodehalogenated pyridine (Table 1, entries 8 and 9). We chose to proceed to the substrate 
scope with DPEPhos due to its favorable reactivity, selectivity, and its inexpensive cost relative 
to the other ligands screened.  
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Table 3.2. Substrate Scope 
 
 Initially the effect of the alkyl group on the 3-amino position was investigated. Benzyl 
groups were well tolerated in this position; for example the 4-methoxybenzyl substituted 
pyridine gave heterocycle 3.28a in 65% isolated yield (Table 3.2). Benzyl-substituted 3.28b and 
2,4-dimethoxybenzyl-substituted 3.28c were each isolated in 57% yield. A 52% yield was 
achieved with dichlorinated 3.28d. 4-Trifluoromethylbenzyl 3.28e and 4-fluorobenzyl 3.28f 
provided 38% and 48% yield, respectively. This method was also tolerant to aliphatic substrates. 
Cyclohexylmethyl-substituted 3.28g was isolated in 58% yield whereas cyclohexyl-substituted 
3.28h was isolated in 50% yield. 
115 
 
 
 
Table 3.3. Palladium Catalyzed Amidation using Acetamide 
 
 Significant structural diversity was tolerated on the 3-amino position, so attention was 
then focused on other sites that could be readily modified utilizing this chemistry. One apparent 
variation would be to employ modified primary amides as partners for the reaction in place of 
formamide. To probe the tolerance of the reaction to this change, acetamide was employed. 
Using acetamide as a coupling partner in place of formamide allowed for formation of 3.31 in 
61% yield (Table 3.3).  
 The incorporation of chloride atoms at other positions in the system was also briefly 
explored. Amidation was also amenable to N-substituted 3-amino-2,5-dichloropyridines (Table 
3.4). For example, chlorinated heterocycle 3.33a was isolated in 96% yield. The 4-
chlorobenzylsubstituted  3.33b was also isolated in 42% yield, as this approach was tolerant to 
yet another aryl chloride. 
116 
 
 
 
Table 3.4. Palladium Catalyzed Amidation of 3-Amino-2,5-Dichloropyridines 
 
  
3.4 Conclusion 
 In closing, the palladium-catalyzed amidation of dichlorinated 3-aminopyridines was 
presented. The regioselective amidation was tolerant to electron poor, electron rich aryl 
substrates, and alkyl substrates, totaling 11 imidazo[4,5-b]pyridines between 38% and 96% 
yield. The method was performed with formamide and acetamide as coupling partners, while it 
was selective with 3-amino-2,5- and 3-amino-2,6-dichloropyridines. This method presents a 
rapid and selective approach toward IPb, improving the outlook for using these heterocycles as 
medicinally relevant targets. Furthermore, the regioselective method targets complex 
heterocyclic systems without complex chelating auxiliaries, directing groups, or steric barriers 
that are difficult to remove in further synthetic elaboration.  
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3.5 Experimental Section: 
For General Experimental, refer to Chapter 1, p. 23-24. 
 General procedure for palladium-catalyzed amidation of polychlorinated 
aminopyridines: An oven-dried 25 mL Schlenk tube equipped with a magnetic stir bar was 
charged with Pd2(dba)3 · CHCl3 (0.008 mmol, 0.02 equiv.), bis-[2-
(diphenylphosphino)phenyl]ether (0.04 mmol, 0.10 equiv.), Cs2CO3 (2.0 mmol, 5.0 equiv.) and 
3.27a-k¸ 3.32a or 3.32b (0.40 mmol, 1 equiv.) and fit with a rubber septum. The vessel was 
evacuated then back-filled with argon.  Formamide (0.60 mmol, 1.5 equiv.) was added via 
syringe as a single portion down the side of Schlenk tube and rinsed down with 2 mL of dioxane 
(0.2M). The reaction mixture was degassed with 3 evacuation/argon purge cycles. The reaction 
vessel was equipped with a cold finger condenser under a positive stream of argon gas and 
immersed in a pre-heated oil bath at 110 °C until the starting material was consumed, as judged 
by thin layer chromatography (5% MeOH:CH2Cl2). The reaction was cooled to room 
temperature, diluted with MeOH, filtered through a Celite plug and concentrated to give a dark 
brown oil. The crude oil was further purified through flash column chromatography to obtain 
imidazopyridines 3.28a-k, 3.31, 3.33a, and 3.33b. 
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5-Chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridine 
(3.28a): Following the general procedure with 0.2 mmol of 
3.27a, 36 mg (65%) of 3.28a was collected after flash column 
chromatography, eluting with 3% MeOH:CH2Cl2. TLC Rf  0.29 (5% MeOH:CH2Cl2); MP: 98-
100 °C; 
1
H NMR (400 MHz, CDCl3)  = 8.24 (s, 1H) 7.52 (d, J=8.4 Hz, 1H) 7.16 (d, J= 8.4 Hz,  
1H), 7.14 (d, J=8.8 Hz, 2H), 6.88 (d, J= 8.8 Hz, 2H), 5.32 (s, 2H), 3.79 (s, 3H); 
13
C NMR (100 
MHz, CDCl3) δ = 160.1, 155.5, 146.3, 145.9, 129.0, 126.0, 125.1, 121.2, 118.9, 114.8, 55.5, 
49.7; FT-IR (NaCl, thin film) ν = 3073, 2999, 2959, 2835, 1513, 1440, 1354 cm-1; Anal. Calcd. 
for C14H12ClN3O: C, 61.43; H, 4.42; N, 15.35; Found: C, 61.49; H, 4.32; N, 15.15. 
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1-Benzyl-5-chloro-1H-imidazo[4,5-b]pyridine (3.28b): Following the 
general procedure, 56 mg (57%) of 3.28b was collected after flash 
column chromatography, eluting with 2% MeOH:CH2Cl2. TLC Rf 0.26 
(5% MeOH:CH2Cl2); MP: 136-137 °C; 
1
H NMR (400 MHz, CDCl3)  = 8.18 (s, 1H), 7.50 (d, J= 
8.4 Hz, 1H), 7.40-7.35 (m, 3H), 7.19 (d, J=8.4 Hz, 1H), 7.19-7.16 (m, 2H) 5.37 (s, 2H); 
13
C 
NMR (100 MHz, CDCl3) δ = 156.1, 146.3, 146.2, 134.3, 129.5, 129.0, 127.3, 125.2, 120.9, 
118.9, 50.0; FT-IR (NaCl, thin film) ν = 3029, 2971, 2926, 1694, 1450, 1365, 1269 cm-1; Anal. 
Calcd. for C13H10ClN3O: C, 64.07; H, 4.14; N, 17.24; Found: C, 64.45; H, 4.16; N, 17.19.  
 
 
 
 
 
 
 
 
 
 
120 
 
 
 
5-Chloro-1-(2,4-dimethoxybenzyl)-1H-imidazo[4,5-
b]pyridine (3.28c): Following the general procedure, 70 mg 
(57%) of 3.28c was collected as a white solid after flash column 
chromatography, eluting with 2% MeOH:CH2Cl2. TLC Rf 0.26 (5% MeOH:CH2Cl2); MP: 114-
116 °C; 
1
H NMR (400 MHz, CDCl3)  = 8.14 (s, 1H) 7.65 (d, J=8.4 Hz, 1H) 7.17 (d, J= 8.4 Hz, 
1H), 7.11 (d, J= 8.9 Hz, 1H), 6.46-6.43 (m, 2H), 5.24 (s, 2H), 3.78 (s, 3H), 3.76 (s, 3H); 
13
C 
NMR (100 MHz, CDCl3) δ = 161.8, 158.6, 155.8, 146.6, 145.7, 130.6, 125.3, 120.8, 118.3, 
115.1, 104.6, 99.0, 55.6, 55.5, 45.2; FT-IR (NaCl, thin film) ν = 3079, 2939, 2836, 1719, 1613, 
1509, 1461, 1266 cm
-1
; Anal. Calcd. for C15H14ClN3O2: C, 59.31; H, 4.65; N, 13.83; Found: C, 
59.35; H, 4.62; N, 13.55. 
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5-Chloro-1-(4-chlorobenzyl)-1H-imidazo[4,5-b]pyridine (3.28d): 
Following the general procedure, 58 mg (52%) of 3.28d was 
collected after flash column chromatography, eluting with 3% 
MeOH:CH2Cl2. TLC Rf  0.24 (5% MeOH:CH2Cl2); MP: 146-147 °C; 
1
H NMR (400 MHz, 
CDCl3)  = 8.40 (s, 1H) 7.50 (d, J=8.4 Hz, 1H) 7.35 (d, J=7.2 Hz, 2H), 7.21 (d, J= 8.4 Hz, 1H), 
7.13 (d, J= 8.4 Hz, 2H), 5.40 (s 2H); 
13
C NMR (100 MHz, CDCl3) δ = 155.0, 146.8, 146.0, 
135.1, 132.7, 129.7, 128.7, 124.9, 121.1, 119.3, 49.6; FT-IR (NaCl, thin film) ν = 3084, 2972, 
1767, 1610, 1560, 1491, 1406, 1376 cm
-1
;
 
Anal. Calcd. for C13H9Cl2N3: C, 56.14; H, 3.26; N, 
15.11; Found: C, 56.05; H, 3.08; N, 15.11. 
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5-Chloro-1-(4-(trifluoromethyl)benzyl)-1H-imidazo[4,5-
b]pyridine (3.28e): Following the general procedure, 47 mg 
(38%) of 3.28e was collected after flash column chromatography, 
eluting with 2% MeOH:CH2Cl2. TLC Rf 0.21 (5% MeOH:CH2Cl2)
 
MP: 158-160 °C; 
1
H NMR 
(400 MHz, CDCl3)  = 8.34 (s, 1H) 7.64 (d, J= 8.4 Hz, 2H) 7.49 (d, J= 8.4 Hz, 1H), 7.28 (d, J= 
8.0 Hz, 2H) 7.23 (d, J= 8.4 Hz, 1H), 5.48 (s, 2H); 
13
C NMR (100 MHz, CDCl3) δ = 156.0, 146.6, 
146.2, 138.4, 131.3 (C-F, q, J= 33.1 Hz), 127.4, 126.5 (C-F, q, J= 3.7 Hz), 125.0, 123.8 (C-F, q, 
J= 272.7 Hz), 120.7, 119.1, 49.3; 
19
F NMR (376.5 MHz, CDCl3)  δ = -62.8; FT-IR (NaCl, thin 
film) ν = 3081, 2926, 2851, 1721, 1560, 1410, 1350, 1247 cm-1; Anal. Calcd. for C14H9ClF3N3: 
C, 53.95; H, 2.91; N, 13.48; Found: C, 54.09; H, 2.85; N, 13.67. 
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5-Chloro-1-(4-fluorobenzyl)-1H-imidazo[4,5-b]pyridine (3.28f): 
Following the general procedure, 50 mg (48%) of 3.28f was 
collected after flash column chromatography, eluting with 2% 
MeOH:CH2Cl2. TLC Rf 0.23 (5% MeOH:CH2Cl2); MP: 133-135C; 
1
H NMR (400 MHz, CDCl3) 
 = 8.16 (s, 1H) 7.48 (d, J=8.4 Hz, 1H) 7.20-7.15 (m, 3H) 7.07 (m, 2H) 5.35 (s, 2H); 13C NMR 
(100 MHz, CDCl3) δ = 162.8 (d, J=246.9 Hz), 156.0, 146.3, 146.0, 130.1 (d, J=3.5 Hz), 129.2 (d, 
J= 8.2 Hz), 125.1, 120.9, 118.8, 116.5 (d, J=21.7 Hz), 49.3; 
19
F NMR (376.5 MHz, CDCl3) δ = -
112.3; FT-IR (NaCl, thin film) ν = 3083, 2943, 2871, 1605, 1510, 1437, 1352, 1219 cm-1; Anal. 
Calcd. for C13H9ClFN3: C, 59.67; H, 3.47; N, 16.06; Found: C, 59.56; H, 3.40; N, 16.02. 
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5-Chloro-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyridine (3.28g): 
Following the general procedure, 58 mg (58%) of 3.28g was collected 
after flash column chromatography, eluting with 3% MeOH:CH2Cl2. 
TLC Rf 0.33 (5% MeOH:CH2Cl2); MP: 127-130 C; 
1
H NMR (400 MHz, CDCl3)  = 8.03 (s, 
1H) 7.67 (d, J= 8.4 Hz, 1H) 7.21 (d, J= 8.4 Hz, 1H), 3.99 (d, J= 7.2 Hz, 2H) 1.83-1.75 (m, 1H) 
1.72-1.65 (m, 3H) 1.60-1.57 (m, 2H) 1.23-1.09 (m, 3H) 1.01-0.92 (m, 2H); 
13
C NMR (100 MHz, 
CDCl3) δ = 155.6, 146.4, 145.8, 125.5, 120.6, 118.5, 52.3, 38.6, 30.8, 26.0, 25.5; FT-IR (NaCl, 
thin film) ν = 3081, 2926, 2851, 1721, 1560, 1410, 1350, 1247 cm-1; Anal. Calcd. for 
C13H16ClN3: C, 62.52; H, 6.46; N, 16.83; Found: C, 62.57; H, 6.36; N, 16.43. 
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5-Chloro-1-cyclohexyl-1H-imidazo[4,5-b]pyridine (3.28h): Following the 
general procedure, 47 mg (50%) of 3.28h was collected after flash column 
chromatography, eluting with 2% MeOH: CH2Cl2. TLC Rf 0.23 (5% 
MeOH:CH2Cl2); MP: 131-133 C; 
1
H NMR (400 MHz, CDCl3)  = 8.19  (s, 1H) 7.73 (d, J=8.4 
Hz, 1H) 7.24 (d, J=8.4 Hz 1H), 4.18 (tt, J=12.1, 3.8 Hz, 1H), 2.20 (app. d, J= 13.0 Hz, 2H) 2.00 
(app. d, J= 13.7 Hz, 2H) 1.86-1.76 (m, 3H) 1.51 (qt, J=13.1, 3.4 Hz, 2H), 1.39-1.39 (m, 1H); 
13
C 
NMR (100 MHz, CDCl3) δ = 155.8, 145.7, 143.5, 124.6, 120.9, 118.1, 56.6, 33.3, 25.6, 25.2; FT-
IR (NaCl, thin film) ν = 3096, 2930, 2857, 1718, 1605, 1560, 1305 cm-1; Anal. Calcd. for 
C12H14ClN3: C, 61.15; H, 5.99; N, 17.83; Found: C, 61.42; H, 6.17; N, 18.09.  
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5-Chloro-1-(4-methoxybenzyl)-2-methyl-1H-imidazo[4,5-
b]pyridine (3.31): Following the general procedure, 70 mg 
(61%) of 3.31 was collected after flash column chromatography, 
eluting with 2% MeOH:CH2Cl2. TLC Rf 0.10 (5% MeOH:CH2Cl2); MP: 118-120 C; 
1
H NMR 
(400 MHz, CDCl3) δ = 7.40 (d, J=8.3 Hz, 1H), 7.10 (d, J=8.3 Hz, 1H), 6.97 (d, J=8.7 Hz, 2H), 
6.84 (d, J=8.8 Hz, 2H), 5.25 (s, 2H), 3.78 (s, 3H), 2.63 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ = 
159.7, 155.7, 155.2, 145.5, 127.8, 126.8, 126.6, 119.7, 117.7, 114.7, 55.5, 47.4, 14.5; Anal. 
Calcd. for C15H14ClN3O: C, 62.61; H, 4.90; N, 14.60; Found: C, 62.96; H, 4.71; N, 14.43; FT-IR 
(NaCl, thin film) ν = 3063, 2964, 2839, 1611, 1515, 1405, 1250 cm-1. 
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6-Chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridine 
(3.33a): Following the general procedure, 105 mg (96%) of 
3.33a was collected after flash column chromatography, eluting 
with 3% MeOH: CH2Cl2. MP: 108-109 C; 
1
H NMR (300 MHz, CDCl3) δ = 8.43 (d, J=2.4 Hz, 
1H), 8.11 (s, 1H), 7.52 (d, J=2.4 Hz, 1H), 7.10 (d, J=8.4 Hz, 2H), 6.84 (d, J=8.7 Hz, 2H), 5.24 (s, 
2H), 3.76 (s, 3H); 
13
C NMR (75.4 MHz, CDCl3) δ = 159.9, 154.9, 146.1, 144.0, 128.8, 126.4, 
126.2, 126.0, 118.2, 114.7, 55.4, 49.3; FT-IR (NaCl, thin film) ν = 3041, 3003, 2934, 2837, 
1611, 1514, 1491, 1406, 1250, 1177, 1032, 917 cm
-1
; Anal. Calcd. for C14H12ClN3O: C, 61.43; 
H, 4.42; N, 15.35; Found: C, 61.60; H, 4.72; N, 14.95.  
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6-Chloro-1-(4-chlorobenzyl)-1H-imidazo[4,5-b]pyridine 
(3.33b): Following the general procedure, 47 mg (42%) of 3.33b 
was collected after flash column chromatography, eluting with 3% 
MeOH: CH2Cl2. TLC Rf 0.17 (4% MeOH:CH2Cl2); MP: 174-175 °C;
 1
H NMR (400 MHz, 
CDCl3): δ = 8.53 (d, 1H, J=2.2 Hz), 8.17 (s, 1H), 7.54 (d, 1H, J=2.2 Hz), 7.37 (dd, 2H, J=9.1, 
2.6 Hz), 7.12 (dd, 2H, J=9.1, 2.5 Hz), 5.32 (s, 2H); 
13
C NMR (100 MHz, CDCl3): δ = 155.1, 
146.2, 144.6, 135.1, 132.7, 129.8, 128.6, 126.7, 126.4, 118.1, 49.1; FT-IR (KBr pellet): v = 3070, 
2980, 2950, 1610, 1493, 1403 cm
-1
; Anal. Calcd. for C14H9Cl2N3: C, 56.14; H, 3.26; N, 15.11; 
Found: C, 56.18; H, 3.26; N, 14.89. 
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4.0 SYNTHESIS OF BOSUTINIB PROBES FOR DRUG ACTION STUDIES 
4.1 Introduction 
 The focus of this portion of the dissertation is on the synthesis of modified analogues of 
the Src kinase inhibitor, bosutinib, that do not cross cell membranes. These probes were prepared 
to interrogate the role of Src kinase that is excreted from cancer cells, as this extracellular kinase 
may play a role in tumor development and metastasis.  
4.2 Background 
 Non-Receptor Tyrosine Kinases (nRTK) and Receptor Tyrosine Kinases (RTK) have  
been the subject of intense study since their discovery. Tyrosine kinases are a class of enzymes 
that govern the phosphorylation of tyrosine residues within proteins. This post-translational 
modification often acts as an on/off switch for enzymatic activity.
137
 One main difference 
between nRTK and RTK is location. nRTK are cytoplasmic enzymes, while RTK exist in the 
cell membrane.
138
 Tyrosine kinases have many important roles that are critical to cell survival, 
including cell proliferation, differentiation, and signal transduction.
138–142
 Consequently, 
mutation or over-expression of tyrosine kinases has been shown to lead to proliferation of 
cancerous cells.
142–144
 The focus of this work is on inhibition of nRTKs. 
 A variety of different nRTKs have been identified including Src, Abl, Jak, Fak, Syk, and 
ZAP 70.
138,142
 Increased activity of Src has been identified in human tumors, making inhibition 
of Src a viable strategy for cancer treatment.
139,140
 This strategy has become a practical option for 
treatment of chronic myeloid leukemia (CML). The RTK inhibitor imatinib was brought to 
market in 2001 as a first generation treatment for late stage CML patients (Figure 4.1).
145
 
Unfortunately some CML cell lines showed immunity to imatinib, so the search for second 
generation drugs became necessary.
146
 In 2001 a small library of quinoline based molecules were 
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synthesized, displaying moderate IC50 values for Src inhibition.
147
 Through medicinal iteration 
and optimization published by several groups was first synthesized bosutinib (formerly called 
SKI-606), though it was not until 2012 before it was brought to market by Pfizer. 
Figure 4.1. Tyrosine Kinase Inhibitors used for Treatment of CML 
 
 Bosutinib, like several other drugs (e.g. nilotinib and dasatinib), treats patients with 
imatinib-resistant CML.
148–150
 Bosutinib inhibits Src selectively, with an IC50 value of 1.2 
nM.
147,151
 The quinoline core of bosutinib sits in the active site of Src, while the piperazine tail is 
solvent exposed.
152,153
 Bosutinib offers several advantages to other first and second generation 
CML drugs. Bosutinib displays higher potency, while patients observed fewer side effects as 
compared to other CML drugs (such as imatinib, nilotinib, and dasatinib).
146,154
 Bosutinib can be 
taken orally, and it has a biological half life of 22.5 hours. Bosutinib has also shown suppression 
of breast,
155
 prostate,
156
 and pancreatic
152,157
 cancer cell lines and inhibition of solid tumors.
158,159
 
4.2.1 Synthesis of Bosutinib 
 Several syntheses of bosutinib have been disclosed in the last 20 years.
147,160–165
 There are 
many unique elements to each approach, but much of the same chemistry is displayed throughout 
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all the reported syntheses of bosutinib. The synthesis of intermediate 4.08 was published in 
2000,
166
 and bosutinib was created from quinoline 4.08 in 2001
147
 as part of a divergent 
medicinal investigation (Scheme 4.1). The synthesis started with a protection of methyl vanillate 
4.05 with 2-bromopropane, before nitration and reduction of the nitro group to amine 4.06. 
Treatment of aniline 4.06 with dimethylformamide dimethyl acetal (DMF-DMA) formed an 
amidine intermediate; ensuing addition of deprotonated acetonitrile provided quinol-4-one 4.07. 
Treatment of 4.07 with phosphoryl oxychloride installed the chlorine at the quinoline 4-position; 
aluminum chloride mediated deprotection of the isopropyl group followed to yield 4.08. A 
Mitsunobu reaction was then carried out to append the 3-chloropropyl tail of 4.09. Nucleophilic 
aromatic substitution using aniline 4.10 then yielded 4-aminoquinoline 4.11. Nucleophilic 
substitution with N-methylpiperazine yielded bosutinib 4.02 in the seminal report of its synthesis.  
Scheme 4.1. Wang's synthesis of Bosutinib 
 
 Li et al. investigated a different approach to form the quinoline of bosutinib
162
 (Scheme 
4.2). Enamine 4.14 was formed from aniline 4.12, using 3,3-diethoxypropionitrile and TFA. 
Under basic conditions, the enamine of 4.14 attacked the ester in an intramolecular fashion and 
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after aromatization, formed the quinoline motif of 4.15. The same conditions were carried out to 
reach bosutinib as in the seminal report (Scheme 4.1).  
Scheme 4.2. Li's Synthesis of Bosutinib 
 
 Mao's approach
161,164
 (Scheme 4.3) started with aniline 4.16, which was subjected to a 
DMA-DMF catalyzed Mannich reaction, providing rapid access to quinoline 4.15. The formal 
total synthesis would be completed from previous reports to afford bosutinib. 
Scheme 4.3. Mao's Synthesis of Bosutinib 
 
 Finally, a report starting from anisole 4.17 carried out alkylation with N-
methylpiperazine,
165
 followed by hydrogenation of intermediate 4.18 to obtain aniline 4.19 
(Scheme 4.4). The resulting aniline, in the presence of ketone 4.20 and triethylorthoformate, 
furnished enamine 4.21, before its subjection to a phosphoryl oxychloride catalyzed 
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intramolecular electrophilic aromatic substitution. After further purification, bosutinib 
monohydrate 4.02 was isolated between 59-67% yield from 4.17. 
Scheme 4.4. Vaidyanathan's Synthesis of Bosutinib 
 
4.3 This Work: Synthesis of Tethered Bosutinib Probes 
 Our collaborators at SUNY Upstate Medical University recently discovered that Src 
exists in both the cytoplasm and the extracellular space of animal cells. This breakthrough was 
unprecedented, as it was previously accepted that Src only existed within the cytoplasm. Studies 
of drug action in bosutinib were therefore incomplete. The role of this extracellular Src has not 
been studied, but there remains the possibility that this kinase may be involved in intercellular 
signaling that influences cell migration or metastasis. The main objective of this study was to 
design and synthesize a series of bosutinib-based probes in order to identify the role of the Src 
kinase in the extracellular matrix. The two strategies discussed herein are the syntheses of biotin- 
and EDANS-bosutinib probes.  
 Retrosynthetically, the probes could be divided into 4 fragments (Scheme 4.5). The main 
components are fairly complex, but all are commercially available. A nucleophilic aromatic 
substitution would bring together the quinoline and aniline fragments of 4.22. Quinoline 4.08 
would be joined with piperazinyl fragment 4.23 by a Mitsunobu reaction. This main intermediate 
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could be converted divergently into several types of bosutinib-derived probes. The first 
synthesized was a biotinylated bosutinib probe. As biotin is well known to prohibit molecules 
from entering the cell membrane, it was thought to be a crucial bosutinib adduct.
167
 The 
proposed probe would therefore allow for selective Src inhibition in the extracellular space, 
rather than inhibition of cytoplasmic Src. This would facilitate the differentiation of the roles of 
the extracellular and intracellular enzymes. A fluorescent dye was also devised for further study 
of bosutinib drug action. The fluorescent probe chosen was the EDANS adduct,
168
 which could 
be readily connected to bosutinib with a linking moiety. The probes would be connected to the 
solvent-exposed piperazine by peptide coupling to prevent its interaction with the active site of 
Src.  
Scheme 4.5. Retrosynthetic Analysis for Bosutinib Probes 
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 Initially, the synthesis of bosutinib was conducted as a positive control for our 
collaborators at SUNY Upstate (Scheme 4.6). Fortunately, precursor 4.08 is commercially 
available, ranging between $80 to $160/g from ArkPharm throughout the duration of this project. 
Starting from quinoline 4.08, an alkylation was carried out to form the 3-chloropropyl tail of 
4.09. A TFA-mediated SNAr reaction was performed on resulting quinoline 4.09 with aniline 
4.10, followed by a nucleophilic substitution of 4.11 and N-methylpiperazine. 
Scheme 4.6. Synthesis of Bosutinib Control 
 
  The synthesis of biotinylated bosutinib 4.30 started from quinoline 4.08 (Scheme 4.7). 
Mitsunobu reaction of the phenolic oxygen of quinoline 4.08 and the alcohol of piperazine 4.27 
provided 4.28 in 55% yield. TFA-mediated SNAr of aniline 4.10 and the prepared quinoline 4.28 
was undertaken, yielding deprotected piperazine 4.29. Finally, peptide coupling of the 
deprotected piperazine with D-biotin afforded the desired probe 4.30.  
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Scheme 4.7. Synthesis of Biotinylated Bosutinib Probe 
 
 A fluorescent linker attached to the bosutinib core was also desired. We envisioned 
attaching an EDANS fluorophore by exploiting a key alkyne-azide cycloaddition to form triazole 
4.37 (Scheme 4.9). The EDANS coupling component was prepared from commercially available 
4.25 and methyl 4-chlorobutanoate 4.31 (Scheme 4.8). Displacement of the chloride with sodium 
azide followed by saponification of the methyl ester provided carboxylic acid 4.33. Peptide 
coupling with EDANS 4.25 yielded the clickable azide 4.34 (prepared by KA Leets) for the next 
step. 
Scheme 4.8. Synthesis of Fluorescent Azide Linker 
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 The synthesis of the desired alkyne started from previously prepared 4.29 (Scheme 4.9). 
A DCC-catalyzed peptide coupling with 4-pentynoic acid provided alkyne 4.36. The copper 
catalyzed triazole synthesis will next be performed with 4.34 and 4.36, to yield fluorophore 4.37. 
Scheme 4.9. Synthesis of EDANS-Bosutinib Probe 
 
4.4 Conclusion 
 Currently the biotin tagged bosutinib 4.30 is being evaluated by collaborators at SUNY 
Upstate Medical University. 4.30 Shows significant inhibition of the Src kinase in in vitro 
assays, and has also been shown not to cross cell membranes. The synthesis of fluorescent 
derivative 4.37 is ongoing, but the linker strategy of using the azide and alkyne to combine 
fluorescent tags with the kinase inhibitor should be applicable to the synthesis of many bosutinib 
derivatives with variable properties which can be tailored to a variety of applications. The data 
collected at the early stages of this project shows a promising outlook toward understanding the 
role bosutinib has in cancer cell inhibition. 
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4.5 Experimental Section 
For General Experimental, refer to Chapter 1, p. 23-24. 
4-Chloro-7-(3-chloropropyl)-6-methoxyquinoline-3-carbonitrile 
(4.09) (AD-4-083): A flame-dried 5 mL round-bottom flask with 
magnetic stir bar was charged with 4.08 (117 mg, 0.5 mmol), 4.26 (149 mg, 0.6 mmol), K2CO3 
(97 mg, 0.7 mmol), and DMF (1 mL, 0.5M). The reaction mixture was placed in a pre-heated oil 
bath at 70 °C for 18 hours. The mixture was cooled to room temperature and concentrated in 
vacuo. The resulting solid was further purified by flash column chromatography to yield 159 mg 
(quantitative yield) of an off-white solid, eluting at 0.5% MeOH:CH2Cl2. Compared to Literature 
Data
147
 
1
H NMR (400 MHz, CDCl3): δ = 8.79 (s, 1H), 7.46 (s, 1H), 7.43 (s, 1H), 4.38 (t, J = 6.0 Hz, 
2H), 4.06 (s, 3H), 3.81 (t, J = 6.2 Hz, 2H), 2.40 (p, J = 5.8 Hz, 2H). 
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[4-(2,4-Dichloro-5-methoxyphenyl)amino]-7-(3-chloropropyl)-6-
methoxyquinoline-3-carbonitrile (4.11) (AD-4-104): A flame-dried 
25 mL round bottom flask with magnetic stir bar was charged with 
4.09 (227 mg, 0.73 mmol), 2,4-dichloro-5-methoxyaniline (280 mg, 1.46 mmol), TFA (0.14 mL, 
1.82 mmol), and TFE (7 mL, 0.1M). The reaction mixture was stirred at 90 °C in a pre-heated oil 
bath for 22 hours. Upon completion, the mixture was concentrated in vacuo, diluted with 3 mL 
of methanol, and 300 mg of K2CO3 was added to the mixture. The slurry was filtered, and dried 
in vacuo. The brown residue was further purified through flash column chromatography into an 
146 mg (43%) of an off-white solid, eluting with 2% MeOH:CH2Cl2. Compared to Literature 
Data
147
 
1
H NMR (400 MHz, DMSO-d6): δ = 9.63 (s, 1H), 8.42 (s, 1H), 7.85 (s, 1H), 7.75 (s, 1H), 7.37 
(s, 1H), 7.34 (s, 1H), 4.29 (t, J = 6.0 Hz, 2H), 3.95 (s, 3H), 3.86 (s, 3H), 3.83 (t, J = 6.5 Hz, 2H), 
2.27 (p, J = 6.2 Hz, 2H). 
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Bosutinib (4.02) (AD-4-100): An oven-dried 20 dram vial with 
magnetic stir bar was charged with 4.11 (23 mg, 0.05 mmol), NaI 
(7.5 mg, 0.05 mmol), N-methylpiperazine (400 mg, 0.1M), and 
DMF (0.5 mL, 0.1M). The reaction was placed in a pre-heated oil bath at 80 °C, and stirred over 
night. The reaction was concentrated in vacuo and the brown oil was further purified via flash 
column chromatography. Bosutinib eluted with 20% MeOH:CH2Cl2 as 20 mg of a white solid 
(77%).
147
 
1
H NMR (400 MHz, DMSO-d6): δ = 9.62 (s, 1H), 8.41 (s, 1H), 7.83 (s, 1H), 7.75 (s, 1H), 7.33 
(s, 1H), 7.32 (s, 1H), 4.19 (t, J = 6.2 Hz, 2H), 3.94 (s, 3H), 3.86 (s, 3H), 2.45 (t, J = 7.2 Hz, 2H), 
2.40-2.30 (m, 8H), 2.17 (s, 3H), 1.95 (p, J = 8.1 Hz, 2H). 
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tert-Butyl 4-(3-hydroxypropyl)piperazine-1-carboxylate (4.27) (AD-
4-012/056): A 250 mL round bottom flask with magnetic stir bar was 
flame-dried and charged with 4-(3-hydroxypropyl)piperazine (1.44 g, 10 mmol) and 
tetrahydrofuran (65 mL, 0.15 M). The mixture was cooled to 0 °C and di-tert-butyl dicarbonate 
(2.18 g, 10 mmol) was added in one portion and the mixture was stirred over night. After 
reaction completion, as judged by TLC, the solvent was removed in vacuo. The clear oil was 
subjected to flash column chromatography (20% ethyl acetate:hexanes), yielding a 1.97 g as a 
white solid (81%).  
TLC Rf: 0.28 (1:1 ethyl acetate:hexanes) 
1
H NMR (400 MHz, CDCl3): δ = 4.87 (bs, 1H), 3.81 (t, J = 5.1 Hz, 2H), 3.44 (bs, 4H), 2.62 (t, J 
= 5.7 Hz, 2H), 2.47 (bs, 4H), 1.74 (p, J = 5.4 Hz, 2H), 1.45 (s, 9H) 
13
C NMR (100 MHz, CDCl3): δ = 155.8, 79.9, 64.6, 59.0, 53.3, 43.6, 28.5, 27.3 
IR (KBr, pellet): ν = 3194, 3006, 2973, 1694, 1414, 1175, 1126 cm-1 
MP = 69-71 °C 
EA Anal. calcd. for C12H24N2O3: C, 58.99; H, 9.90; N, 11.47; found: C, 58.98; H, 10.10; N, 
11.55 
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7-(3-(1-tert-Butylcarboxypiperazin-4-yl)propoxy)quinoline-4-
chloro-6-methoxy-3-carbonitrile (4.28) (AD-4-024/AD-5-125): 
A flame-dried 50 mL round bottom flask with magnetic stir bar 
was charged with triphenylphosphine (1.56 g, 5.97 mmol) and THF (20 mL, 0.15M), and the 
mixture was cooled to 0 °C. DIAD (1.2 mL, 5.97 mmol) was added dropwise and stirred for 20 
minutes in the cooling bath. Piperazine 4.27 (728 mg, 2.98 mmol) was added in one portion, and 
the reaction mixture was stirred for 1 hour. Quinoline 4.08 (700 mg, 2.98 mmol) was added, the 
reaction was removed from the cooling bath, and was left to stir over night. Upon reaction 
completion, the mixture was concentrated in vacuo. The yellow residue was taken up in 20 mL 
Et2O, triturated and filtered. The filtrate was rinsed with Et2O, and the crude compound was 
further purified through flash column chromatography. Quinoline 4.28 eluted at 3% 
MeOH:CH2Cl2 as 750 mg of an off-white solid (55%). 
TLC Rf: 0.10 (5% MeOH:CH2Cl2) 
1
H NMR: (400 MHz, CDCl3): δ = 8.78 (s, 1H), 7.46 (s, 1H), 7.42 (s, 1H), 4.30 (t, J=6.6 Hz, 2H), 
4.06 (s, 3H), 3.44 (bs, 4H), 2.57 (t, 6.9 Hz, 2H), 2.42 (bs, 4H), 2.13 (p, J=6.6 Hz, 2H), 1.46 (s, 
9H) 
13
C NMR (100 MHz, CDCl3): δ = 155.1, 154.9, 152.4, 148.3, 147.4, 143.9, 121.1, 115.6, 109.3, 
105.5, 102.1, 79.8, 67.9, 56.5, 54.9, 53.2, 28.6, 26.3 (one signal was not resolved) 
IR (KBr, pellet): ν = 2962, 2813, 2229, 1691, 1555, 1290, 1159 cm-1 
MP = 200-201 °C 
Anal. calcd. for C23H29ClN4O4: C, 59.93; H, 6.34; N, 12.15; found: C, 60.05; H, 6.32; N, 11.92 
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N-Demethylbosutinib (4.29) (AD-4-111): Quinoline 4.28 (417 
mg, 1 mmol), aniline 4.10 (384 mg, 2 mmol), TFA (0.19 mL, 2.5 
mmol), and TFE (10 mL, 0.1M) were mixed in a flame-dried 10 
mL round bottom flask with magnetic stir bar, and placed in a pre-heated oil bath at 90 °C. The 
contents were refluxed over night, before cooling the reaction to room temperature and 
concentration in vacuo. 300mg of K2CO3 and 5 mL of MeOH were added to the brown residue. 
The K2CO3 was filtered from the mother liquor with a coarse porosity fritted funnel, the liquor 
was dried in vacuo and purified through flash column chromatography. Compound 4.29 eluted at 
30% MeOH:CH2Cl2 as 400 mg of an off white solid (78%). Compared to literature data
147
 
1
H NMR (400 MHz, DMSO-d6): δ = 9.65 (s, 1H), 8.60, (bs, 1H), 8.41 (s, 1H), 7.84 (s, 1H), 7.75 
(s, 1H), 7.34 (s, 1H), 7.33 (s, 1H), 4.35 (t, J=5.2 Hz, 1H), 4.21 (t, J=6.6 Hz, 2H), 3.94 (s, 3H), 
3.86 (s, 3H), 3.14-3.07 (m, 4H), 2.63-2.56 (m, 4H), 1.99 (p, J=7.5 Hz, 2H). 
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N-Biotinylbosutinib (4.30) (AD-4-110): To an 
oven-dried 20 dram vial with magnetic stir bar was 
added HBTU (91 mg, 0.24 mmol), 
diisopropylethylamine (52 µL, 0.30 mmol), biotin 
(59 mg, 0.24 mmol), and DMF (2 mL, 0.1M). The reaction was stirred for 1 hour before 
quinoline 4.29 (103 mg, 0.2 mmol) was added in an additional 2 mL of DMF. The reaction was 
stirred overnight, then concentrated in vacuo. Compound 4.30 was further purified by flash 
column chromatography (deactivated with 1% triethylamine:dichloromethane), eluting with 1% 
NEt3:5% MeOH:CH2Cl2, yielding 67 mg of a mixture of benzotriazole byproduct and the desired 
4.30. The residue was taken up in CH2Cl2, and quenched with 2M HCl(aq). The aqueous phase 
was removed and free-based with 2M NaOH(aq). The free-based aqueous phase was extracted 
with CH2Cl2, and the organics were collected, dried with MgSO4, filtered through a coarse 
porosity fritted funnel, and concentrated in vacuo. The resulting oil was triturated with Et2O, 
affording 10 mg of an off-white solid. 
1
H NMR (400 MHz, DMSO-d6): δ = 9.61 (s, 1H), 8.42 (s, 1H), 7.83 (s, 1H), 7.75 (s, 1H), 7.34 
(s, 1H), 7.33 (s, 1H), 6.43 (bs, 1H), 6.35 (bs, 1H), 4.32-4.28 (m, 1H), 4.21 (t, J=6.4 Hz, 2H), 
4.16-4.12 (m, 1H), 3.95 (s, 3H), 3.86 (s, 3H), 3.47-3.42 (m, 4H), 2.82 (dd, J=12.4, 5.0 Hz, 1H), 
2.57 (d, J=12.8 Hz, 1H), 2.42-2.37 (m, 4H), 2.29 (t, J=7.2 Hz, 2H), 2.02-1.96 (m, 4H), 1.52-1.42 
(m, 4H).  
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N-(Pentyn-4-amidyl)-bosutinib (4.36) (AD-5-127): An 
oven-dried vial with magnetic stir bar was charged with 
dicyclohexylcarbodiimide (18 mg, 0.087 mmol), pent-4-
ynoic acid (8.5 mg, 0.087 mmol), 4-
dimethylaminopyridine (1.5 mg, 0.012 mmol), and CH2Cl2 (0.5 mL, 0.10 M). The mixture was 
stirred for 1 hour and cooled to 0 °C, before 4.29 (30 mg, 0.058 mmol) was added in 0.5 mL (to 
bring the concentration to 0.05 M) of CH2Cl2. The reaction mixture was stirred over night, then 
concentrated in vacuo. The residue was further purified through flash column chromatography, 
eluting with 3% MeOH:CH2Cl2 as an oil. The oil was triturated with diethyl ether, precipitating 
21 mg of an off-white solid (61%). 
TLC Rf 0.19 (10% MeOH:CH2Cl2) 
1
H NMR (400 MHz, CDCl3): δ = 8.71 (s, 1H), 7.49 (s, 1H), 7.44 (s, 1H), 6.91 (s, 1H), 6.76 (s, 
1H), 6.47 (s, 1H), 4.27 (t, J=6.5 Hz, 2H), 3.78 (s, 3H), 3.67 (s, 3H), 3.65 (t, J=4.8 Hz, 2H), 3.49 
(t, J=4.8 Hz, 2H), 2.60-2.53 (m, 6H), 2.51-2.44 (m, 4H), 2.12 (p, J=6.6 Hz,2H), 1.97 (app t, 
J=2.3 Hz, 1H). 
13
C NMR (100 MHz, CDCl3): δ = 169.4, 154.5, 154.1, 150.5, 149.9, 147.8, 147.7, 137.1, 130.8, 
118.7, 117.4, 116.5, 115.0, 110.0, 105.7, 101.3, 94.5, 83.6, 68.9, 67.6, 56.7, 56.2, 54.8, 53.4, 
52.9, 45.4, 41.2, 32.3, 26.2, 14.6. 
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Methyl 4-azidobutyrate (4.32) (KL-1-107): To an oven dried round bottom 
flask, methyl 4-chlorobutyrate (5.0 g, 36.61 mmol) was dissolved in dimethyl 
sulfoxide (17 mL). Sodium azide (3.33 g, 51.25 mmol) was added, the reaction mixture was 
heated to 45°C and stirred for 24 hours. The reaction mixture was cooled to room temperature 
then extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with 
brine (1 x 15 mL), dried over magnesium sulfate, filtered, and concentrated to give a colorless 
liquid (4.95 g, 94%) 
1
H NMR (300 MHz, CDCl3) δ = 3.69 (s, 3H), 3.35 (t, J=6.7 Hz, 2H), 2.42 (t, J =7.3 Hz, 2H), 
1.91 (p, J=6.9 Hz, 2H).  
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4-Azidobutyric acid (4.33) (KL-1-108): To an oven dried round bottom flask, 
methyl 4-azidobutyrate (4.95 g, 34.58 mmol) was dissolved in 2N sodium 
hydroxide solution (2.5 mL, 69.16 mmol). About 2 mL of methanol was added to the reaction 
mixture to make a homogenous solution. The reaction mixture was stirred at room temperature 
for 48 hours. The methanol was removed under vacuo and the aqueous layer was washed with 
diethyl ether (4 x 8mL). The aqueous layer was then acidified with concentrated HCl until pH = 
1. The compound was extracted with diethyl ether (4 x 15 mL) and the combined organic layers 
were washed with brine (1 x 15 mL), dried over magnesium sulfate, filtered, and concentrated to 
give a colorless liquid (0.56 g, 13%)  
1
H NMR (300 MHz, CDCl3) δ = 11.25 (br s, 1H), 3.38 (t, J=6.7 Hz, 2H), 2.48 (t, J=7.2 Hz, 2H), 
1.92 (p, J=6.9 Hz, 2H).  
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 5 - [(2 - Aminoethyl)amino]naphthalene-1-sulfonic acid-4-
azidobutyramide (4.34) (KL-1-115): To an oven dried test tube 4-
azidobutyric acid (72 µg, 0.56 mmol) was dissolved in DMF (2 
mL).  HOBt (0.05 g, 0.37 mmol), EDC (0.11 g, 0.56 mmol), and Et3N (0.15 mL, 1.11 mmol) 
were added and the reaction mixture stirred at room temperature for 1 hr. 5-(2-
Aminoethylamino)- 1-naphthalenesulfonic acid (0.1 g, 0.56 mmol) was added and the reaction 
was stirred at room temperature for 24 hrs. The reaction mixture was washed with H2O (3 x 10 
mL) and the aqueous layer was concentrated. 
1
H NMR (400 MHz, D2O) δ = 8.17-8.13 (m, 2H), 
8.07 (d, J = 8.6 Hz, 1H), 7.59-7.50 (m, 2H), 6.89 (d, J = 7.6 Hz, 1H), 3.59-3.55 (m, 2H), 3.46 (t, 
J = 5.8 Hz, 2H), 3.23 (t, J = 6.7 Hz, 2H), 2.26 (t, J = 7.3 Hz, 2H), 1.76 (p, J = 6.9 Hz, 2H). 
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5.0 SPECTRA 
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